

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 00:36:13 ; Search time 456 Seconds
(without alignments)
9951.264 Million cell updates/sec

Title: US-10-007-010-3
Perfect score: 2015
Sequence: 1 cggaggcaggaagatgagg.....ataaatgcaagtcttaag 2015

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2185239 seqs, 1125999159 residues

Word size : 0
Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N_Geneseq_101002.*
1: /SID22/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID22/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID22/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID22/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID22/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID22/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID22/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID22/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID22/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID22/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID22/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID22/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID22/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID22/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID22/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID22/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID22/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID22/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID22/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID22/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID22/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID22/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2015	100.0	2015	24	ABK83939 Human cDNA differe
2	2015	100.0	2015	24	ABL66673 Lung cancer relate
3	1552	77.0	1926	24	ABK83940 Human cDNA differe
4	183	9.1	183	24	ABL61214 Human nucleotide f
5	181	9.0	1416	24	ABL61215 Rat/human fusion c
6	181	9.0	1542	24	ABL61216 Rat/human fusion c
7	169	8.4	369	16	AAI19957 Human gene signatu
8	133	6.6	171	22	ABA50558 Human breast cell
9	133	6.6	171	22	ABA68516 Human foetal liver

10	133	6.6	171	22	ABA35497 Probe #13963 for g
11	133	6.6	171	22	AAK16884 Human brain expres
12	133	6.6	171	22	AAK42654 Human bone marrow
13	133	6.6	171	22	AAI23408 Probe #13341 for g
14	133	6.6	171	22	AAI48728 Probe #17414 used
15	133	6.6	171	22	AAI09035 Probe #9026 used t
16	133	6.6	171	24	ABS16706 Human genome-deriv
17	113	5.6	415	22	ABA45430 Human breast cell
18	113	5.6	415	22	ABA5928 Human foetal liver
19	113	5.6	415	22	ABA25595 Probe #4061 for ge
20	113	5.6	415	22	AAK04142 Human brain expres
21	113	5.6	415	22	AAK29623 Human bone marrow
22	113	5.6	415	22	AAI14202 Probe #4135 for ge
23	113	5.6	415	22	AAI35833 Probe #4269 used t
24	113	5.6	415	22	AAI04039 Probe #4030 used t
25	113	5.6	415	24	ABS04179 Human genome-deriv
26	112	5.6	1592	20	AAZ227241 Human secreted pro
27	78	3.9	409	22	AAH99174 Human protein enco
28	77	3.8	334	21	AAAS2650 Eosinophil activat
29	68	3.4	1911	24	ABK63704 Rat sequence diff
30	66	3.3	274	22	AAK68573 Human immune/haema
31	65	3.2	1926	24	ABK83940 Human cDNA differe
32	31	1.5	31	22	AAI30734 Human single nucle
33	31	1.5	31	22	AAI30735 Human single nucle
34	31	1.5	31	22	AAI30736 Human single nucle
35	31	1.5	31	22	AAI30737 Human single nucle
36	31	1.5	31	22	AAI30738 Human single nucle
37	28	1.4	2298	24	ABK83935 Human cDNA differe
38	27	1.3	33	22	AAH41498 Human tyrosine kin
39	26	1.3	32	22	AAH41491 Human tyrosine kin
40	26	1.3	32	22	AAH41492 Human tyrosine kin
41	26	1.3	1602	14	AAQ46687 Chicken pp60 c-src
42	26	1.3	1759	21	AAZ29700 Wild-type chicken
43	26	1.3	1759	22	AAH28357 Nucleotide sequenc
44	25	1.2	32	22	AAH41501 Human tyrosine kin
45	25	1.2	51	23	ABL00375 Human silent nonco

ALIGNMENTS

RESULT 1
ABK83939
ID ABK83939 standard; cDNA; 2015 BP.
XX AC
XX ABK83939;
XX AC
DT 14-AUG-2002 (first entry)
XX
DE Human cDNA differentially expressed in granulocytic cells #510.
DE
DE Human; ss: granulocytic cell; DNA chip; bacterial infection;
KW Human; ss: granulocytic cell; DNA chip; bacterial infection;
KW viral infection; parasitic infection; protozoal infection;
KW fungal infection; sterile inflammatory disease; psoriasis;
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW adult respiratory distress syndrome; inflammatory bowel disease;
KW Crohn's disease; ulcerative colitis; periodontal disease;
KW granulocyte activation; chronic inflammation; allergy.
XX
OS Homo sapiens.
XX
PN WO200228999-A2.
XX
PD 11-APR-2002.
XX
XX
PF 03-OCT-2001; 2001WO-US30821.
XX
XX
PR 03-OCT-2000; 2000US-237189P.
XX
XX
PA (GENE-) GENE LOGIC INC.
XX
XX
PI Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;

1381	DB	CTGTAAGCCATCAACTTTGGCTCCTTACACATCAAGTCAGACGTCGGTCTTTGGTATC	1440
1441	QY	CTGCTGATGGAGATCGTCACTACGCGCGGATCCCTTACCAGGGATGTCAAAACCCCTGAA	1500
1441	DB	CTGCTGATGGAGATCGTCACTACGCGCGGATCCCTTACCAGGGATGTCAAAACCCCTGAA	1500
1501	QY	GTGATCGGAGCTCTGGAGCGTGATACCGGATGCCCTGCCCGACAGAACTGCCACAGGAG	1560
1501	DB	GTGATCGGAGCTCTGGAGCGTGATACCGGATGCCCTGCCCGACAGAACTGCCACAGGAG	1560
1561	QY	CTCTACAACATCATGATCGCTGCTGAAAAACCGTCCGGAGGAGCGCGACCTTCGAA	1620
1561	DB	CTCTACAACATCATGATCGCTGCTGAAAAACCGTCCGGAGGAGCGCGACCTTCGAA	1620
1621	QY	TACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAGAGACCGTACCAACAGCAG	1680
1621	DB	TACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAGAGACCGTACCAACAGCAG	1680
1681	QY	CCATGATAGGAGGAGACCAAGGCGAGGGGTGCCAGGTGGTGGCTCGAAGGTGGCT	1740
1681	DB	CCATGATAGGAGGAGACCAAGGCGAGGGGTGCCAGGTGGTGGCTCGAAGGTGGCT	1740
1741	QY	CCAGCACATCCGCCAGGGGCCACACCCCTTCTACTCCACACACCCACCCCTCGCTTC	1800
1741	DB	CCAGCACATCCGCCAGGGGCCACACCCCTTCTACTCCACACACCCACCCCTCGCTTC	1800
1801	QY	AGCCACAGTTTCCTCATCTGTCCAGTGGGTAGTTGGACTGGAAAACTCTTTTGACTC	1860
1801	DB	AGCCACAGTTTCCTCATCTGTCCAGTGGGTAGTTGGACTGGAAAACTCTTTTGACTC	1860
1861	QY	TTGCAATCCCAATCTGCATCTCTCAGTAAGCCCCCAAGTTGATATTTCTATTTCCCTGGA	1920
1861	DB	TTGCAATCCCAATCTGCATCTCTCAGTAAGCCCCCAAGTTGATATTTCTATTTCCCTGGA	1920
1921	QY	ATGCTTCGATTTTAGTTACAGCTGTGATTTGGAAGGGAACCTTCAAAATAGTCAAAATGA	1980
1921	DB	ATGCTTCGATTTTAGTTACAGCTGTGATTTGGAAGGGAACCTTCAAAATAGTCAAAATGA	1980
1981	QY	ATATTTAAATAAAGATATAAATGCAAGTCTTAGC	2015
1981	DB	ATATTTAAATAAAGATATAAATGCAAGTCTTAGC	2015

RESULT 2	
ABL66673	
. ID	ABL66673 standard; DNA; 2015 BP.
XX	
AC	ABL66673;
XX	
DT	15-MAY-2002 (first entry)
. XX	
DE	Lung cancer related gene sequence SEQ ID NO:5010.
XX	
KW	Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW	stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW	cystostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW	gene; ds.
XX	
OS	Homo sapiens.
XX	
PN	WO200194629-A2.
XX	
PD	13-DEC-2001.
XX	
PF	30-MAY-2001; 2001WO-US10838.
XX	
PR	05-JUN-2000; 2000US-209473P.
PR	05-JUN-2000; 2000US-209531P.
PR	18-SEP-2000; 2000US-233133P.
PR	18-SEP-2000; 2000US-233617P.
PR	20-SEP-2000; 2000US-234009P.
PR	20-SEP-2000; 2000US-234034P.

PR	20-SEP-2000;	2000US-234052P.
PR	22-SEP-2000;	2000US-234059P.
PR	22-SEP-2000;	2000US-234567P.
PR	25-SEP-2000;	2000US-234923P.
PR	25-SEP-2000;	2000US-234924P.
PR	25-SEP-2000;	2000US-235072P.
PR	25-SEP-2000;	2000US-235082P.
PR	25-SEP-2000;	2000US-235134P.
PR	25-SEP-2000;	2000US-235280P.
PR	26-SEP-2000;	2000US-235637P.
PR	26-SEP-2000;	2000US-235638P.
PR	27-SEP-2000;	2000US-237111P.
PR	27-SEP-2000;	2000US-235720P.
PR	27-SEP-2000;	2000US-235840P.
PR	27-SEP-2000;	2000US-235863P.
PR	28-SEP-2000;	2000US-236028P.
PR	28-SEP-2000;	2000US-236032P.
PR	28-SEP-2000;	2000US-236033P.
PR	28-SEP-2000;	2000US-236034P.
PR	28-SEP-2000;	2000US-236109P.
PR	28-SEP-2000;	2000US-236111P.
PR	29-SEP-2000;	2000US-236842P.
PR	29-SEP-2000;	2000US-236891P.
PR	02-OCT-2000;	2000US-237172P.
PR	02-OCT-2000;	2000US-237173P.
PR	02-OCT-2000;	2000US-237278P.
PR	02-OCT-2000;	2000US-237294P.
PR	02-OCT-2000;	2000US-237295P.
PR	02-OCT-2000;	2000US-237316P.
PR	03-OCT-2000;	2000US-237325P.
PR	03-OCT-2000;	2000US-237598P.
PR	03-OCT-2000;	2000US-237604P.
PR	03-OCT-2000;	2000US-237606P.
PR	03-OCT-2000;	2000US-237608P.
PR	01-NOV-2000;	2000US-244867P.
PR	01-NOV-2000;	2000US-245084P.
XX	(AVAL-)	AVALON PHARM.
PA		
XX		
PI	Young PE, Augustus M, Cart	
PI	Soppet DR, Weaver Z;	
XX		
XX	WPI: 2002-188264/24.	

(AVAL-) AVALON PHARM.

Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
Soppet DR, Weaver Z;
WPI: 2002-188264/24.

Screening for anti-neoplastic agent involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, and determining a change in expression of a gene of a signature gene set

Claim 1: SEO ID 5010: 440p: English

The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of a signature gene set, where (I) comprises a sequence (S) selected from 8447 sequences (given in ABL61664 to ABL70110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytostatic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, esophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.

Sequence 2015 BP: 512 A; 540 C; 580 G; 383 T; 0 other; ;

Query Match	Score 2015;	DB 24;	Length 2015;
100.0%	Score 2015;	DB 24;	Length 2015;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2015; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Human cDNA differentially expressed in granulocytic cells #511.

Human; ss; granulocytic cell; DNA chip; bacterial infection;
viral infection; parasitic infection; protozoal infection;
fungal infection; sterile inflammatory disease; psoriasis;
rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
cardiac reperfusion injury; renal reperfusion injury; ARDS;
adult respiratory distress syndrome; inflammatory bowel disease;
Crohn's disease; ulcerative colitis; periodontal disease;
granulocyte activation; chronic inflammation; allergy.

Homo sapiens.

WO200228999-A2.

11-APR-2002.

03-OCT-2001; 2001WO-US30821.

03-OCT-2000; 2000US-237189P.

(GENE-) GENE LOGIC INC.

Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;

WPI; 2002-435328/46.

Detecting granulocyte activation by detecting differential expression
of genes associated with granulocyte activation, which serves as
diagnostic markers that is useful for monitoring disease states and
drug toxicity

Claim 1: SEQ ID No 511; 114pp; English.

The invention relates to detecting (M1) granulocyte (GC) activation
(GCA), by detecting the level of expression of gene(s) (Gs) identified by
DNA chip analysis as given in the specification, and comparing
the expression level to an expression level in an unactivated
GC, where differential expression of Gs is indicative of GCA.

Also included are modulation of at least one gene in Gs; (2) screening (M3)
that alters the expression of at least one gene in Gs; (2) screening (M3)
for an agent capable of modulating GCA or an inflammation (especially
chronic) in a tissue, an allergic response in a subject, exposure of a
subject to a pathogen or sterile inflammatory disease using the
gene expression profile; (3) detecting (M4) an inflammation (especially
chronic) in a tissue, an allergic response in a subject, exposure of a
subject to a pathogen or sterile inflammatory disease, by detecting the
level of expression in a sample of the tissue of gene(s) from Gs, where
the level of expression of the gene is indicative of inflammation;

(4) treating (M5) an inflammation (especially chronic) or in a tissue,
an allergic response in a subject, exposure of a subject to a pathogen
or sterile inflammatory disease, by contacting a tissue having
inflammation with an agent that modulates the expression of gene(s)
from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
modulating GA; M3 is useful for screening an agent capable of modulating
GCA preferably in an inflammation in a tissue; M4 is useful for

detecting an inflammation (especially chronic) in a tissue, an allergic
response in a subject, exposure of a subject to a pathogen or sterile
inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
inflammation injury, ARDS, adult respiratory distress syndrome,
inflammatory bowel disease, Crohn's disease, ulcerative colitis,
periodontal disease; also bacterial infection, viral infection,
parasitic infection, protozoal infection, fungal infection and M5 is
useful for treating one of the above conditions. The present
sequence represents a gene differentially expressed in granulocytes.

Note: The sequence data for this patent did not form part
of the printed specification, but was obtained in electronic
format directly from WIPO at

ftp.wipo.int/pub/published_pct_sequences.

Sequence 1926 BP; 497 A; 522 C; 520 G; 387 T; 0 other;

	Query Match	77.0%	Score 1552;	DB 24;	Length 1926;
	Best Local Similarity	100.0%;	Pred. No. 0;		
	Matches 1552;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	178	ATGAAGTCCAAAGTTCTCCAGTGGAGGCAATACATTTCTCAAAAACTGAAACACGCGC	237		
Db	85	ATGAAGTCCAAAGTTCTCCAGTGGAGGCAATACATTTCTCAAAAACTGAAACACGCGC	144		
QY	238	AGCCACACATGTCCTGTGTACGTCCGGATCCACATCCACATCAAGCGGGGCTAAT	297		
Db	145	AGCCACACATGTCCTGTGTACGTCCGGATCCACATCCACATCAAGCGGGGCTAAT	204		
QY	298	AGCCACAAACAGCAACACACAGGAATCAGGGAGGAGGCTCTGAGGACATCATCTGNGTT	357		
Db	205	AGCCACAAACAGCAACACACAGGAATCAGGGAGGAGGCTCTGAGGACATCATCTGNGTT	264		
QY	358	GCCTGTATGATTACGAGGCCATTACACAGGAAGACCTCAGCTTCCAGAGGGGACACAG	417		
Db	265	GCCTGTATGATTACGAGGCCATTACACAGGAAGACCTCAGCTTCCAGAGGGGACACAG	324		
QY	418	ATGGTGGTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGGCCACCCGGAAG	477		
Db	325	ATGGTGGTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGGCCACCCGGAAG	384		
QY	478	GAGGGGTACATCCCAAGCAACTATGTCCGCCGCTTGAATCTCTGAGAGACAGAGGAGTG	537		
Db	385	GAGGGGTACATCCCAAGCAACTATGTCCGCCGCTTGAATCTCTGAGAGACAGAGGAGTG	444		
QY	538	TTTTTCAAGGGCATCAGCGGGAAGGAGCGAGCGCCAACTGCTGGCTCCCGGCAACATG	597		
Db	445	TTTTTCAAGGGCATCAGCGGGAAGGAGCGAGCGCCAACTGCTGGCTCCCGGCAACATG	504		
QY	598	CTGGGTCTCTCATGATCCGGGATAGGAGACACACTAAAGAGAGCTACTTTTGTCCTG	657		
Db	505	CTGGGTCTCTCATGATCCGGGATAGGAGACACACTAAAGAGAGCTACTTTTGTCCTG	564		
QY	658	CGAGCTACGACCTCGGAGGAGATACCGTGAACATTTACAAGATCCGGACCCCTGGAC	717		
Db	565	CGAGCTACGACCTCGGAGGAGATACCGTGAACATTTACAAGATCCGGACCCCTGGAC	624		
QY	718	AAGGGGGTCTTACATATCCCTCCCAAGACCTTCAGACACTCTGAGGAGCTGGTGGAC	777		
Db	625	AAGGGGGTCTTACATATCCCTCCCAAGACCTTCAGACACTCTGAGGAGCTGGTGGAC	684		
QY	778	CACCTAAGAGGGGAGGAGGAGCTGCGCAAGAACTGTGGTGGCTGCTGCTCTCC	837		
Db	685	CACCTAAGAGGGGAGGAGGAGCTGCGCAAGAACTGTGGTGGCTGCTGCTCTCC	744		
QY	838	AAGCCCGAGAGCTTTGGGAGAAAGATGCTGGAGATCCCTCGGGAATCCCTCAAGCTG	897		
Db	745	AAGCCCGAGAGCTTTGGGAGAAAGATGCTGGAGATCCCTCGGGAATCCCTCAAGCTG	804		
QY	898	GAGAAGAACTTGGAGCTGGGAGTTTGGGAGTCTGGATGGCCACCTACACAGAC	957		
Db	805	GAGAAGAACTTGGAGCTGGGAGTTTGGGAGTCTGGATGGCCACCTACACAGAC	864		
QY	958	ACCAAGGTGGCAGTGAAGACGATGAAGCCAGGAGCATGCTGGTGGAGGCTTCTTGGCA	1017		
Db	865	ACCAAGGTGGCAGTGAAGACGATGAAGCCAGGAGCATGCTGGTGGAGGCTTCTTGGCA	924		
QY	1018	GAGGCCAAGTGTATGAAAACCTTGCAGCATGACAAAGCTGGTCAAACTCATCGGTGTC	1077		
Db	925	GAGGCCAAGTGTATGAAAACCTTGCAGCATGACAAAGCTGGTCAAACTCATCGGTGTC	984		
QY	1078	ACCAAGGAGGCTTACATCATCAGGAGTTTCATGGCCAAAGAGAGCTTGTGGACTTT	1137		
Db	985	ACCAAGGAGGCTTACATCATCAGGAGTTTCATGGCCAAAGAGAGCTTGTGGACTTT	1044		
QY	1138	CTGAAAAGTGTAGGCGGAGCAAGCCATTGCGCAAACTCATTTGACTTCTCAGCCAG	1197		
Db	1045	CTGAAAAGTGTAGGCGGAGCAAGCCATTGCGCAAACTCATTTGACTTCTCAGCCAG	1104		
QY	1198	ATTGCAAGAGGCTATGCCCTTTCATCGAGCAGAGAACTACATCCACCGAGACCTCCGAGCT	1257		

Db 1105 ATTGCAGAGGCGTCCCTTCATCGAGCAGAGAACTACATCCCGAGAGCTCGAGCT 1164
Qy 1258 GCCAACATCTTGGTCTCTGCATCCCTCGTGTGTAGATGCTGACTTTGGCGTGGCCCGG 1317
Db 1165 GCCAACATCTTGGTCTCTGCATCCCTCGTGTGTAGATGCTGACTTTGGCGTGGCCCGG 1224
Qy 1318 GTCATTGAGGACAGTACAGCGCTCGGGAAGGGCCCAAGTTCCTCCATCAAGTGGACA 1377
Db 1225 GTCATTGAGGACAGTACAGCGCTCGGGAAGGGCCCAAGTTCCTCCATCAAGTGGACA 1284
Qy 1378 GTCCTCTGAAGCCATCACTTTGGCTCTTCCATCAAGTCAAGTCTGCTGCTTTGGT 1437
Db 1285 GTCCTCTGAAGCCATCACTTTGGCTCTTCCATCAAGTCAAGTCTGCTGCTTTGGT 1344
Qy 1438 ATCTCTCTGATGAGATGCTACCTACGCGCGGATCCCTTACCCAGGAGTGTCAAAACCT 1497
Db 1345 ATCTCTCTGATGAGATGCTACCTACGCGCGGATCCCTTACCCAGGAGTGTCAAAACCT 1404
Qy 1498 GAAGTATCGGAGCTCTGAGCGTGGATACCGGATGCCCTCGCCAGAGAACTGCCAGAG 1557
Db 1405 GAAGTATCGGAGCTCTGAGCGTGGATACCGGATGCCCTCGCCAGAGAACTGCCAGAG 1464
Qy 1558 GAGCTCTACAACATCATGATGCTGCTGTGGAACAAACCGTCTCGGAGAGCGGCCGACCTTC 1617
Db 1465 GAGCTCTACAACATCATGATGCTGCTGTGGAACAAACCGTCTCGGAGAGCGGCCGACCTTC 1524
Qy 1618 GATATCATCCAGATGCTGCTGATGACTTCTACAGCGCCACAGAGAGCCAGTACCAACAG 1677
Db 1525 GAATACATCCAGATGCTGCTGATGACTTCTACAGCGCCACAGAGAGCCAGTACCAACAG 1584
Qy 1678 CAGCCATGATAGGAGGACAGGCGAGGCGAGGGGTGCCAGGTGGTGGCT 1729
Db 1585 CAGCCATGATAGGAGGACAGGCGAGGCGAGGGGTGCCAGGTGGTGGCT 1636

RESULT 4

ABL61214
ID ABL61214 standard; DNA; 183 BP.
AC ABL61214;
XX
DT 04-SEP-2002 (first entry)
DE Human nucleotide fragment capable of inactivating HIV Nef protein.
XX
DE Nef protein; fusion protein; virucide; anti-HIV; accessory protein;
KW pathogenicity; diagnosis; AIDS; human; ds.
XX Homo sapiens.
OS
PN DE10109532-C1.
XX
PD 13-JUN-2002.
XX
PF 28-FEB-2001; 2001DE-1009532.
XX
PR 28-FEB-2001; 2001DE-1009532.
XX
PA (GEYE/) GEYER M.
XX (PACK/) FACKLER O.
PI
Geyer M;
XX
WPI; 2002-418264/45.
XX
PT New fusion protein that blocks Nef protein, useful for treatment or
diagnosis of acquired immune deficiency syndrome, has high specificity
and affinity

Claim 12; Page 14; 22pp; German.

This invention describes a novel fusion protein for blocking the Nef

CC protein of human immune deficiency virus (HIV) which comprises: (i)
CC protein domain 1 that binds to a di-leucine (LL) motif; (ii) a
CC linker domain 2 that binds to a Pxxp motif; and (iii) a polypeptide
CC protein between protein domains 1 and 2. The products of the invention
CC have virucide and anti-HIV activity and are capable of neutralising Nef,
CC an accessory protein essential for pathogenicity of HIV-1. The fusion
CC protein of the invention comprises the LL domain of the beta-subunit of
CC the adapter-protein complex Ap-1 and the Pxxp binding SH3 domain of
CC tyrosine kinase Hck, linked through a 60 amino acid peptide. The products
CC of the invention are used for in vitro diagnosis of AIDS and for
CC treatment of AIDS. The LL and Pxxp motifs are specific for Nef, which,
CC unlike HIV protease, has no human homologue, so the fusion protein (which
CC binds Nef with very high affinity) should cause essentially no side
CC effects. This sequence represents a human derived nucleotide fragment
CC used in the construction of the fusion protein of the invention and which
CC contains a PXXP-motif binding motif useful to the invention.

XX Sequence 183 BP; 41 A; 50 C; 56 G; 36 T; 0 other;

Query Match 9.1%; Score 183; DB 24; Length 183;
Best Local Similarity 100.0%; Pred. No. 1.8e-79;
Matches 183; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 337 TCTGAGGACATCATCGTGTGGTGGCTGTATGATTACGAGGCCATTCCACGAGACCTC 396
Db 1 TCTGAGGACATCATCGTGTGGTGGCTGTATGATTACGAGGCCATTCCACGAGACCTC 60
Qy 397 AGCTTCCAGAGGGGGACCATGATGGTGTCTCTAGAGGAATCCGGGAGTGTGGAAGGCT 456
Db 61 AGCTTCCAGAGGGGGACCATGATGGTGTCTCTAGAGGAATCCGGGAGTGTGGAAGGCT 120
Qy 457 CGATCCCTGGCCACCCCGAAGAGGGCTACATCCCAAGCAATATGTCCGCCCGCTTGAC 516
Db 121 CGATCCCTGGCCACCCCGAAGAGGGCTACATCCCAAGCAATATGTCCGCCCGCTTGAC 180
Qy 517 TCT 519
Db 181 TCT 183

RESULT 5

ABL61215
ID ABL61215 standard; DNA; 1416 BP.
XX
AC ABL61215;
XX
DT 04-SEP-2002 (first entry)
DE Rat/human fusion construct capable of inactivating HIV Nef protein.
XX
DE Nef protein; fusion protein; virucide; anti-HIV; accessory protein;
KW pathogenicity; diagnosis; AIDS; rat; human; ds.
XX
OS Rattus sp.
OS Homo sapiens.
OS Synthetic.
XX
PN DE10109532-C1.
XX
PD 13-JUN-2002.
XX
PF 28-FEB-2001; 2001DE-1009532.
XX
PR 28-FEB-2001; 2001DE-1009532.
XX
PA (GEYE/) GEYER M.
XX (PACK/) FACKLER O.
PI
Geyer M;
XX
WPI; 2002-418264/45.

New fusion protein that blocks Nef protein, useful for treatment or

XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI WPI; 2001-488901/53.
XX Human genome-derived single exon nucleic acid probes useful for
DR analyzing gene expression in human cervical epithelial cells -
XX Claim 25; SEQ ID No 13341; 487pp; English.
XX The present invention relates to human single exon nucleic acid probes
CC (SENPs). The present sequence is one such probe. The SENPs are derived
CC from human HeLa cells. The SENPs can be used to produce a single exon
CC microarray, which can be used for measuring human gene expression in a
CC sample derived from human cervical epithelial cells. By measuring gene
CC expression, the probes are therefore useful in grading and/or staging
CC of diseases of the cervix, notably cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;
SQ
Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1352 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 1411
DB 1 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 60
QY 1412 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 1471
DB 61 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 120
QY 1472 TCCCTTACCAGG 1484
DB 121 TCCCTTACCAGG 133
RESULT 14
AAI48728
ID AAI48728 standard; DNA; 171 BP.
XX AAI48728;
XX 17-OCT-2001 (first entry)
XX Probe #17414 used to measure gene expression in human placenta sample.
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX Homo sapiens.
XX WO200157272-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US00663.
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI WPI; 2001-488901/53.
XX Human genome-derived single exon nucleic acid probes useful for
DR analyzing gene expression in human cervical epithelial cells -
XX Claim 25; SEQ ID No 13341; 487pp; English.
XX The present invention relates to human single exon nucleic acid probes
CC (SENPs). The present sequence is one such probe. The SENPs are derived
CC from human HeLa cells. The SENPs can be used to produce a single exon
CC microarray, which can be used for measuring human gene expression in a
CC sample derived from human cervical epithelial cells. By measuring gene
CC expression, the probes are therefore useful in grading and/or staging
CC of diseases of the cervix, notably cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;
SQ
Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1352 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 1411
DB 1 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 60
QY 1412 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 1471
DB 61 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 120
QY 1472 TCCCTTACCAGG 1484
DB 121 TCCCTTACCAGG 133
RESULT 15
AAI09035
ID AAI09035 standard; DNA; 171 BP.
XX AAI09035;
XX 09-OCT-2001 (first entry)
XX Probe #9026 used to measure gene expression in human breast sample.
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX Homo sapiens.
XX WO200157270-A2.
XX 09-AUG-2001.
XX 29-JAN-2001; 2001WO-US00661.
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression
XX in a human breast -
XX Claim 25; SEQ ID No 9026; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes.

DR WPI; 2001-48897/53.
XX Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human placenta -
XX Claim 25; SEQ ID No 17414; 654pp; English.
XX The present invention relates to single exon nucleic acid probes (SENPs).
CC The present sequence is one such probe. The probes are useful for
CC producing a microarray for predicting, measuring and displaying gene
CC expression in samples derived from human placenta. The probes are useful
CC for antenatal diagnosis of human genetic disorders.
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;
SQ
Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1352 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 1411
DB 1 GGGCCAAAGTTCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 60
QY 1412 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 1471
DB 61 TCAAGTCAGACGTCTGGTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGCGCGGA 120
QY 1472 TCCCTTACCAGG 1484
DB 121 TCCCTTACCAGG 133
RESULT 15
AAI09035
ID AAI09035 standard; DNA; 171 BP.
XX AAI09035;
XX 09-OCT-2001 (first entry)
XX Probe #9026 used to measure gene expression in human breast sample.
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX Homo sapiens.
XX WO200157270-A2.
XX 09-AUG-2001.
XX 29-JAN-2001; 2001WO-US00661.
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression
XX in a human breast -
XX Claim 25; SEQ ID No 9026; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes.

The present sequence is one such probe. The probes are useful for measuring human gene expression in a human breast sample, where the probe hybridises at high stringency to a nucleic acid expressed in the human breast. The probes are useful for predicting, diagnosing, grading, staging, monitoring and prognosing diseases of the human breast, particularly those diseases with polygenic aetiology. The diseases include: breast cancer, disorders of development, inflammatory diseases of the breast, fibrocystic changes, proliferative breast disease and non-carcinoma tumours.

Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.

Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;

	Query Match	6.6%	Score 133;	DB 22;	Length 171;
	Best Local Similarity	100.0%;	Pred. No. 7.1e-55;		
	Matches 133;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1352	GGGCCAAGTTC	CCCCATCAAGTGGACAGCTCCTCAAGCCATCAACTTTGGCTCCTTCACCA	1411	
Db	1	GGGCCAAGTTC	CCCCATCAAGTGGACAGCTCCTCAAGCCATCAACTTTGGCTCCTTCACCA	60	
QY	1412	TCAAGTCAGACGCTCTGGTCTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGGCCGGA	1471		
Db	61	TCAAGTCAGACGCTCTGGTCTCTTTGGTATCCTGCTGATGGAGATCGTCACCTACGGCCGGA	120		
QY	1472	TCCCTTACCCAGG	1484		
Db	121	TCCCTTACCCAGG	133		

Search completed: July 4, 2003, 02:31:01
Job time : 458 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 00:38:48 ; Search time 5238 Seconds
(without alignments)
11195.524 Million cell updates/sec

Title: us-10-007-010-3
Perfect score: 2015
Sequence: 1 cggagcagcgaagatgagg.....atataaatcaagtcttacg 2015

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2054640 seqs, 14551402878 residues

Word size : 0

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :

GenEmbl:.*
1: gb_ba.*
2: gb_htg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pt.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*
15: em_ba.*
16: em_fun.*
17: em_hum.*
18: em_in.*
19: em_mu.*
20: em_om.*
21: em_or.*
22: em_ov.*
23: em_pat.*
24: em_ph.*
25: em_pl.*
26: em_ro.*
27: em_sts.*
28: em_un.*
29: em_vi.*
30: em_htg_hum.*
31: em_htg_inv.*
32: em_htg_other.*
33: em_htg_mus.*
34: em_htg_pln.*
35: em_htg_rpd.*
36: em_htg_mam.*
37: em_htg_vrt.*
38: em_sy.*
39: em_htgo_hum.*
40: em_htgo_mus.*
41: em_htgo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	2015	100.0	2015	6	AX334501	AX334501 Sequence
2	2015	100.0	2015	9	HUMHCKA	M16591 Human hemop
3	1606	79.7	2044	9	BC014435	BC014435 Homo sapi
4	1555	77.2	2105	9	AK026432	AK026432 Homo sapi
5	1552	77.0	1926	9	HUMHCKB	M16592 Human hemop
6	423	21.0	4507	9	HS7411	X58743 H.sapiens H
7	303	15.0	111694	9	HS7836N17	AL049539 Human DNA
8	274	13.6	333	11	G06122	G06122 human STS W
9	182	9.0	5268	9	HSCKE69	X58741 H.sapiens H
10	157	7.8	2167	9	HSCKE11	X58742 H.sapiens H
11	112	5.6	25010	9	AL353092	AL353092 Human DNA
12	107	5.3	1515	9	MFA320181	AJ320181 Macaca fa
13	82	4.1	366	11	G25924	G25924 human STS E
14	77	3.8	958	9	HUMHCK	M73233 Human hemop
15	76	3.8	10348	9	AB071605	AB071605 Homo sapi
16	68	3.4	1911	6	AX401935	AX401935 Sequence
17	68	3.4	1911	10	RATHCTK	M83666 Rattus norv
18	68	3.4	1911	10	S74141	S74141 hck-tyrosin
19	68	3.4	1940	10	RRCKMR	X62345 R.rattus hc
20	65	3.2	1926	9	HUMHCKB	M16592 Human hemop
21	56	2.8	86196	9	AL592046	AL592046 Human DNA
22	56	2.8	16913	2	AC031980	AC031980 Homo sapi
23	47	2.3	1960	10	MMHCK	Y00487 Mouse hck g
24	47	2.3	2002	10	MUSBMK	J03023 Murine macr
25	47	2.3	2104	10	BC010478	BC010478 Mus muscu
26	47	2.3	200329	10	AC078911	AC078911 Mus muscu
27	47	2.3	208718	2	AL807380	AL807380 Mus muscu
28	32	1.6	2298	5	AF321110	AF321110 Salmo sal
29	32	1.6	211607	2	AC094844	AC094844 Rattus no
30	30	1.5	145542	2	AC087618	AC087618 Homo sapi
31	30	1.5	191622	2	AC022239	AC022239 Homo sapi
32	29	1.4	301	11	HS180113S	AL031189 H.sapiens
33	29	1.4	1965	9	HS804186	AL832875 Homo sapi
34	29	1.4	2210	9	BC007371	BC007371 Homo sapi
35	29	1.4	2235	9	HSBITPTK	Z33998 H.sapiens m
36	29	1.4	2251	9	BC032413	BC032413 Homo sapi
37	29	1.4	2608	9	S76617	S76617 blk=protein
38	29	1.4	211607	2	AC094844	AC094844 Rattus no
39	28	1.4	1518	9	HUMLYNTK	M79321 Human Lyn B
40	28	1.4	2298	9	HUMLYN	M16038 Human Lyn m
41	28	1.4	184349	9	AC046176	AC046176 Homo sapi
42	27	1.3	180424	2	AC090496	AC090496 Mus muscu
43	26	1.3	72	14	ALFRSGB	J02351 Rous sarcom
44	26	1.3	1016	14	REASV3	V01167 Avian sarco
45	26	1.3	1578	14	S37068	S37068 src (tsuPl)

ALIGNMENTS

RESULT 1
AX334501
LOCUS AX334501
DEFINITION Sequence 5010 from Patent WO0194629.
ACCESSION AX334501
VERSION AX334501.1 GI:18125220
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Young, P. E., Augustus, M., Carter, K. C., Ebner, R., Endress, G.,
Horrigan, S., Soppet, D. R. and Weaver, Z.
TITLE Cancer gene determination and therapeutic screening using signature

gene sets									
JOURNAL	Patent: WO 0194629-A 5010 13-DEC-2001;								
FEATURES	Avalon Pharmaceuticals (US)								
source	Location/Qualifiers								
	1..2015								
	/organism="Homo sapiens"								
BASE COUNT	512 a	540 c	580 g	383 t					
ORIGIN									
Query Match	100.0%; Score 2015; DB 6; Length 2015;								
Best Local Similarity	100.0%; Pred. No. 0;								
Matches 2015; Conservative	0; Mismatches 0; Indels 0; Gaps 0;								
Qy	1	CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGAGATGA	60						
Db	1	CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGAGATGA	60						
Qy	61	AGACGATGACGACGATGGCTCTGAGGGGACCTCAGGGGCTGCCGAGCTGGGGGGCGCTC	120						
Db	61	AGACGATGACGACGATGGCTCTGAGGGGACCTCAGGGGCTGCCGAGCTGGGGGGCGCTC	120						
Qy	121	AAGCTGCGAGGATCGGGCTGCCCGGAGACGAGGAGCGGGCGCCAGGATGGGGTCGATG	180						
Db	121	AAGCTGCGAGGATCGGGCTGCCCGGAGACGAGGAGCGGGCGCCAGGATGGGGTCGATG	180						
Qy	181	AAGTCCAAAGTTCTCCAGGTCGGAGGCAATACATCTCAAAACTGAAACACAGCGCCAGC	240						
Db	181	AAGTCCAAAGTTCTCCAGGTCGGAGGCAATACATCTCAAAACTGAAACACAGCGCCAGC	240						
Qy	241	CCACACTGTCTGTAGCTGCCGGATCCCACTCCACCATCAAGCCGGGGCTTAATAGC	300						
Db	241	CCACACTGTCTGTAGCTGCCGGATCCCACTCCACCATCAAGCCGGGGCTTAATAGC	300						
Qy	301	CACACAGCAACACACAGGAATCAGGAGGAGCGAGTCTTGAGGACATCATCGTGGTTGCC	360						
Db	301	CACAACAGCAACACACAGGAATCAGGAGGAGCGAGTCTTGAGGACATCATCGTGGTTGCC	360						
Qy	361	CTGTATGATTACGAGGCCATTACACACAGAGCTCAGCTTCCAGAAAGGGGACACAGATG	420						
Db	361	CTGTATGATTACGAGGCCATTACACAGAGCTCAGCTTCCAGAAAGGGGACACAGATG	420						
Qy	421	GTGCTCTTAGAGGAATCGGGGAGTGGTGAAGGCTCGATCCCTGGCCACCCGGAAGAG	480						
Db	421	GTGCTCTTAGAGGAATCGGGGAGTGGTGAAGGCTCGATCCCTGGCCACCCGGAAGAG	480						
Qy	481	GGCTACATCCCAAGCAACTATGTGCCCGGTTGACTCTCTGGAGACAGAGAGTGGTTT	540						
Db	481	GGCTACATCCCAAGCAACTATGTGCCCGGTTGACTCTCTGGAGACAGAGAGTGGTTT	540						
Qy	541	TTCAAGGGCATCAGCCGGAAGGAGCGAGCGCAACTGCTGGCTCCCGCAACATGCTG	600						
Db	541	TTCAAGGGCATCAGCCGGAAGGAGCGAGCGCAACTGCTGGCTCCCGCAACATGCTG	600						
Qy	601	GGCTCTTTCATGATCCGGGATAGCGAGACCACTTAAGGAAGTACTCTTTGTCCGTCCGA	660						
Db	601	GGCTCTTTCATGATCCGGGATAGCGAGACCACTTAAGGAAGTACTCTTTGTCCGTCCGA	660						
Qy	661	GACTACGACCTCTGGCAGGAGATACCGTGAACATTTACAAGATCCGACCTTGGACAAC	720						
Db	661	GACTACGACCTCTGGCAGGAGATACCGTGAACATTTACAAGATCCGACCTTGGACAAC	720						
Qy	721	GGGGCTTTCATATATCCCCCGAAGCACCTTCAGCACTCTGCAGGAGCTGGTGACCAC	780						
Db	721	GGGGCTTTCATATATCCCCCGAAGCACCTTCAGCACTCTGCAGGAGCTGGTGACCAC	780						
Qy	781	TACAAGAGGGGAACGACGGGCTCTGCGAGAAACTGTGCGTGCCTGCATGCTTCCAAG	840						
Db	781	TACAAGAGGGGAACGACGGGCTCTGCGAGAAACTGTGCGTGCCTGCATGCTTCCAAG	840						
Qy	841	CCCCAGAGCCTTGGGAGAAGATGCTGGGAGATCCCTCGGGAATCCCTCAAGCTGGAG	900						
Db	841	CCCCAGAGCCTTGGGAGAAGATGCTGGGAGATCCCTCGGGAATCCCTCAAGCTGGAG	900						

QY	901	AAGAACTTGGAGCTGGCAGTTTGGGAAGTCTGGATGGCCACCTACAACAGCACACC	960
Db	901	AAGAACTTGGAGCTGGCAGTTTGGGAAGTCTGGATGGCCACCTACAACAGCACACC	960
QY	961	AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCCCTTCCTGGCAGAG	1020
Db	961	AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCCCTTCCTGGCAGAG	1020
QY	1021	GCCAACTGATGAAACTCTGCAGCATGACAAGCTGGTCAAACTTCATCGGTGGTGCACC	1080
Db	1021	GCCAACTGATGAAACTCTGCAGCATGACAAGCTGGTCAAACTTCATCGGTGGTGCACC	1080
QY	1081	AAGAGCCCATCTACATCATCATCAGGAGTTTCATGGCCAAAGAGCTTGTGACTTTCG	1140
Db	1081	AAGAGCCCATCTACATCATCATCAGGAGTTTCATGGCCAAAGAGCTTGTGACTTTCG	1140
QY	1141	AAAAGTATGAGGGCAGCAGCAGCCATTGCCAAACTCATTTGACTTCTCAGCCAGATT	1200
Db	1141	AAAAGTATGAGGGCAGCAGCAGCCATTGCCAAACTCATTTGACTTCTCAGCCAGATT	1200
QY	1201	GCAGAAGGATGCGCTTCATCAGCAGAGAGAACTACATCCAGAGACCTCCAGCTGCC	1260
Db	1201	GCAGAAGGATGCGCTTCATCAGCAGAGAGAACTACATCCAGAGACCTCCAGCTGCC	1260
QY	1261	AACATCTTGGTCTCTGCATCCCTCGTGTGAAGATTGCTGACTTTGGCTTGGCCCGGGTC	1320
Db	1261	AACATCTTGGTCTCTGCATCCCTCGTGTGAAGATTGCTGACTTTGGCTTGGCCCGGGTC	1320
QY	1321	ATTGAGGACAGGATGACAGGCTCGGGAAGGGGCAAGTTCCCATCAAGTGGACAGCT	1380
Db	1321	ATTGAGGACAGGATGACAGGCTCGGGAAGGGGCAAGTTCCCATCAAGTGGACAGCT	1380
QY	1381	CCTGAAGCCATCAACTTTGGCTCCTTACCATCAAGTCAAGTCTGGTCTTGGTATC	1440
Db	1381	CCTGAAGCCATCAACTTTGGCTCCTTACCATCAAGTCAAGTCTGGTCTTGGTATC	1440
QY	1441	CTGCTGATGGAGATCGTACCTTACGGCGGATCCCTTACCCAGGAGTGTCAAACTGAA	1500
Db	1441	CTGCTGATGGAGATCGTACCTTACGGCGGATCCCTTACCCAGGAGTGTCAAACTGAA	1500
QY	1501	GTGATCCGAGCTCTGAGGCTGGATACCGGATCGCTCGCCAGAGAACTGCCAGAGAG	1560
Db	1501	GTGATCCGAGCTCTGAGGCTGGATACCGGATCGCTCGCCAGAGAACTGCCAGAGAG	1560
QY	1561	CTCTAACAATCATGATGCGTCTGGAATAAAACCGTCCGGAGGAGCGCCGACCTTCGAA	1620
Db	1561	CTCTAACAATCATGATGCGTCTGGAATAAAACCGTCCGGAGGAGCGCCGACCTTCGAA	1620
QY	1621	TACATCCAGAGTGTGCTGATGACTTCTACAGGGCCACAGAGAGCCAGTACCAACAGCAG	1680
Db	1621	TACATCCAGAGTGTGCTGATGACTTCTACAGGGCCACAGAGAGCCAGTACCAACAGCAG	1680
QY	1681	CCATGATAGGAGGAGCAGGCGGAGGGGTGCCAGAGTGGTGGCTCGAAGTGGCT	1740
Db	1681	CCATGATAGGAGGAGCAGGCGGAGGGGTGCCAGAGTGGTGGCTCGAAGTGGCT	1740
QY	1741	CCAGACCATTCGCCAGGCCCCACACCCCTTCTTCTCAGAGACACCCACCTCGCTTC	1800
Db	1741	CCAGACCATTCGCCAGGCCCCACACCCCTTCTTCTCAGAGACACCCACCTCGCTTC	1800
QY	1801	AGCCACAGTTTCTCATCTGTCCAGTGGTGGTGGACTGGAAATCTCTTTTGGACTC	1860
Db	1801	AGCCACAGTTTCTCATCTGTCCAGTGGTGGTGGACTGGAAATCTCTTTTGGACTC	1860
QY	1861	TTGCAATCCACAATCTGACATTTCTCAGGAAGCCCCCAAGTTGATATTTCTATTTCCCTGGA	1920
Db	1861	TTGCAATCCACAATCTGACATTTCTCAGGAAGCCCCCAAGTTGATATTTCTATTTCCCTGGA	1920
QY	1921	ATGGTTGGATTTAGTTACAGCTGTGATTTGGAAGGGAACCTTTCAAAATAGTGAATGA	1980
Db	1921	ATGGTTGGATTTAGTTACAGCTGTGATTTGGAAGGGAACCTTTCAAAATAGTGAATGA	1980

QY 1981 ATATTAAATAAAGATATAAATCAAGTCTTACG 2015
|||||
Db 1981 ATATTAAATAAAGATATAAATCAAGTCTTACG 2015

RESULT 2

HUMHCKA
LOCUS
DEFINITION Human hemopoietic cell protein-tyrosine kinase (HCK) gene, complete cds, clone lambda-a2/1a.

ACCESSION M16591

VERSION M16591.1

KEYWORDS GI:183911

SOURCE Human hemopoietic cell, cDNA to mRNA, clone lambda-a2/1a.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

1 (bases 1 to 2015)

Quintrell,N., Lebo,M.O., and Rowley,J.D.

Beau,M.M., Diaz,M.O., and Rowley,J.D.

Identification of a human gene (HCK) that encodes a

protein-tyrosine kinase and is expressed in hemopoietic cells

Mol. Cell. Biol. 7 (6), 2267-2275 (1987)

87257942

3496523

FEATURES

Location/Qualifiers

1..2015

/organism="Homo sapiens"

/db_xref="taxon:9606"

/map="20q11-q12"

1..2015

/gene="HCK"

<1..2015

/gene="HCK"

/product="HCK mRNA"

169..1686

/gene="HCK"

/note="protein-tyrosine kinase"

/codon_start=1

/protein_id="AA52643.1"

/db_xref="GI:306832"

/db_xref="GDB:600-119-303"

/translation="MGSMSKFLQVGGNFTSKTSTSPHCPVYVPDPTSTIKPQNS

HNSNTPGIREAGEDIIIVVLDYEAIHEDLSFKQDMVLEESGEWVKARSLATR

KEGYTPSNVAVDLSLETFEFGISRKDAEROLLAPGNMLGSMFMRDSTTKGSYS

LSVRDYPDQGGTYVHYKIRLDNGFVISPRESFSLQELVDHYKNGNDLCKLWS

PCMSKPORPEKDWELPRESLKEKLGAGQGEVMMATYNKHTVAVAKMPGSM

SVEAFLEAANVMTLOHDKLVKLHVAVTKEPIYIITEFMAGSLDLFLKSDGSKQL

PKLIDFSAIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLRVIEDNEYTA

REGAFPIKWPENAFINFGSFTIKSDVMSFGILLMEIVTYGRIPYPMSPNPEVIRALE

RGYRMPRPENPEELYNIMRCWKNRPERPTFEVIOQLDDFVYATESQYQQQP"

BASE COUNT 512 a 540 c 580 g 383 t

ORIGIN 130 bp upstream of BamHI site; chromosome 20q11-q12.

Query Match 100.0%; Score 2015; DB 9; Length 2015;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2015; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGAGGCACGGAAGATGAGGAGATGATCAGGAGGATGATGAAGTGAAGAGGAGATGA 60

|||||

Db 1 CGAGGCACGGAAGATGAGGAGATGATCAGGAGGATGATGAAGTGAAGAGGAGATGA 60

|||||

QY 61 AGACGATGACGAGATGGCTCTGAGGGACCTCAGGGCTCGCGAGCTGGGGGCGCTC 120

|||||

Db 61 AGACGATGACGAGATGGCTCTGAGGGACCTCAGGGCTCGCGAGCTGGGGGCGCTC 120

|||||

QY 121 AAGCTCGGAGATCGGGCTGCCCGGAGACGAGGAGCGGGCGCCAGGATGGGTTCGATG 180

|||||

Db 121 AAGCTCGGAGATCGGGCTGCCCGGAGACGAGGAGCGGGCGCCAGGATGGGTTCGATG 180

|||||

QY 181 AAGTCCAAAGTTCTCCAGTCTGGAGGCAATACATTTCTCAAAACTGAAACACGCCAGC 240

|||||

Db 181 AAGTCCAAAGTTCTCCAGTCTGGAGGCAATACATTTCTCAAAACTGAAACACGCCAGC 240

QY 241 CCACACTGCTCTGTACGTGCGGATCCACATCCACATCAAGCCGGGCTTAATAGC 300
|||||
Db 241 CCACACTGCTCTGTACGTGCGGATCCACATCCACATCAAGCCGGGCTTAATAGC 300
|||||
QY 301 CACAACAGCAACACACAGGAATCAGGAGGAGGCTCTGAGGACATCATCTGTGGTGGC 360
|||||
Db 301 CACAACAGCAACACACAGGAATCAGGAGGAGGCTCTGAGGACATCATCTGTGGTGGC 360
|||||
QY 361 CTGTATGATTACGAGGCCATTCCACAGAGACCTCAGCTTCCAGAAAGGGGACACAGATG 420
|||||
Db 361 CTGTATGATTACGAGGCCATTCCACAGAGACCTCAGCTTCCAGAAAGGGGACACAGATG 420
|||||
QY 421 GTGCTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGCCACCACCGGAAGAG 480
|||||
Db 421 GTGCTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGCCACCACCGGAAGAG 480
|||||
QY 481 GGCTACATCCCAAGCAACTATGTCGCCCGCTTACTCTCTGGAGACAGAGAGTGGTTT 540
|||||
Db 481 GGCTACATCCCAAGCAACTATGTCGCCCGCTTACTCTCTGGAGACAGAGAGTGGTTT 540
|||||
QY 541 TTCAAGGGCATCAGCCGGAAGGACGAGAGCGCAACTGCTGCTCCCGCAACATGCTG 600
|||||
Db 541 TTCAAGGGCATCAGCCGGAAGGACGAGAGCGCAACTGCTGCTCCCGCAACATGCTG 600
|||||
QY 601 GGCTCTCTTACATGATCCGGGATAGCAGACCACTAAAGGAAGCTTACTTCTTCCGTCGA 660
|||||
Db 601 GGCTCTCTTACATGATCCGGGATAGCAGACCACTAAAGGAAGCTTACTTCTTCCGTCGA 660
|||||
QY 661 GACTACGACCTCGGAGGAGATACCGTGAACATATTACAAGATCCGGACCTTGACAAAC 720
|||||
Db 661 GACTACGACCTCGGAGGAGATACCGTGAACATATTACAAGATCCGGACCTTGACAAAC 720
|||||
QY 721 GGGGGCTTACATATCCCGCAAGCACTTCCAGCAGCTGCGAGAGCTGGTGACAC 780
|||||
Db 721 GGGGGCTTACATATCCCGCAAGCACTTCCAGCAGCTGCGAGAGCTGGTGACAC 780
|||||
QY 781 TACAAGAGGGGAACGACGGCTCTGCCAGAACTTCTGGTGGCCCTGCATGCTTCCCAAG 840
|||||
Db 781 TACAAGAGGGGAACGACGGCTCTGCCAGAACTTCTGGTGGCCCTGCATGCTTCCCAAG 840
|||||
QY 841 CCCAGAGCTTGGGAGAAAGATGCTGGGAGATCCCTCGGGAATCCCTCAAGCTGGAG 900
|||||
Db 841 CCCAGAGCTTGGGAGAAAGATGCTGGGAGATCCCTCGGGAATCCCTCAAGCTGGAG 900
|||||
QY 901 AAGAACTTGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAG 960
|||||
Db 901 AAGAACTTGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAGTGGGAG 960
|||||
QY 961 AAGTGGCAGTGAAGAGGATGAAGCCAGGAGGATGCTGGTGGAGGCTTCTCTGGCAGAG 1020
|||||
Db 961 AAGTGGCAGTGAAGAGGATGAAGCCAGGAGGATGCTGGTGGAGGCTTCTCTGGCAGAG 1020
|||||
QY 1021 GCCAAGCTGATGAAACTCTGCAGCATGACAAGCTGGTGAACCTTATGCGGTGGTCAAC 1080
|||||
Db 1021 GCCAAGCTGATGAAACTCTGCAGCATGACAAGCTGGTGAACCTTATGCGGTGGTCAAC 1080
|||||
QY 1081 AAGGAGCCCATCTACATCATCAGGAGTTCATGCCAAAGAAAGCTTGTCTGGAGCTTCTG 1140
|||||
Db 1081 AAGGAGCCCATCTACATCATCAGGAGTTCATGCCAAAGAAAGCTTGTCTGGAGCTTCTG 1140
|||||
QY 1141 AAAAGTGTATGAGGCGACAAAGCAGCCATTGCCAAAACCTTACTTCTCAGCCAGATT 1200
|||||
Db 1141 AAAAGTGTATGAGGCGACAAAGCAGCCATTGCCAAAACCTTACTTCTCAGCCAGATT 1200
|||||
QY 1201 GCAGAGGCTTCTTATCAGGAGGAGGAACTACATCCAGGAGACCTCCAGAGCTGCC 1260
|||||
Db 1201 GCAGAGGCTTCTTATCAGGAGGAGGAACTACATCCAGGAGACCTCCAGAGCTGCC 1260
|||||
QY 1261 AACATCTTGTCTCTGATCCCTGGTGTGAAGATTGCTGCTTGTGCTGGCCCGGGTC 1320
|||||
Db 1261 AACATCTTGTCTCTGATCCCTGGTGTGAAGATTGCTGCTTGTGCTGGCCCGGGTC 1320
|||||

```
QY 1321 ATTGAGGACACGAGTACACGGCTCGGGAAGGGCCCAAGTTCCTCCATCAAGTGGACAGCT 1380
Db 1321 ATTGAGGACACGAGTACACGGCTCGGGAAGGGCCCAAGTTCCTCCATCAAGTGGACAGCT 1380
QY 1381 CCTGAAGCCATCAACTTTGGCTCTTCCACCATCAAGTCAGACGCTCTGGTCTTGGTATC 1440
Db 1381 CCTGAAGCCATCAACTTTGGCTCTTCCACCATCAAGTCAGACGCTCTGGTCTTGGTATC 1440
QY 1441 CTGCTGATGGAGATCGTCACTAGCGCGGATCCCTTACCAGGAGTGTCAAAACCCCTGAA 1500
Db 1441 CTGCTGATGGAGATCGTCACTAGCGCGGATCCCTTACCAGGAGTGTCAAAACCCCTGAA 1500
QY 1501 GTGATCCGAGCTCTGGAGCTGGATACCGGATCGCTCGCCACAGAACTGCCACAGAGAG 1560
Db 1501 GTGATCCGAGCTCTGGAGCTGGATACCGGATCGCTCGCCACAGAACTGCCACAGAGAG 1560
QY 1561 CTCTACACATCATGATGCGCTGCTGGAAAACCGTCCGGAGGAGCGCGACCTTCGAA 1620
Db 1561 CTCTACACATCATGATGCGCTGCTGGAAAACCGTCCGGAGGAGCGCGACCTTCGAA 1620
QY 1621 TACATCCAGAGTGTCTGGATGACTTCTACACGGCCACAGAGAGCCAGTACCAACAGCAG 1680
Db 1621 TACATCCAGAGTGTCTGGATGACTTCTACACGGCCACAGAGAGCCAGTACCAACAGCAG 1680
QY 1681 CCATGATAGGAGGACACAGGCGAGGGGTGCCAGGTGTGGCTCGAAGTGGCT 1740
Db 1681 CCATGATAGGAGGACACAGGCGAGGGGTGCCAGGTGTGGCTCGAAGTGGCT 1740
QY 1741 CCAGCACCATCCGCGAGGGCCACACCCCTTCTACTCCAGACACCCACCTCGCTTC 1800
Db 1741 CCAGCACCATCCGCGAGGGCCACACCCCTTCTACTCCAGACACCCACCTCGCTTC 1800
QY 1801 AGCCACAGTTTCTCATCTGCTCCAGTGGGTGGAGTGGAGTGGAAATCTCTTTTGAATC 1860
Db 1801 AGCCACAGTTTCTCATCTGCTCCAGTGGGTGGAGTGGAGTGGAAATCTCTTTTGAATC 1860
QY 1861 TTGAATCCCAATCTGACATCTCAGAGAGCCCCCAAGTGTATATTTCTTCTGGA 1920
Db 1861 TTGAATCCCAATCTGACATCTCAGAGAGCCCCCAAGTGTATATTTCTTCTGGA 1920
QY 1921 ATGTTGGATTTTATGTTACAGCTGTGATTTGGAGGAGAACTTCAAAATAGTGAATGA 1980
Db 1921 ATGTTGGATTTTATGTTACAGCTGTGATTTGGAGGAGAACTTCAAAATAGTGAATGA 1980
QY 1981 ATATTTAAATGAATATTAATCAAGTCTTAGG 2015
Db 1981 ATATTTAAATGAATATTAATCAAGTCTTAGG 2015

RESULT 3
BC014435
LOCUS Homo sapiens, clone MGC:22922 IMAGE:4855747, mRNA, complete cds.
ACCESSION BC014435
VERSION BC014435.1 GI:15680176
KEYWORDS MGC.
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 2044)
Strausberg, R.
Direct Submission
Submitted (17-SEP-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA.
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabps-r@mail.nih.gov
Tissue Procurement: Louis Staudt
cDNA Library Preparation: Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
```

DNA Sequencing by: Genome Sequence Centre,
BC Cancer Agency, Vancouver, BC, Canada
info@bcsc.bc.ca
Steven Jones, Jennifer Asano, Ian Bosdet, Yaron Butterfield,
Susanna Chan, Readman Chiu, Chris Fjell, Erin Garland, Ran Guin,
Leticia Hsiao, Martin Krzywinski, Reta Kutsche, Oliver Lee, Soo
Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven
Ness, Pawan Pandoh, Anna-Liisa Prabhu, Parvaneh Saeedi, Jacqueline
Schein, Duane Smailus, Michael Smith, Lorraine Spence, Jeff Stott,
Michael Thorne, Miranada Tsai, Natasja van den Bosch, Jill Vardy,
George Yang, Scott Zuyderduyn, Marco Marra.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 34 Row: d Column: 12
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 10439295.

FEATURES

Location/Qualifiers
1..2044
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="MGC:22922 IMAGE:4855747"
/tissue_type="Primary B-Cells from Tonsils"
/clone_lib="NIH_MGC_48"
/lab_host="DH10B-R"
/note="Vector: pOTB7"
187..1704
/codon_start=1
/product="Unknown (protein for MGC:22922)"
/protein_id="AAH14435.1"
/db_xref="GI:15680177"

CDS

BASE COUNT 523 a 572 c 566 g 383 t
ORIGIN
Query Match 79.7%; Score 1606; DB 9; Length 2044;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1826; Conservative 0; Mismatches 2; Indels 1; Gaps 1;
QY 178 ATGAAGTCCAAAGTTCCTCCAGTCCGAGGCAATACATTCCTCAAAACCTGAACACGCGCC 237
Db 196 ATGAAGTCCAAAGTTCCTCCAGTCCGAGGCAATACATTCCTCAAAACCTGAACACGCGCC 255
QY 238 AGCCCAACACTGTCTGTGTACGTGCGGATCCACATCCACATCAAGCCGGGCGCTAAT 297
Db 256 AGCCCAACACTGTCTGTGTACGTGCGGATCCACATCCACATCAAGCCGGGCGCTAAT 315
QY 298 AGCCCAACACTGTCTGTGTACGTGCGGATCCACATCCACATCAAGCCGGGCGCTAAT 357
Db 316 AGCCCAACACTGTCTGTGTACGTGCGGATCCACATCCACATCAAGCCGGGCGCTAAT 375
QY 358 GCCTGTATGATTACGAGGCCATTCACACGAAGACCTCAGCTTCCACAGGGGAGCCAG 417
Db 376 GCCTGTATGATTACGAGGCCATTCACACGAAGACCTCAGCTTCCACAGGGGAGCCAG 435
QY 418 ATGTGGTCTCTAGAGGAATCCGGGAGTGTGGAGGCTCGATCCCTGCCACCCGGAAG 477
Db 436 ATGTGGTCTCTAGAGGAATCCGGGAGTGTGGAGGCTCGATCCCTGCCACCCGGAAG 495
QY 478 GAGGCTTACATCCCAAGCAACTATGTCGCCGCTTGTGACTCTCTGGAGACAGAGAGTGG 537
Db 496 GAGGCTTACATCCCAAGCAACTATGTCGCCGCTTGTGACTCTCTGGAGACAGAGAGTGG 555
QY 538 TTTTCAAGGGCATCAGCCGGAAGACGACAGAGCGCCAACTGCTGGCTCCCGGCAACATG 597

Db 556 TTTTCAAGGGCATCAGCGGAAGGACGACGAGCGCCAACTGCTGGCTCCCGCAACATG 615
QY 598 CTGGGCTCTTCATCATCGGATAGCAGACCACTAAAGAACTACTCTTTGTCGGTG 657
Db 616 TTTTTCATGATCCGGATAGCAGACCACTAAAGAACTACTCTTTGTCGGTG 675
QY 658 CGAGACTACGACCTCGGAGGAGATACCGTGAACATTAAGATCCGACCCCTGGAC 717
Db 676 CGAGACTACGACCTCGGAGGAGATACCGTGAACATTAAGATCCGACCCCTGGAC 735
QY 718 AACGGGGCTTCTACATATCCCGGAAGACCTTTCAGACTCTGAGGAGCTGGTGGAC 777
Db 736 AACGGGGCTTCTACATATCCCGGAAGACCTTTCAGACTCTGAGGAGCTGGTGGAC 795
QY 778 CACTACAAGAGGGGAGCGGCTCTGCAGAACTGTCGGTCCCTGCATGCTTCC 837
Db 796 CACTACAAGAGGGGAGCGGCTCTGCAGAACTGTCGGTCCCTGCATGCTTCC 855
QY 838 AAGCCCCAAGAGCTTGGGAGAAAGATGCTGGGAGATCCCTCGGAATCCCTCAAGCTG 897
Db 856 AAGCCCCAAGAGCTTGGGAGAAAGATGCTGGGAGATCCCTCGGAATCCCTCAAGCTG 915
QY 898 GAGAAGAACTTGGAGCTGGGAGTGGGGAAGTCTGGATGGCCACTACAACAAGAC 957
Db 916 GAGAAGAACTTGGAGCTGGGAGTGGGGAAGTCTGGATGGCCACTACAACAAGAC 975
QY 958 ACCAAGTGGCAGTGAAGACCATGAAGCCAGGAGCATGTCGGTGGAGGCTTCTCGCA 1017
Db 976 ACCAAGTGGCAGTGAAGACCATGAAGCCAGGAGCATGTCGGTGGAGGCTTCTCGCA 1035
QY 1018 GAGGCCAAGCTGATGAAAACCTCTGCAGCATGACAAGCTGGTCAAACTTCATCGCGTGGTC 1077
Db 1036 GAGGCCAAGCTGATGAAAACCTCTGCAGCATGACAAGCTGGTCAAACTTCATCGCGTGGTC 1095
QY 1078 ACCAAGGAGCCCTACATCATCAGGAGTTCATGGCCAAAGAGCTGCTGGACTTT 1137
Db 1096 ACCAAGGAGCCCTACATCATCAGGAGTTCATGGCCAAAGAGCTGCTGGACTTT 1155
QY 1138 CTGAAAGCTGATGAGGCGAGCAAGCAGCATTCGCAAACTTCATGACTCTCAGCCAG 1197
Db 1156 CTGAAAGCTGATGAGGCGAGCAAGCAGCATTCGCAAACTTCATGACTCTCAGCCAG 1215
QY 1198 ATTGCAAGGAGCTGGCTTTCATCAGCAGAGGAACTACATCCACCGAGACCTCCGAGCT 1257
Db 1216 ATTGCAAGGAGCTGGCTTTCATCAGCAGAGGAACTACATCCACCGAGACCTCCGAGCT 1275
QY 1258 GCCACATCTTGGTCTCTGCATCCCTGGTGTGAAGTTCGCTGACTTTGGCTGGCCCGG 1317
Db 1276 GCCACATCTTGGTCTCTGCATCCCTGGTGTGAAGTTCGCTGACTTTGGCTGGCCCGG 1335
QY 1318 GTCAATTGAGGACACGAGTACACGCTCGGGAAGGCGCAAGTTCCCCATCAAGTGAC 1377
Db 1336 GTCAATTGAGGACACGAGTACACGCTCGGGAAGGCGCAAGTTCCCCATCAAGTGAC 1395
QY 1378 GCTCTGAAGCCATCAACTTTGGCTCTTCCATCAAGTCAAGTCAAGTCAAGTCAAGT 1437
Db 1396 GCTCTGAAGCCATCAACTTTGGCTCTTCCATCAAGTCAAGTCAAGTCAAGTCAAGT 1455
QY 1438 ATCTGCTGATGAGAGCTGCTACCTACGCGGATCCCTTACCCAGGATGTCNAACCT 1497
Db 1456 ATCTGCTGATGAGAGCTGCTACCTACGCGGATCCCTTACCCAGGATGTCNAACCT 1515
QY 1498 GAAGTATCCGAGCTGGAGCTGGATACCGGATGCTCGCCAGAGAACTGCCACAG 1557
Db 1516 GAAGTATCCGAGCTGGAGCTGGATACCGGATGCTCGCCAGAGAACTGCCACAG 1575
QY 1558 GAGCTCTACAACATCATGATGCTGCTGGAAGAAACCGTCCGGAGGAGCGCCGACCTTC 1617
Db 1576 GAGCTCTACAACATCATGATGCTGCTGGAAGAAACCGTCCGGAGGAGCGCCGACCTTC 1635
QY 1618 GAATACATCCAGAGTGGTGGATGACTTCTACAGGCCACAGAGACCCAGTACCAACAG 1677
Db 1636 GAATACATCCAGAGTGGTGGATGACTTCTACAGGCCACAGAGACCCAGTACCAACAG 1695

QY 1678 CAGCCATGATAGGAGACAGGCGAGGG--CAGGGGGTCCCGAGGTGGTGGCTCGAAGT 1736
Db 1696 CAGCCATGATAGGAGAGACAGGCGAGGGGTCGCCAGGTGGTGGCTCGAAGT 1755
QY 1737 GGCTCCAGCACCACCTCCGCGAGGCGCCACACCCCTTCTACTCCAGACACCCACCTCG 1796
Db 1756 GGCTCCAGCACCACCTCCGCGAGGCGCCACACCCCTTCTACTCCAGACACCCACCTCG 1815
QY 1797 CTTGAGCCACAGTTTCTCATCTGTCTCAGTGGTAGTGGTGGAGTGGAAATCTCTTTTG 1856
Db 1816 CTTGAGCCACAGTTTCTCATCTGTCTCAGTGGTAGTGGTGGAGTGGAAATCTCTTTTG 1875
QY 1857 ACTCTTGCATCCACATCTGCATCTCAGGAAGCCCCCAAGTGTATTTCTATTTC 1916
Db 1876 ACTCTTGCATCCACATCTGCATCTCAGGAAGCCCCCAAGTGTATTTCTATTTC 1935
QY 1917 TGAATGGTGGATTTTAGTTACAGCTGTGATTTGGAAGGAACTTTCAAATAGTGAA 1976
Db 1936 TGAATGGTGGATTTTAGTTACAGCTGTGATTTGGAAGGAACTTTCAAATAGTGAA 1995
QY 1977 ATGAATATTTAAATAAAGATATAAATGC 2005
Db 1996 ATGAATATTTAAATAAAGATATAAATGC 2024

RESULT 4
AK026432
LOCUS Homo sapiens cDNA: FLJ22779 fis, clone KA1A1741. 2105 bp mRNA linear PRI 29-SEP-2000
DEFINITION AK026432
ACCESSION AK026432
VERSION 1 GI:10439295
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens ileal mucosa cDNA to mRNA, clone_lib:kaia
clone:KA1A1741.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (sites)
Kawakami,T., Noguchi,S., Itoh,T., Shigeta,K., Senba,T.,
Matsumura,K., Nakajima,Y., Mizuno,T., Morinaga,M., Tanigami,A.,
Fujiwara,T., Ono,T., Yamada,K., Fujii,Y., Ozaki,K., Hirao,M.,
Ohmori,Y., Ota,T., Suzuki,Y., Obayashi,M., Nishi,T., Shibahara,T.,
Tanaka,T., Nakamura,Y., Isogai,T. and Sugano,S.
NEDO human cDNA sequencing project
Unpublished
2 (bases 1 to 2105)
Sugano,S., Suzuki,Y., Ota,T., Obayashi,M., Nishi,T., Isogai,T.,
Shibahara,T., Tanaka,T. and Nakamura,Y.
Direct Submission
Submitted (29-AUG-2000) Sumito Sugano, Institute of Medical Science,
University of Tokyo, Laboratory of Genome Structure Analysis, Human
Genome Center, Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639,
Japan (E-mail:cdna@ims.u-tokyo.ac.jp, Tel:81-3-5449-5286,
Fax:81-3-5449-5416)
NEDO human cDNA sequencing project supported by Ministry of
International Trade and Industry of Japan; cDNA full insert
sequencing: Research Association for Biotechnology; cDNA library
construction, 5'- & 3'-end one pass sequencing: Department of
Virology and Human Genome Center, Institute of Medical Science,
University of Tokyo (partly supported by Science and Technology
Agency).
Location/Qualifiers
1. .2105
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="KA1A1741"
/tissue.type="ileal mucosa"
/clone_lib="kaia"
/note="cloning vector pME18SFL3"
235. .1752
/code="unnamed protein product"
/codon_start=1

FEATURES
source
CDS

/protein_id="BAB15482.1"
/db_xref="GI:10439296"
/translation="MGCKSKFLVGGVNTFSKTSASPHCPVYVPDPTSTIKPQPN
HNSYPIREAGSEDIIVVLYDEAIHEDLSFOQVGVVLESGWKAARSILATR
KSGYIPSNVAVDSLETERFEFKGISRDKAEROLLAPGNMIGSPMIDSETTKGSYS
LSVRDYPQGGDTVHYKIRTLIDNGGFYISPRSTESTLOELVDHYHKKNDGLCQKLSV
PCMSKPKQPKWKDAWETPRESLKLKGLGAFGEVMTAKYKTKVAVKTRKPSM
SVFAFLAEANVAKTIQHDKLVLKHAHVTKETPIYITEFMAGSLDLFLKSDGSKQPL
PKLIDFSAQIAGEMAFIEQYNIHRDLRAANILVASLVCKIADFLARVIEDNEDYTA
REGAKPPIKWTAPELNFQSEYIKSDVMSFGILLMEIVTYGRIPYPMGNPNPEVIRALE
RGYMRPENCPELYNIMRCWKNPPEPPIFYIQSLVDLDFYATESQYQQQP"
BASE COUNT 541 a 585 c 587 g 392 t
ORIGIN

Query Match		77.2%; Score 1555; DB 9; Length 2105;
Best Local Similarity		99.8%; Pred. No. 0;
Matches 1825; Conservative		0; Mismatches 3; Indels 1; Gaps 1;
Qy	178	ATGAAGTCCAAAGTTCCTCAGGTGCGAGGCAATACATTTCTCAAAACTGAAACACGCGCC 237
Db	244	ATGAAGTCCAAAGTTCCTCAGGTGCGAGGCAATACATTTCTCAAAACTGAAACACGCGCC 303
Qy	238	AGCCACACTGTCCTGTGTACGTGCGCGGATCCACATCCACATCAAGCCGGGCTAAT 297
Db	304	AGCCACACTGTCCTGTGTACGTGCGCGGATCCACATCCACATCAAGCCGGGCTAAT 363
Qy	298	AGCCACAACAGCAACACACCAGGAATCAGGAGGCGAGGCTCTGAGGACATCATCTGTGTT 357
Db	364	AGCCACAACAGCAACACACCAGGAATCAGGAGGCGAGGCTCTGAGGACATCATCTGTGTT 423
Qy	358	GCCTGTATGATTACAGGGCCATTACCGAAGAGCCTCAGCTTCCAGAAGGGGACACG 417
Db	424	GCCTGTATGATTACAGGGCCATTACCGAAGAGCCTCAGCTTCCAGAAGGGGACACG 483
Qy	418	ATGTGTCTCTACAGGAATCCGGGGAGTGGTGAAGCTCGATCCCTGCGCCACCCGGAAG 477
Db	484	ATGTGTCTCTACAGGAATCCGGGGAGTGGTGAAGCTCGATCCCTGCGCCACCCGGAAG 543
Qy	478	GAGGGCTACATCCCAAGCAACTATGTGCGCGCGTTGACTCTCTGGAGACAGAGGAGTG 537
Db	544	GAGGGCTACATCCCAAGCAACTATGTGCGCGCGTTGACTCTCTGGAGACAGAGGAGTG 603
Qy	538	TTTTTCAAGGGCATCAGCCGGAAGGAGCGAGCGCCCACTGTGCTCCCGCAACATG 597
Db	604	TTTTTCAAGGGCATCAGCCGGAAGGAGCGAGCGCCCACTGTGCTCCCGCAACATG 663
Qy	598	CTGGGCTCCTTCATGATCCGGGATAGCGAGCACCTAAAGGAAGCTACTTTTGTCCGTG 657
Db	664	CTGGGCTCCTTCATGATCCGGGATAGCGAGCACCTAAAGGAAGCTACTTTTGTCCGTG 723
Qy	658	CGAGACTACAGCCCTCGGACGGAGATACCGTGAACATPACAAAGATCCGGACCCCTGGAC 717
Db	724	CGAGACTACAGCCCTCGGACGGAGATACCGTGAACATPACAAAGATCCGGACCCCTGGAC 783
Qy	718	AACGGGGCTTCTACATATCCCCCGAAGCACCTTCAGCACTCTGAGGAGCTGGTGGAC 777
Db	784	AACGGGGCTTCTACATATCCCCCGAAGCACCTTCAGCACTCTGAGGAGCTGGTGGAC 843
Qy	778	CACCTACAAAGAGGGGAACGAGGCTCTGCCAGAAACTGTGCGTGGCCCTGCATGTCTTC 837
Db	844	CACCTACAAAGAGGGGAACGAGGCTCTGCCAGAAACTGTGCGTGGCCCTGCATGTCTTC 903
Qy	838	AAGCCCCAGAACGCTTGGGAGAAAGATGCTGGAGATCCCTCGGGAATCCCTCAAGCTG 897
Db	904	AAGCCCCAGAACGCTTGGGAGAAAGATGCTGGGAGATCCCTCGGGAATCCCTCAAGCTG 963
Qy	898	GAGAGAAACTTGGAGCTGGGAGTGGGGAAGTCTGGATGCCACTPACAAACAAGCAC 957
Db	964	GAGAGAAACTTGGAGCTGGGAGTGGGGAAGTCTGGATGCCACTPACAAACAAGCAC 1023
Qy	958	ACCAAGGTGGCAGTGAAGAGGATGAAGCCAGGGAGCATGTGCGTGGAGGCTTCTCTGGCA 1017
Db	1024	ACCAAGGTGGCAGTGAAGAGGATGAAGCCAGGGAGCATGTGCGTGGAGGCTTCTCTGGCA 1083

RESULT 5
HUMHCKB
LOCUS

HUMHCKB 1926 bp mRNA linear PRI 08-NOV-1994

DEFINITION Human hemopoietic cell protein-tyrosine kinase (HCK) gene, complete cds, clone HK24.

ACCESSION M16592

VERSION M16592.1 GI:183913

KEYWORDS kinase; protein kinase; protein-tyrosine kinase.

SOURCE Human mitogen-stimulated leukocyte, cDNA to mRNA, clone HK24.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1926)

AUTHORS Ziegler, S.F., Marth, J.D., Lewis, D.B. and Perlmuter, R.M.

TITLE Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin

JOURNAL Mol. Cell. Biol. 7 (6), 2276-2285 (1987)

MEDLINE 87257943

PUBMED 3453117

FEATURES

Location/Qualifiers

1..1926

/organism="Homo sapiens"

/db_xref="taxon:9606"

/map="20q11-q12"

1..1926

/gene="HCK"

<1..1926

/gene="HCK"

/product="HCK mRNA"

76..1593

/gene="HCK"

/note="protein-tyrosine kinase"

/codon_start=1

/protein_id="AAA52644.1"

/db_xref="GI:306833"

/db_xref="GDB:G00-119-303"

/translation="MGCKSKFLQVGGNTSKTETSNSPHCPVYVDPDTIKPGNS
HNSPTGIRAGSDIIVVALIDYEAIHEDLSIFQKQDQVLEESGEWMKARSLATR
KEGYIPNVARVDSLETEFFKISRKDAERQLAPGNMLGSMIRSETTKGYS
LSVRDYPROGDTVKHYKIRTLONGGFIISPRSTFSTLQELVDHYKKNDGLCKLSV
PCMSKPKQWEKDAWEPRESLKLKLGAGQGEVWMATYKNKHTKVAVTKPGSM
SVEFLAEANVMKTLQHDKLVLKLVAVTKPIYIITEFMAGSLDLDFKSDGSKOPL
PKLJDSQIAEGMAFTEORNYIHRDLRAANILVSALVCKIADFLARVIEDNEYTA
REGAFPIKWTAPNAIFNGFSFTIKSDVWSFGILLMEIVTGRPIYFGMSNPEVIRALE
RGYMRPENCPEELINIMKRCNMPERPTFEYIOSVLDDFYATATESYQOQOP"

BASE COUNT 497 a 522 c 520 g 387 t

ORIGIN 1 bp upstream of EcoRI site; chromosome 20q11-q12.

Query Match 77.0%; Score 1552; DB 9; Length 1926;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1552; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 178 ATGAAGTCCAAAGTTCTCCAGGTGGAGGCAATACATTCATAAACTGAAACCCAGCGCC 237
|||||
DB 85 ATGAAGTCCAAAGTTCTCCAGGTGGAGGCAATACATTCATAAACTGAAACCCAGCGCC 144
QY 238 AGCCACACTGTCTGTAGTGGCGGATCCACATCCACCATCAAGCGGGGCCCTAAT 297
|||||
DB 145 AGCCACACTGTCTGTAGTGGCGGATCCACATCCACCATCAAGCGGGGCCCTAAT 204
QY 298 AGCCACACACACACACACAGGAATCAGGAGGAGCGCTCTGAGGACATCATCGTGGTT 357
|||||
DB 205 AGCCACACACACACACAGGAATCAGGAGGAGCGCTCTGAGGACATCATCGTGGTT 264
QY 358 GCCCTGTATGATTACGAGGCCATTACACACGAAGACCTCAGCTTCCAGAGGGGGACCA 417
|||||
DB 265 GCCCTGTATGATTACGAGGCCATTACACACGAAGACCTCAGCTTCCAGAGGGGGACCA 324
QY 418 ATGTTGGTCTTAGAGGAATCCGGGAGTGTGGAGGTCGATCCCTGGCCACCCGGAAG 477
|||||
DB 325 ATGTTGGTCTTAGAGGAATCCGGGAGTGTGGAGGTCGATCCCTGGCCACCCGGAAG 384
QY 478 GAGGCTACATCCCAAGCAACTATCTGCCCGCTTGACTCTCTGGAGACAGAGGAGTGG 537
|||||
DB 385 GAGGCTACATCCCAAGCAACTATCTGCCCGCTTGACTCTCTGGAGACAGAGGAGTGG 444

QY 538 TTTTTCAGGGGCATCAGCGCGAAAGACGCAGAGCGCCAACTGCTGCTCCCGGCAACATG 597
|||||
DB 445 TTTTTCAGGGGCATCAGCGCGAAAGACGCAGAGCGCCAACTGCTGCTCCCGGCAACATG 504
QY 598 CTGGGCTCTTCATGATCGGGATAGCAGACCACCTAAAGAAAGTACTCTTTGTCCGTG 657
|||||
DB 505 CTGGGCTCTTCATGATCGGGATAGCAGACCACCTAAAGAAAGTACTCTTTGTCCGTG 564
QY 658 CGAGACTAGACCCCTCGGCAGGAGATACCGGTGAACAACTTACAAGATCCGGACCTGGAC 717
|||||
DB 565 CGAGACTAGACCCCTCGGCAGGAGATACCGGTGAACAACTTACAAGATCCGGACCTGGAC 624
QY 718 AACGGGGCTTCTACATATCCCCCAGAACCTTTTCAGACTCTCTCGAGAGTGTGGAC 777
|||||
DB 625 AACGGGGCTTCTACATATCCCCCAGAACCTTTTCAGACTCTCTCGAGAGTGTGGAC 684
QY 778 CACTACAAGAGGGGAACGACGGCTCTGCCAGAACTGTGCGTGCCTGATGCTCTCC 837
|||||
DB 685 CACTACAAGAGGGGAACGACGGCTCTGCCAGAACTGTGCGTGCCTGATGCTCTCC 744
QY 838 AAGCCCCAGAACCTTTGGGAGAAAGATGCTGGAGATCCCTCGGGAATCCCTCAAGCTG 897
|||||
DB 745 AAGCCCCAGAACCTTTGGGAGAAAGATGCTGGAGATCCCTCGGGAATCCCTCAAGCTG 804
QY 898 GAGAGAAACTTTGGAGCTGGGAGTTGGGGAAGTCTGGATGGCCACCTTACAACAGCAC 957
|||||
DB 805 GAGAGAAACTTTGGAGCTGGGAGTTGGGGAAGTCTGGATGGCCACCTTACAACAGCAC 864
QY 958 ACCAAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTGCGTGGAGGCTTCTTGCA 1017
|||||
DB 865 ACCAAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTGCGTGGAGGCTTCTTGCA 924
QY 1018 GAGGCCAACGCTGATGAAAACTCTGCAGCATGACAACTGGTCAAACTTCATCGGTGGTC 1077
|||||
DB 925 GAGGCCAACGCTGATGAAAACTCTGCAGCATGACAACTGGTCAAACTTCATCGGTGGTC 984
QY 1078 ACCAAGGACCCCTTACATCATCAGGAGTTTCATGGCCAAAGAGCTTGTGCGACTTT 1137
DB 985 ACCAAGGACCCCTTACATCATCAGGAGTTTCATGGCCAAAGAGCTTGTGCGACTTT 1044
QY 1138 CTGAAAGTGAAGGAGGAGCAGCAGCAGCCATTTGCCAAACTCATGACTTCTCAGCCAG 1197
|||||
DB 1045 CTGAAAGTGAAGGAGGAGCAGCAGCAGCCATTTGCCAAACTCATGACTTCTCAGCCAG 1104
QY 1198 ATTGCAGAAAGGATGCGCTTTCATCGAGCAGAGGAACTACATCCACGAGACCTCCGAGCT 1257
|||||
DB 1105 ATTGCAGAAAGGATGCGCTTTCATCGAGCAGAGGAACTACATCCACGAGACCTCCGAGCT 1164
QY 1258 GCCAACATCTTGGTCTCTGCATCCCTGGTGTGTAAGATTGCTGACTTTGGGCTGGCCCGG 1317
|||||
DB 1165 GCCAACATCTTGGTCTCTGCATCCCTGGTGTGTAAGATTGCTGACTTTGGGCTGGCCCGG 1224
QY 1318 GTCATTTGAGGACACAGGTACAGGCTCGGGAAGGGGCCAAGTTCCCCATCAAGTGGACA 1377
|||||
DB 1225 GTCATTTGAGGACACAGGTACAGGCTCGGGAAGGGGCCAAGTTCCCCATCAAGTGGACA 1284
QY 1378 GCTCTCGAAGCCATCAACTTTGGCTCTTCAACCATCAAGTTCAGAGCTCTGGTCTTTGGT 1437
DB 1285 GCTCTCGAAGCCATCAACTTTGGCTCTTCAACCATCAAGTTCAGAGCTCTGGTCTTTGGT 1344
QY 1438 ATCCTGCTGATGAGATCGTCACTACGGCCGGATCCCTTACCCAGGATGTCAAACTT 1497
DB 1345 ATCCTGCTGATGAGATCGTCACTACGGCCGGATCCCTTACCCAGGATGTCAAACTT 1404
QY 1498 GAAGTGTCCGAGCTCTGGAGCGTGTACCGGATCGCTCGCCAGAGAACTGCCACAGAG 1557
DB 1405 GAAGTGTCCGAGCTCTGGAGCGTGTACCGGATCGCTCGCCAGAGAACTGCCACAGAG 1464
QY 1558 GAGCTCTTACAACATCATGATGCTCTGGAATAACCGCTCCGAGGAGGGCGGACCTTTC 1617
DB 1465 GAGCTCTTACAACATCATGATGCTCTGGAATAACCGCTCCGAGGAGGGCGGACCTTTC 1524
QY 1618 GAATACATCCAGAGTGTGCTGGATGACTTCTTACACGGCCACAGAGAGCCAGTACCAACAG 1677

30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one plasmid subclone or more than one M13 subclone; and the assembly was confirmed by restriction digest. RF5-836N17 is from the library RPCI-5 constructed by the group of Pieter de Jong. For further details see <http://www.chori.org/bacpac/home.htm>

FEATURES

source

Location/Qualifiers
 1..111694
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="20"
 /map="g11.1-11.21"
 /clone="RP5-836N17"
 /clone_lib="RPCI-5"
 1..62

repeat_region /note="AluJ/FLAM repeat: matches 1..62 of consensus"

repeat_region 73..173 /note="L2 repeat: matches 2597..2709 of consensus"

repeat_region 243..302 /note="15 copies 4 mer catc 98% conserved"

repeat_region 601..898 /note="AluSq repeat: matches 1..295 of consensus"

repeat_region 1188..1345 /note="MER5A repeat: matches 1..185 of consensus"

repeat_region 1364..1668 /note="AluSx repeat: matches 1..307 of consensus"

repeat_region 2074..2381 /note="AluSp repeat: matches 3..313 of consensus"

repeat_region 2583..2904 /note="AluY repeat: matches 1..311 of consensus"

repeat_region 2993..3134 /note="MIR repeat: matches 2..143 of consensus"

repeat_region 3135..3439 /note="AluSx repeat: matches 1..305 of consensus"

repeat_region 3440..3503 /note="MIR repeat: matches 143..206 of consensus"

repeat_region 3491..3594 /note="MIR repeat: matches 60..164 of consensus"

repeat_region 3866..4024 /note="MER69 repeat: matches 66..236 of consensus"

repeat_region 4033..4126 /note="MER69 repeat: matches 2422..2510 of consensus"

repeat_region 4334..26412 /note="match: GSS: Em:AQ339627"

gene /gene="HCK"

mRNA join(<4334..4437,8454..8603,8951..9103,11188..11367,13128..13204,18423..18576,23564..23695,25877..26412)

/gene="HCK"

/product="dJ836N17.1 (hemopoietic cell kinase)"

/note="match: CDNAS: Em:J03023 Em:M83666 Em:S74141 Em:X62345 Em:X00487 Em:M12056 Em:M57697 Em:M36881 Em:M57696 Em:U23852 Em:M30903 Em:U01349 Em:X03533 Em:L14823 Em:M42191 Em:U70324 Em:M19722 Em:M17031 Em:X15345 Em:U35365 Em:M79321 Em:J03579 Em:AF000302 Em:M64608 Em:AF000301 Em:X13529 Em:AF000300 Em:X12461 Em:M23422 Em:L14951 Em:X54970 Em:X54971 Em:M14676 Em:M27266 Em:AF130457 Em:X52822 Em:S76617 Em:L16440 Em:M16592 Em:M16591 Em:M16038 Em:M14333 Em:L14782 Em:AF081803 Em:X05027 Em:X57018 Em:X13207 Em:Z33998 Em:U07236 Em:X67786 Em:X67677 Em:M24704 match: ESTS: Em:AA763708 Em:AA149096 Em:W87315 Em:AI912730 Em:AI220607 Em:AI572095"

/evidence=not_experimental

join(<4334..4437,8454..8603,8951..9103,11188..11367,13128..13204,18423..18576,23564..23695,25877..26079)

/gene="HCK"

/note="Continues in Em:AL353092 as dJ180113.1

match: proteins: Sw:P06239 Sw:P06240 Sw:P08103 Sw:P50545 Tr:Q13084 Sw:P42683 Sw:P08631 Sw:Q07014 Sw:P07948

/codon_start=2

CDS

join(<4334..4437,8454..8603,8951..9103,11188..11367,13128..13204,18423..18576,23564..23695,25877..26079)
 /gene="HCK"
 /note="Continues in Em:AL353092 as dJ180113.1
 match: proteins: Sw:P06239 Sw:P06240 Sw:P08103 Sw:P50545
 Tr:Q13084 Sw:P42683 Sw:P08631 Sw:Q07014 Sw:P07948

/evidence=not_experimental
 /product="dJ836N17.1 (hemopoietic cell kinase)"
 /protein_id="CAB75606.1"
 /db_xref="GI:7018398"
 /db_xref="SPTREMBL:Q9NUA4"
 /translation="WFFGIGSRKDAEROLLAPGNMGLSFMTRDSETKGYSLSVROYDPQGDYTKHYKIIRTLNNGFYIISPRSTFSLQELVDHYKKGNDGLCKLSVPCMSKPKQWEKDAWEIPRESLKLKGLAGQGEYVMATYKNKHTKAVTKMPSMSVEAFLEAVNMKTLQHDKLVKHAVTKPIYIITEFMAKGSLLDFLKSDGSKOPLPKLIDFSAQIAEGMAFTEORNYIHRDLRAANILVSALCKIADFGIARVIDENYETAREGAKFPKWTAPAEINFGSTIKSDVMSFGILLMEIVTYGRIPYPCMSPEVIRALERGYRMPRENCPEELINIMRCWKNRPERTFEIIQSVLDDFTATESIQQQP"
 /note="AluSc repeat: matches 1..306 of consensus" 4751..5056
 /note="AluJb repeat: matches 24..295 of consensus" 5059..5348
 /note="AluJb repeat: matches 24..295 of consensus" 5406..5666
 /note="AluJo repeat: matches 41..300 of consensus" complement(5985..6147)
 /note="match: STS: Em:AA443921" 6602..6796
 /note="MIR repeat: matches 10..205 of consensus" 6860..6919
 /note="MIR repeat: matches 187..242 of consensus" 6920..7219
 /note="AluSx repeat: matches 1..300 of consensus" 7220..7328
 /note="MIR repeat: matches 64..187 of consensus" 7378..7456
 /note="MADE1 repeat: matches 2..80 of consensus" 7461..7926
 /note="MLTLD repeat: matches 1..505 of consensus" 8095..8311
 /note="MIR repeat: matches 35..261 of consensus" 9492..9524
 /note="L2 repeat: matches 2652..2686 of consensus" 9791..10099
 /note="AluSx repeat: matches 1..308 of consensus" 10223..10555
 /note="L2 repeat: matches 2141..2482 of consensus" 10576..10867
 /note="AluY repeat: matches 12..303 of consensus" 10880..11054
 /note="MIR repeat: matches 21..188 of consensus" 11862..12205
 /note="AluJo repeat: matches 257..302 of consensus" 12206..12501
 /note="AluY repeat: matches 1..295 of consensus" 12502..12764
 /note="AluJo repeat: matches 1..257 of consensus" 13048..13092
 /note="MADE1 repeat: matches 36..79 of consensus" complement(13162..13462)
 /note="match: STS: Em:HS180113S" complement(13162..13412)
 /note="match: STS: Em:AL031189" 13302..13417
 /note="MIR repeat: matches 151..262 of consensus" 13418..13810
 /note="MLTLD repeat: matches 99..540 of consensus" 13835..13922
 /note="MIR repeat: matches 101..182 of consensus" 13921..13981
 /note="MIR repeat: matches 76..137 of consensus" 13951..14131
 /note="L2 repeat: matches 2505..2726 of consensus" 14285..14527
 /note="L2 repeat: matches 2300..2551 of consensus" 15366..15471
 /note="MIR repeat: matches 23..135 of consensus" 15483..15707
 /note="MIR repeat: matches 1..256 of consensus" 15855..16037

```
/note="MIR repeat: matches 12. .193 of consensus"
16288. .16567
/note="AluJo repeat: matches 5. .312 of consensus"
16872. .16920
/note="MIR repeat: matches 125. .173 of consensus"
17077. .17497
/note="L2 repeat: matches 2098. .2595 of consensus"
17498. .17804
/note="Alusx repeat: matches 1. .307 of consensus"
complement(17780. .18196)
/note="match: GSS: Em:AQ590401"
17805. .17925
/note="L2 repeat: matches 2595. .2710 of consensus"
complement(17926. .18196)
/note="match: GSS: Em:AQ590401"

Query Match 15.0%; Score 303; DB 9; Length 111694;
Best Local Similarity 99.4%; Pred. No. 1e-162;
Matches 523; Conservative 0; Mismatches 2; Indels 1; Gaps 1;

QY 1481 CAGGATGTCAAAACCTGAAGTATCCGAGCTCTGGAGCGTGGATACCGGATCCCTCGCC 1540
DDB 25874 CAGGATGTCAAAACCTGAAGTATCCGAGCTCTGGAGCGTGGATACCGGATCCCTCGCC 25933
QY 1541 CAGAGAACTGCCAGAGAGCTCTACAACATCATGATGCCCTGCTGGAAGAAACCGTCCGG 1600
DDB 25934 CAGAGAACTGCCAGAGAGCTCTACAACATCATGATGCCCTGCTGGAAGAAACCGTCCGG 25993
QY 1601 AGGAGCGCGGACCTTCGAATACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAG 1660
DDB 25994 AGGAGCGCGGACCTTCGAATACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAG 26053
QY 1661 AGACCCAGTACCAACAGACGACATGATAGGAGGACACAGGCGAGGG-CAGGGGGTGCCTCA 1719
DDB 26054 AGACCCAGTACCAACAGACGACATGATAGGAGGACACAGGCGAGGGCGAGGGGTGCCCA 26113
QY 1720 GGTGGTGCCTCGAGGCGCTCCAGACCATCCGCGAGGCGCCACACCCCCCTTCTTACTC 1779
DDB 26114 GGTGGTGCCTCGAGGCGCTCCAGACCATCCGCGAGGCGCCACACCCCCCTTCTTACTC 26173
QY 1780 CCAGACACCCACCCCTCGCTTCAGCCAGTTTCTCATCTGTCCAGTGGGTAGTTGGAC 1839
DDB 26174 CCAGACACCCACCCCTCGCTTCAGCCAGTTTCTCATCTGTCCAGTGGGTAGTTGGAC 26233
QY 1840 TGGAAATCTCTTTTTCAGCTTTCGAATCCACAATCTGACATCTCAGGAAGCCCCCAG 1899
DDB 26234 TGGAAATCTCTTTTTCAGCTTTCGAATCCACAATCTGACATCTCAGGAAGCCCCCAG 26293
QY 1900 TTGATATTTCTATTTCTCGAATGGTTGGATTTTAGTTACAGCTGTGATTTTGAAGGAA 1959
DDB 26294 TTGATATTTCTATTTCTCGAATGGTTGGATTTTAGTTACAGCTGTGATTTTGAAGGAA 26353
QY 1960 ACTTCAAAATAGTGAATGAATTAATAAAGATATAAATGC 2005
DDB 26354 ACTTCAAAATAGTGAATGAATTAATAAAGATATAAATGC 26399

RESULT 8
G06122 333 bp DNA linear STS 19-OCT-1995
LOCUS human STS WI-7020, sequence tagged site.
DEFINITION G06122
ACCESSION G06122
VERSION G06122.1 GI:859367
KEYWORDS STS; STS sequence; primer; sequence tagged site.
SOURCE Homo sapiens STSS derived from sequences in dbEST and the Unigene collection.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 333)
REFERENCE
AUTHORS Hudson, T.
TITLE Whitehead Institute/MIT Center for Genome Research; Physically
Mapped ESTs
```

JOURNAL
COMMENT

Unpublished (1995)

Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu

Primer A: TAGGAGGACACAGGGCAG
Primer B: TGGTAAAGACTTTGGCATTATATC
STS size: 333
PCR Profile:
Presoak:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:

Protocol:
Template: 10 ng
Primer: each 5 pM
dNTPs: each 4 nM
Taq Polymerase: 0.025 units/ul
Total Vol: 20 ul

Buffer:
MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCL: 10 mM
pH: 9.3

Prepared with primer pairs derived from X58743 -- Unigene.

FEATURES
Source

1.333
/organism="Homo sapiens"

/db_xref="taxon:9606"

/map="734_E.7; 908_C.6; 768_C.11; (808,809)_(G.A)_(1,6)"

STS
1.333

primer_bind
1.18

primer_bind complement(309..333)

BASE COUNT 87 a 83 c 77 g 86 t

ORIGIN

Query Match 13.6%; Score 274; DB 11; Length 333;

Best Local Similarity 100.0%; Pred. No. 4.8e-146;

Matches 274; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1732 AGGTGGCTCCAGCACCATCCGCGAGGCGCCACACCCCTTCTTACTCCGAGACACCCAC 1791

DB 46 AAGTGGCTCCAGCACCATCCGCGAGGCGCCACACCCCTTCTTACTCCGAGACACCCAC 105

QY 1792 CCTCGCTTCAGCCACAGTTTCTCATCTGTCCAGTGGGTAGTTGGACTGGAAATCTCT 1851

DB 106 CCTCGCTTCAGCCACAGTTTCTCATCTGTCCAGTGGGTAGTTGGACTGGAAATCTCT 165

QY 1852 TTTTGACTCTTGGCAATCCACAATCTGACATCTCAGGAAGCCCCCAAGTTGATATTTCTA 1911

DB 166 TTTTGACTCTTGGCAATCCACAATCTGACATCTCAGGAAGCCCCCAAGTTGATATTTCTA 225

QY 1912 TTTTCTGGAATGGTTGGATTTTACCTACAGCTGTGATTTGGAAGGAACTTTCAATA 1971

DB 226 TTTTCTGGAATGGTTGGATTTTACCTACAGCTGTGATTTGGAAGGAACTTTCAATA 285

QY 1972 GTGAATCAATATTTAAATAAAGATATAAATGC 2005

DB 286 GTGAATCAATATTTAAATAAAGATATAAATGC 319

RESULT 9

HSCKE69

LOCUS

HSCKE69 5268 bp DNA linear PRI 27-AUG-1999

DEFINITION	H.sapiens HCK gene for tyrosine kinase (PTK), exons 6-9.
ACCESSION	X58741 X59741
VERSION	X58741.1 GI:32045
KEYWORDS	proto-oncogene; src family; T-cell receptor alpha-chain; Tyrosine kinase; V-alpha gene segment; variable region.
SOURCE	Homo sapiens.
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	1 (bases 1 to 5268)
TITLE	Hradetzky,D., Streibhardt,K. and Rubsamen-Waigmann,H.
TITLE	The genomic locus of the human hemopoietic-specific cell protein tyrosine kinase (PTK)-encoding gene (HCK) confirms conservation of exon-intron structure among human PTKs of the src family
JOURNAL	Gene 113 (2), 275-280 (1992)
MEDLINE	92241680
PUBMED	1572549
REFERENCE	2 (bases 1 to 5268)
AUTHORS	Hradetzky,D.
TITLE	Direct Submission
JOURNAL	Submitted (14-JUN-1991) D. Hradetzky, Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Paul Ehrlich Str 42-44, 6000 Frankfurt-70, Federal Republic of Germany
COMMENT	See also X58736-X58740, X58744-X58769
COMMENT	See also X58742 and X58743.
FEATURES	Location/Qualifiers
source	1..5268
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
	/chromosome="20"
	/map="q11-12"
	/clone="H530R"
	/tissue_type="spleen"
	/clone_lib="genomic; TS48"
	/dev_stage="adult"
	<1..835
	/number=5
intron	Join(836..5227,X58742.1:16..1065,X58743.1:3807..4342)
gene	Join(836..985,1333..1485,3572..3751,5151..5227,X58742.1:16..169,X58742.1:934..1065,X58743.1:3807..4342)
mRNA	/partial
	/gene="HCK"
	/label="HCK_mRNA"
	Join(836..985,1333..1485,3572..3751,5151..5227,X58742.1:16..169,X58742.1:934..1065,X58743.1:3807..4009)
	/partial
	/gene="HCK"
	/codon_start=3
	/label="HCK_cds"
	/product="tyrosine kinase"
	/protein_id="CAA1565.2"
	/db_xref="GI:5804911"
	/translation="SYSLSVSDYDPDROGDIVKHVYKIFTLONGFYISPRFTFTLQELVHYKTKGNDGCKLQSVPCMSKPKWEKDIAEIPRESLKEKLGAGQFGFVWMTVNHKTKVAKTKPKGMSVEAFIAEANYMTKLQHDKLVLHVVTKPEYIIITFMAKIGLLDFKSDGSKOPLKPLIDFSAQIAEGMAFTEQRNIHRLRAANILVLSASLVCKIADFLGARVIDENYPTAREGAKFPIKWTAPAINFGSFTIKSDWSFGILLMEIVYGRTPYPCMSNPVIRALERGYRMPRENCPEELYNIMRCWKNRPERPTFEYIQSVLD DRYATESQIQOOP"
exon	836..985
	/gene="HCK"
	/number=6
intron	986..1332
	/gene="HCK"
	/number=6
exon	1333..1485
	/gene="HCK"
	/number=7
intron	1486..3571
	/gene="HCK"
	/number=7
repeat_region	2182..2482

```

/db_xref="taxon:9606"
/chromosomes="20"
/map="q11-12"
/clone="D640 H"
/tissue_type="spleen"
/clone_lib="genomic; TS48"
/dev_stage="adult"
<1..15
/intron
  /number=9
  /usedin=X58741:HKC_cds
  /usedin=X58741:HKC_mRNA
  /number=10
  /gene="HCK"
  /number=10
  /note="ALU repeat V"
  /number=11
  /usedin=X58741:HKC_cds
  /usedin=X58741:HKC_mRNA
  /number=11
  /note="ALU repeat VI"
  /number=1281..1592
  /note="ALU repeat VII"
  /number=1835..2167
  /note="ALU repeat VII"
  /number=477 a 626 c 485 g 579 t
BASE COUNT
ORIGIN
  Query Match 7.8% Score 157; DB 9; Length 2167;
  Best Local Similarity 100.0%; Pred. No. 2.4e-78;
  Matches 157; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1196 AGATTGCGAAGGATGGCTTCATCGAGCAGAGGAACATACATCCACGAGACCTCCGAG 1255
      |||||||
Db 14 AGATTGCGAAGGATGGCTTCATCGAGCAGAGGAACATACATCCACGAGACCTCCGAG 73

Qy 1256 CTGCCACATCTGGTCTCTGCATCCCTGGTGTGAAGATTGCTGACTTTGGCTGGCC 1315
      |||||||
Db 74 CTGCCACATCTGGTCTCTGCATCCCTGGTGTGAAGATTGCTGACTTTGGCTGGCC 133

Qy 1316 GGGTCATTGAGGACAAGCAGTACACGCTCGGGAAG 1352
      |||||||
Db 134 GGGTCATTGAGGACAAGCAGTACACGCTCGGGAAG 170

RESULT 11
LOCUS AL353092 25010 bp DNA linear PRI 11-FEB-2001
DEFINITION Human DNA sequence from clone RPI-180113 on chromosome 20 contains
5' end of the HKC gene for hemopoietic cell kinase (protein
tyrosine kinase), contains ESTs, STSS, GSSs and a CpG island,
complete sequence.
ACCESSION AL353092
VERSION AL353092.6 GI:9650539
KEYWORDS HTG; CpG island; HKC; tyrosine kinase.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 25010)
Almeida, J.
REFERENCE
AUTHORS Direct Submission
TITLE Submitted (08-FEB-2001) Sanger Centre, Hinxton, Cambridgeshire,
JOURNAL CB10 ISA, UK. E-mail enquiries: humquery@sanger.ac.uk
requests: clonerequest@sanger.ac.uk
COMMENT On Aug 1, 2000 this sequence version replaced gi:9187765.

During sequence assembly data is compared from overlapping clones.
where differences are found these are annotated as variations
together with a note of the overlapping clone name. Note that the
variation annotation may not be found in the sequence submission
corresponding to the overlapping clone, as we submit sequences with
only a small overlap as described above.
The following abbreviations are used to associate primary accession
numbers given in the feature table with their source databases:
Em:, EMBL; Sw:, SWISSPROT; Tr:, TREMBL; Wp:, WORMPEP; Information
on the WORMPEP database can be found at
http://www.sanger.ac.uk/Projects/C_elegans/wormpep This sequence
was generated from part of bacterial clone contigs of human
chromosome 20, constructed by the Sanger Centre Chromosome 20
Mapping Group. Further information can be found at
http://www.sanger.ac.uk/HGP/Chr20
IMPORTANT: This sequence is not the entire insert of clone
RPI-180113 It may be shorter because we sequence overlapping
sections only once, except for a 100 base overlap.
The true left end of clone RP5-836N17 is at 24911 in this sequence.
The true right end of clone RPI-310013 is at 100 in this sequence.
This sequence was finished as follows unless otherwise noted: all
regions were either double-stranded or sequenced with an alternate
chemistry or covered by high quality data (i.e., phred quality >=
30); an attempt was made to resolve all sequencing problems, such
as compressions and repeats; all regions were covered by at least
one plasmid subclone or more than one M13 subclone; and the
assembly was confirmed by restriction digest. RPI-180113 is from
the library RPCI-1 constructed by the group of Pieter de Jong. For
further details see
http://www.chori.org/bacpac/home.htm
VECTOR: pCYPAC2.
Location/Qualifiers
1..25010
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="20"
/clone="RPI-180113"
/clone_lib="RPCI-1"
1..43
/note="AluJo/FLAM repeat: matches 76..118 of consensus"
complement(39..567)
/note="match: GSS: Em:AQ386884"
58..175
/note="5S repeat: matches 1..119 of consensus"
265..455
/note="MER20 repeat: matches 26..218 of consensus"
510..586
/note="L2 repeat: matches 1966..2045 of consensus"
692..906
/note="match: GSS: Em:AQ486790"
772..843
/note="2 copies 36 mer 93% conserved"
1576..2453
/note="CpG island"
/evidence="not_experimental"
1846..24191
/gene="HCK"
Join(1846..1956,21132..21252,22789..22831,23186..23288,
24093..>24191)
/gene="HCK"
/product="dJ180113.1 (hemopoietic cell kinase)"
/note="match: CDNAS: Em:M15591 Em:X62345 Em:S74141
Em:J03023 Em:M16592 Em:M83666 Em:Y00487 Em:X60380
Em:J03579 Em:X67786 Em:AF000300 Em:AF000301 Em:AF000302
Em:M17031 Em:X52822 Em:X57018 Em:X15345 Em:M27454
Em:M57290 Em:X57684 Em:M85043 Em:M19722
match: ESTs: Em:AW307786"
/evidence="not_experimental"
complement(2102..2519)
/note="match: GSS: Em:AQ382576"
complement(2108..2557)
/note="match: GSS: Em:AQ461389"
complement(2196..2570)
misc_feature
misc_feature
misc_feature

```


gene
CDS
1. .1515
/gene="hck"
1. .1515
/gene="hck"
/function="tyrosine kinase"
/codon_start=1
/product="hck protein"
/protein_id="CAC44031.1"
/db_xref="GI:14627116"
/translation="MGCKSKFLQAGNTFSKTSANPHCPVYPDPSTIKPGPNS
NNRNTGIGESDIIVVALDYEAIIHEDLSFGKQDMVLGESEGNWKAISLATRK
EGVPSNYVARVDSLETEFEFGISRKDAERQLLAGNMLGSEMRDSTTKGSYSL
SVRDYPRGDDYVKKIKITLNGFEYISPRSTFYLQELVDHYHKGSDGLCQKLSVP
CVSSKPKWEKMDAMPRESLKLKKUGAGQFGEVWMATYKNTKVAVKTMKPGSMS
VEAFLEAKMLTQHDKLVLKHAVVTEPIYIITEFMAKGSLLDFLAKSDGSKQPLP
KLIDFSAQIAEGMAFTEQRNYIHRDLRAANILVSALVCKIADFLGIENDEYTA
EGAKFKIKVTAEPAINFGSSTIKSDWSFGLIMEIVTYGRIPYPCMSNPEVIRALER
GYRMPREPCPELYNIMRWKNPPEPTFEYIQSVLDDFYTATESQYQQP"
BASE COUNT 388 a 424 c 419 g 284 t
ORIGIN
Query Match 5.3%; Score 107; DB 9; Length 1515;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 580 CTGGCTCCCGGCAACATGCTGGGCTCCTTCATGATCCGGGATAGCGAGACCCTAAAGGA 639
Db 409 CTGGCTCCCGGCAACATGCTGGGCTCCTTCATGATCCGGGATAGCGAGACCCTAAAGGA 468
QY 640 AGCTACTCTTTGCTCGGAGACTACGACCCCTCGCAGGGAGATAC 686
Db 469 AGCTACTCTTTGCTCGGAGACTACGACCCCTCGCAGGGAGATAC 515
RESULT 13
G25924
LOCUS human STS EST50744, 366 bp DNA linear STS 02-JUN-1996
DEFINITION human STS EST50744, sequence tagged site.
ACCESSION G25924
VERSION G25924.1 GI:1348156
KEYWORDS STS; STS sequence; primer; sequence tagged site.
SOURCE Homo sapiens STSs derived from sequences in dbEST and the Unigene collection.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 366)
AUTHORS Hudson,T.
TITLE Whitehead Institute/MIT Center for Genome Research; Physically
Mapped STSs
JOURNAL Unpublished (1995)
COMMENT Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu
Primer A: GATCCGAGCTCTGGAGCG
Primer B: CCGGTAGAGTCATCCAGC
STS size: 150
PCR Profile:
Presoak:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:
Protocol:
Template: 10 ng
Primer: each 5 pM

dNTPs: each 4 mM
Taq Polymerase: 0.025 units/ul
Total Vol: 20 ul
Buffer:
MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCl: 10 mM
pH: 9.3
Derived from dbEST (genbank accession D20116).
FEATURES
source
1.366
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="180.1 cR from top of Chr20 linkage group"
STS
1.150
primer_bind
1.18
primer_bind complement(131..150) 73 t 18 others
BASE COUNT 83 a 95 c 97 g 73 t 18 others
ORIGIN
Query Match 4.1%; Score 82; DB 11; Length 366;
Best Local Similarity 100.0%; Pred. No. 5.3e-35;
Matches 82; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 CTTTGAATACATCCAGAGTGTGCTGGATGACTTCTACAGGCCACAGAGCCAGTACC 1672
Db 109 CTTTGAATACATCCAGAGTGTGCTGGATGACTTCTACAGGCCACAGAGCCAGTACC 168
QY 1673 AACAGCAGCCATGATAGGAGG 1694
Db 169 AACAGCAGCCATGATAGGAGG 190
RESULT 14
HUMHCK
LOCUS Human hemopoietic cell kinase (HCK) gene, exon 1.
DEFINITION
ACCESSION M73233
VERSION M73233.1 GI:485365
KEYWORDS hemopoietic cell kinase.
SOURCE Homo sapiens DNA.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 958)
AUTHORS Lichtenberg,U., Quintrell,N. and Bishop,J.M.
TITLE Human protein-tyrosine kinase gene HCK: expression and structural
analysis of the promoter region
JOURNAL Oncogene 7 (5), 849-858 (1992)
MEDLINE 92237010
PUBMED 1373873
FEATURES
source
1.958
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="20q11-q12"
/cell_type="lymphocyte"
1..663
664..958
/gene="HCK"
664..807
/gene="HCK"
/product="hemopoietic cell kinase"
/note="G00-119-303"
/number=1
808..>958
/gene="HCK"
/note="G00-119-303"
BASE COUNT 177 a 219 c 379 g 183 t
ORIGIN

Query Match 3.8%; Score 77; DB 9; Length 958;
Best Local Similarity 100.08; Pred. No. 4.3e-32;
Matches 77; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 89 ACCTCAGGGCTGCCAGCTGGGGGGCGCTCAAGCTCGAGGATCGGGCTGCCCGCA 148
|||||
DB 728 ACCTCAGGGCTGCCAGCTGGGGGGCGCTCAAGCTCGAGGATCGGGCTGCCCGCA 787
|||||

QY 149 GACGAGGAGCGGGCGCC 165
|||||
DB 788 GACGAGGAGCGGGCGCC 804
|||||

RESULT 15
AB071605 10348 bp mRNA linear PRI 02-AUG-2002
LOCUS Homo sapiens mRNA for HECT domain protein LASU1, complete cds.
DEFINITION AB071605
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
REFERENCE
AUTHORS
TITLE

Gu,J., Ren,K., Dubner,R. and Iadarola,M.J.
Cloning of a DNA binding protein that is a tyrosine kinase
substrate and recognizes an upstream initiator-like sequence in the
promoter of the preproendorphin gene
Brain Res. Mol. Brain Res. 24 (1-4), 77-88 (1994)
95058008
7968380

2
Gu,J., Dubner,R., Fornace,J.A. and Iadarola,M.
UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53
transactivation
Oncogene 16, 2175-2178 (1995)

3
Miyazaki,K., Okamoto,Y., Sakamoto,M., Kato,C., Ozaki,T.,
Watanabe,K. and Nakagawara,A.
Homo sapiens LASU1 (large structure of UREB1) mRNA, complete cds
Unpublished
4 (bases 1 to 10348)
Nakagawara,A. and Miyazaki,K.
Direct Submission
Submitted (16-SEP-2001) Akira Nakagawara, Chiba Cancer Center
Reserch Institute, Division of Biochemistry; 666-2 Nitona, Chuoh-ku
Chiba, Chiba 260-8717, Japan
(E-mail: akiranak@chiba-cc.pref.chiba.jp, Tel:81-43-264-3431,
Fax:81-43-265-4459)

FEATURES
Source
1..10348
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="X"
/map="Xp11.22"
/tissue.type="brain"
/dev_stage="fetus"
1..10348
/gene="LASU1"
1..145
/gene="LASU1"
146..10228
/gene="LASU1"
/note="Homo sapiens upstream regulatory element binding
protein 1 (UREB1) is completely included in the 3'part of
this gene (9234-10160).
K1AA0312; HSPC272; KIAA1578; ATP synthase, H+ transporting,
mitochondrial F1complex; alpha subunit, isoform 1
large structure of UREB1 (LASU1)"
/codon_start=1
/evidence=experimental
/product="HECT domain protein LASU1"

misc_feature
misc_feature
3'UTR
BASE COUNT 2684 a 2656 g 2251 t
ORIGIN
Query Match 3.8%; Score 76; DB 9; Length 10348;

/protein_id="BAC06833.1"
/db_xref="GI:22090626"
/translation="MVTHWLPWRQNNLLQTLRLANKSHQWMLPELSKSSLCYQASSR
LGRALAEFLGLLVKLCVSPFQRQRSHHAASITTTAPTAARSTASALPKLLNGLSWQ
PPYPTTLRLRTFTICSVGFTSPMLFDERKYPYHLMLQKFLCSGHNALEPKLPGVQN
SMGKVPVSEGLEHSLPDGTGEFLDLMVLMKVMNPTTVLESHPHSLPAKLPQGVQN
FQGFSAFLRVVTQAAATCIRKNWRKPKVYGGMAESMLAILCHLRGPVIRER
LSEKEGSGEEDTGOEGGSRREPOVNOOQLQDMGFTREHAMEALLNTSTMEQA
TEYLLTHPPIMGGVVVDLSMSDEQDMRAIAMSLGQDIPMDQRAESPEEVACKEE
ERKAREQEEAKCLEKQDADPLEDELHTFTDTMLPCHLDELDPDVYVCDL
IMTAIKRNGADRMILKQVNOVWEAADVLKALPLTSDTKVTSWISOMATLPQ
ASNLATRIILLTLEELKPCAAVYESSGILNVLKLEVVQPCQAQKEQVOTP
KWITPVLLIDFYEKTAISRRQAQMTKYLQSNMNRWDDRSQWCSYASNNSTI
DSAWKSGETSVRFAGRRYTVQFTMVQVNEETGNRPVMTLLRPRLNKNKSN
GOLEKTSKESKMDIKRKENGNDTFLALETNETKETSLEETKIGETLIQGLTDEM
VTVLIRACVSMGLGVDPDTHATLRLCLRLPDHKKYAMFAELKSTMLNLATOSSG
FNGFTPLVLLRHIIETPCVTHMEKVVRSAAATSGAGSTTSGVVSGLSGREINYL
LRVLPAAACRNPDIETEVANCCIRIALPAPRGSTASDDFENLRKGNPAVLQVKT
PLKPSLPVPIPTIKVYIDMLNLAAYHAPEADKSPKPGVMTQEVQQLQDMGDD
VYOQYSLTRQSDFTQSGFSINQVFAADGASTSAGTSGQEAETPEESRDGKK
DKGDRASEGKQKGGSKPLMPTSTILRLAELVRSYVGIATLANYSYTVGQSELI
KEDCSVLAVLDHLLPHTQNAEDKTPALARLEFLASLAAGSTDAQVALVNEKAL
GRALAMAEKTERHARLQAVMCIIISTINESCPSTSSYSATAKTQHGNNILRLFLK
KGLVNDLARPVHSLDLSNPMANTVNAALPLETISRIVNPPSSLPSSKSSAKNKE
QDAQASQDSSNQDQPGFGEAEVQEDHDVTQTEVADGDMDEAEVSVIAGQP
EVLSSQEMOVENELEDILDELRQGGSGNSTIIVSRGDESEDEDEDEDEDEDE
ASTLOANREDSNNILDEPEEHTQEDSSGNEDEDDSDDEDEDEDEDEDEDEDE
GEGDEDDDDGSEMELDEDYPMNASPLVRPEREDDILLIEDNMESSTADIPPS
PGNIPTHPLMVRHADYSLLTIGSGSTTLTGIGRSORTLRQLTANTGHTIHHYPP
GNQPNPPLILQGLGPSAAADILQSSLPQSGRRLVGNDDHVIARSDELL
DDFFHQSTATSQAGTSSITALTATRWTECKYLDAESMHDCSVVVKSVIVNHFELR
DELEERREKRRKQAEETKITDKGKEDKENRQSAQCTASKNDSTBNLSQDTPM
PDSYPTPSTDAATSEKETLGTLSQSOQPTLPTPALGVPOBLQSPAGEGSSST
QLLMYPEPELGPTRPSGAETOMELSPAPTISLSPERAEDSALTAVLSQLEGSP
EDSSPASSESSTSDSAVAGSRSGLIEEPLPSTSEEDDPLAGISLPGGVDPSP
EVLQAOQRAEQRRLEAQNASSDTPMDPVTFTQLPSDLRRSVLEDMEDSVLAVPPIQ
IAEAQALRQEAROROLMHERLFHGSSTALSALSRPAPTSLRSGNVRQVYTRLA
VORGCTFOMGGSSSHNRPSGNSVDTLRLGRLLLDHEALSCILLVLFVDEPKLNTSR
LHVRNLNLYHAQTRHWVRSLLSILQSESELCTETPKLTISEKGGKSSKSGSS
SHENRPLDLLHMKESKNOLSWLSVMDAAGCCTNIFQIQSGRKKHKKHASKGS
SSSGIGCTDFWDLVLKNNVNRKGNKSVSPVSGAGEGETSPYSLASPLQLMN
TVHIHPAAPVPCVRHVDLTILQAKVPFPHSTQQRKTENKESDRGRNKAQSPSSQ
MLGHPVIRSSLLTEKLLRLLSIALPENKYSVSEAQAANGSGASTTATSTTTT
TTAASITPTPTAPTPTSPALVATAATSTVVAASITVTTTPTTATTVSPTTKG
SKSPAKVSDGSSSTDEKWSYSLTENQLSVEVLTSHCSEEGLEADANVLQLSR
GDSGTRDVLKLLNGARHLGYTLCKIGTGLLAELEYNLEQORRAQCTSLPDGLPE
EQPTTKLKGKMQSRFDMANVVIVASQKRPLGRLQLPSSMLTSKTSOKFFLVR
LQVILQIDDTTRANKAKQTRGSGSGSSIAQAVRQLEAEADATIQVREGOR
ARQQAQATSESSQASVRRSESPMDVQPSAQDTQSIASDGTPOGKEKEERP
ELPLLSOLSLDELMDMLGCLAEESHDQHAVLVLOPAVEAFFLVHATERSKPPV
RDRRESQALHIKDEPPPLSPAPLTPATPSLDFEFREPSSMHISSLPDQTKFLRF
AETHRTVLNQLIKRQSTHLDAGPFVAVLDYIRVDFDVRKKYFRQELERDEGLRKE
MAYHVRDHFVEDSYRELHRKSPENKRLIYVFEGEQODAGGLRLREYMLISREMF
NPMYALFTSPGDRVYTIINPSSHCNKLHLYEFKFGYRIVAKAYDNRLLEYCTFSF
YKHLGKSVRYTDMESDYHYQGLVTLGIDVSTLGYDLTFTFEQERQCEVDRDLK
PNGANILVTEENKKEYVHLVCOMRTGAIRKQALAELEGFYETIPKRLISIFTEQELE
LLISGLPTIDIDLKSNTEYHKYQSNISIQWFWRALRSFDQADRAKFLQVYTGTSKV
PLOGFAALEGMNGIKFQIHRDRDRSDRLPSAHTCFNQLDLPAYSEFEKLRHMLLAI
QECSEGFGLA"
1952..2131
/gene="LASU1"
/note="HWE domain"
9305..10225
/gene="LASU1"
/note="HECT-domain (ubiquitin-transferase)"
10229..10348
/gene="LASU1"
BASE COUNT 2684 a 2656 g 2251 t
ORIGIN
Query Match 3.8%; Score 76; DB 9; Length 10348;

Best Local Similarity 100.0%; Pred. No. 1.8e-31;
 Matches 76; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 10 GGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGAGATGAAGACGATGA 69
 Db 4420 GGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGAGATGAAGACGATGA 4479
 QY 70 CGACGATGGCTCTGAG 85
 Db 4480 CGACGATGGCTCTGAG 4495

Search completed: July 4, 2003, 03:58:32
 Job time : 5242 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model
Run on: July 4, 2003, 00:36:13 ; Search time 456 Seconds
(without alignments)
9951.264 Million cell updates/sec

Title: US-10-007-010-3
Perfect score: 2015
Sequence: 1 cggaggcaggaatgagg.....atataaatgcaagtcttacg 2015

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2185239 seqs, 1125999159 residues

Word size : 0
Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N_Geneseq_101002.*			
1:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*		
2:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*		
3:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*		
4:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*		
5:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*		
6:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*		
7:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*		
8:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*		
9:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*		
10:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*		
11:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*		
12:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*		
13:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*		
14:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*		
15:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*		
16:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*		
17:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*		
18:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*		
19:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*		
20:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*		
21:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*		
22:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*		
23:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*		
24:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*		

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2015	100.0	2015	24	ABK83939 Human cDNA differe
2	2015	100.0	2015	24	ABL66673 Lung cancer relate
3	1552	77.0	1926	24	ABK83940 Human cDNA differe
4	183	9.1	183	24	ABL61214 Human nucleotide f
5	181	9.0	1416	24	ABL61215 Rat/human fusion c
6	181	9.0	1542	24	ABL61216 Rat/human fusion c
7	169	8.4	369	16	AAT19957 Human gene signatu
8	133	6.6	171	22	ABA50558 Human breast cell
9	133	6.6	171	22	ABA69516 Human foetal liver

10	133	6.6	171	22	ABA35497	Probe #13963 for g
11	133	6.6	171	22	AAK16884	Human brain expres
12	133	6.6	171	22	AAK42654	Human bone marrow
13	133	6.6	171	22	AAI23408	Probe #13341 for g
14	133	6.6	171	22	AAI48728	Probe #17414 used t
15	133	6.6	171	22	AAI09035	Probe #9026 used t
16	133	6.6	171	24	ABSI6706	Human genome-deriv
17	113	5.6	415	22	ABA45430	Human breast cell
18	113	5.6	415	22	ABA55928	Human foetal liver
19	113	5.6	415	22	ABA25595	Probe #4061 for ge
20	113	5.6	415	22	AAK04142	Human brain expres
21	113	5.6	415	22	AAK29623	Human bone marrow
22	113	5.6	415	22	AAI14202	Probe #4135 for ge
23	113	5.6	415	22	AAI35583	Probe #4269 used t
24	113	5.6	415	22	AAI04039	Probe #4030 used t
25	113	5.6	415	24	ABS04179	Human genome-deriv
26	112	5.6	1592	20	AAZ27241	Human secreted pro
27	78	3.9	409	22	AAH99174	Human protein enco
28	77	3.8	334	21	AAA52650	Eosinophil activat
29	68	3.4	1911	24	AAK63704	Rat sequence diffe
30	66	3.3	274	22	AAK68573	Human immune/haema
31	65	3.2	1926	24	AAK83940	Human cDNA differe
32	31	1.5	31	22	AAI30734	Human single nucle
33	31	1.5	31	22	AAI30735	Human single nucle
34	31	1.5	31	22	AAI30736	Human single nucle
35	31	1.5	31	22	AAI30737	Human single nucle
36	31	1.5	31	22	AAI30738	Human single nucle
37	28	1.4	2298	24	ABK83935	Human cDNA differe
38	27	1.3	33	22	AAH41498	Human tyrosine kin
39	26	1.3	32	22	AAH41491	Human tyrosine kin
40	26	1.3	32	22	AAH41492	Human tyrosine kin
41	26	1.3	1602	14	AAQ46687	Chicken pp60 c-src
42	26	1.3	1759	21	AAZ29700	Wild-type chicken
43	26	1.3	1759	22	AAH28357	Nucleotide sequenc
44	25	1.2	32	22	AAH41501	Human tyrosine kin
45	25	1.2	51	23	ABL00375	Human silent nonco

ALIGNMENTS

RESULT 1

ABK83939

ID

ABK83939 standard; cdNA; 2015 BP.

AC

ABK83939;

XX

DT

14-AUG-2002 (first entry)

XX

XX

Human cDNA differentially expressed in granulocytic cells #510.

DE

XX

Human; ss; granulocytic cell; DNA chip; bacterial infection;

KW

XX

viral infection; parasitic infection; protozoal infection;

KW

XX

fungal infection; sterile inflammatory disease; psoriasis;

KW

XX

rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;

KW

XX

cardiac reperfusion injury; renal reperfusion injury; ARDS;

KW

XX

adult respiratory distress syndrome; inflammatory bowel disease;

KW

XX

Crohn's disease; ulcerative colitis; periodontal disease;

KW

XX

granulocyte activation; chronic inflammation; allergy.

OS

XX

Homo sapiens.

XX

XX

WO200228999-A2.

PN

XX

11-APR-2002.

PD

XX

03-OCT-2001; 2001WO-US30821.

XX

XX

03-OCT-2000; 2000US-237189P.

XX

XX

(GENE-) GENE LOGIC INC.

PA

XX

Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;

PI

ALIGNMENTS

RESULT 1
ABK83939
ID ABK83939 standard; cDNA; 2015 BP.
XX
AC ABK83939;
XX
14-AUG-2002 (first entry)
XX
Human cDNA differentially expressed in granulocytic cells #510.
XX
Human; ss; granulocytic cell; DNA chip; bacterial infection;
XX
viral infection; parasitic infection; protozoal infection;
XX
fungal infection; sterile inflammatory disease; psoriasis;
XX
rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
XX
cardiac reperfusion injury; renal reperfusion injury; ARDS;
XX
adult respiratory distress syndrome; inflammatory bowel disease;
XX
Crohn's disease; ulcerative colitis; periodontal disease;
XX
granulocyte activation; chronic inflammation; allergy.
XX
Homo sapiens.
XX
WO200228999-A2.
XX
11-APR-2002.
XX
03-OCT-2001; 2001WO-US30821.
XX
03-OCT-2000; 2000US-237189P.
XX
(GENE-) GENE LOGIC INC.
XX
Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;
PI

XX WPI: 2002-435328/46.
DR
XX
PT Detecting granulocyte activation by detecting differential expression
PT of genes associated with granulocyte activation, which serves as
PT diagnostic markers that is useful for monitoring disease states and
PT drug toxicity -
XX
XX Claim 1: SEQ ID No 510; 114pp; English.
XX
CC The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing
CC the expression level to an expression level in an unactivated
CC GC, where differential expression of Gs is indicative of GCA.
CC Also included are modulating (M2) GA by contacting GC with an agent
CC that alters the expression of at least one gene in Gs; (2) screening (M3)
CC for an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from Gs, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GCA; M3 is useful for screening an agent capable of modulating
CC GCA preferably in an inflammation in a tissue; M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease; also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions. The present
CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2015 BP; 512 A; 540 G; 580 G; 383 T; 0 other;

Query Match 100.0%; Score 2015; DB 24; Length 2015;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2015; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGATGCA 60
Db 1 CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGATGCA 60

Qy 61 AGACGATGACGACGATGGCTTCTGAGGGGACCTCAGGGGCTGCCAGCTGGGGGGGGCTC 120
Db 61 AGACGATGACGACGATGGCTTCTGAGGGGACCTCAGGGGCTGCCAGCTGGGGGGGGCTC 120

Qy 121 AAGCTGCGAGGATCCGGGCTGCCGCGAGACGAGGAGGGGGCCAGGATGGGGTCGATG 180
Db 121 AAGCTGCGAGGATCCGGGCTGCCGCGAGACGAGGAGGGGGCCAGGATGGGGTCGATG 180

Qy 181 AAGTCCAAAGTTCTCCAGGTGCGGAGCAATACATTTCTCAAAACTGAAACCGCGCAGC 240
Db 181 AAGTCCAAAGTTCTCCAGGTGCGGAGCAATACATTTCTCAAAACTGAAACCGCGCAGC 240

Qy 241 CCACACTGTCTGTGTACGTGCGGGATCCACATCCACCATCAAGCCGGGGCTAATAGC 300
Db 241 CCACACTGTCTGTGTACGTGCGGGATCCACATCCACCATCAAGCCGGGGCTAATAGC 300

Qy 301 CACAACACACACACACAGGATCAGGAGGAGGCTCTGAGGACATCATCTGTTGCC 360
Db 301 CACAACACACACACACAGGATCAGGAGGAGGCTCTGAGGACATCATCTGTTGCC 360

Qy 361 CTGTATGATTACGAGGCACTTACCACGAAGACCTCAGCTTCCAGAAAGGGGACAGATG 420
Db 361 CTGTATGATTACGAGGCACTTACCACGAAGACCTCAGCTTCCAGAAAGGGGACAGATG 420

Qy 421 GTGCTCTTAGAGGAATCCGGGGAGTGTGGAAGGCTCGATCCCTGGCCACCCGGAAGGAG 480
Db 421 GTGCTCTTAGAGGAATCCGGGGAGTGTGGAAGGCTCGATCCCTGGCCACCCGGAAGGAG 480

Qy 481 GGCTACATCCCAACCACTATGTCCCGCGTCTGACTCTCTGGAGACAGAGGAGTGTGTTT 540
Db 481 GGCTACATCCCAACCACTATGTCCCGCGTCTGACTCTCTGGAGACAGAGGAGTGTGTTT 540

Qy 541 TTCAAGGGCATCAGCCGGAAGGACGAGAGCGCAACTGTGCTCCCGCAACATGCTG 600
Db 541 TTCAAGGGCATCAGCCGGAAGGACGAGAGCGCAACTGTGCTCCCGCAACATGCTG 600

Qy 601 GGCTCCTTCATGATCCGGGATAGCGAGACCACTAAAGGAAGCTTACTCTTTGTCGGTGG 660
Db 601 GGCTCCTTCATGATCCGGGATAGCGAGACCACTAAAGGAAGCTTACTCTTTGTCGGTGG 660

Qy 661 GACTACGACCTCGCGAGGAGATACCGTGAACATTTACAAGATCCGACCTCGGACCAAC 720
Db 661 GACTACGACCTCGCGAGGAGATACCGTGAACATTTACAAGATCCGACCTCGGACCAAC 720

Qy 721 GGGGCTCTTACATATCCCCCGAAGCACTTTCAGCACTCTGCAAGAGCTGGTGACAC 780
Db 721 GGGGCTCTTACATATCCCCCGAAGCACTTTCAGCACTCTGCAAGAGCTGGTGACAC 780

Qy 781 TACAAGAGGGGAACGAGCGGCTCTGCCAGAACTGTCGGTCCCTCATCTGTTCCAAG 840
Db 781 TACAAGAGGGGAACGAGCGGCTCTGCCAGAACTGTCGGTCCCTCATCTGTTCCAAG 840

Qy 841 CCCAGAGCCCTCGGAGAAAGATGCTCGGAGATCCCTCGGGAATCCCTCAAGCTGGAG 900
Db 841 CCCAGAGCCCTCGGAGAAAGATGCTCGGAGATCCCTCGGGAATCCCTCAAGCTGGAG 900

Qy 901 AAGAACTTGGAGCTGGGACGTTTGGGAACTCTGGATGCCACCTACAAACAGCACACC 960
Db 901 AAGAACTTGGAGCTGGGACGTTTGGGAACTCTGGATGCCACCTACAAACAGCACACC 960

Qy 961 AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCTTCTCCGCGAGAG 1020
Db 961 AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCTTCTCCGCGAGAG 1020

Qy 1021 GCCAACGTGATGAAAACCTCTCAGCATGACAAGCTGGTCAAACTTCATGCGGTGGTCACC 1080
Db 1021 GCCAACGTGATGAAAACCTCTCAGCATGACAAGCTGGTCAAACTTCATGCGGTGGTCACC 1080

Qy 1081 AAGAGGCCATCTACATCATCAGCAGTTTCATGCCAAAGGAAGCTTGTGGAGTTTCTG 1140
Db 1081 AAGAGGCCATCTACATCATCAGCAGTTTCATGCCAAAGGAAGCTTGTGGAGTTTCTG 1140

Qy 1141 AAAAGTGTAGGGGACGAGCCATTCGCAAACTTCGCAAACTTCATGAGCCAGATT 1200
Db 1141 AAAAGTGTAGGGGACGAGCCATTCGCAAACTTCGCAAACTTCATGAGCCAGATT 1200

Qy 1201 CGAGAAGCATGCGCTTCATCGAGCAGAGGAACATACATCCACCGAGACCTCCGAGCTGCC 1260
Db 1201 CGAGAAGCATGCGCTTCATCGAGCAGAGGAACATACATCCACCGAGACCTCCGAGCTGCC 1260

Qy 1261 AACATCTTGGTCTCTGCATCCCTGGTGTGAAGATTTGCTGACTTTGGCCCTGGCCGGGTC 1320
Db 1261 AACATCTTGGTCTCTGCATCCCTGGTGTGAAGATTTGCTGACTTTGGCCCTGGCCGGGTC 1320

Qy 1321 ATTGAGGACACGAGTACACGCTCGGGAAGGGCCCAAGTTCCCATCAAGTGCACAGCT 1380
Db 1321 ATTGAGGACACGAGTACACGCTCGGGAAGGGCCCAAGTTCCCATCAAGTGCACAGCT 1380

Qy 1381 CCTGAAGCATCAACTTTTGGTCTCTTACCATCAAGTCAGACGCTCTGCTCTTGGTATC 1440

Qy	1	CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGGAGATGA	60
Db			
Qy	1	CGGAGGCACGGAAGATGAGGAAGATGATCAGGAGGATGATGAAGGTGAAGAGGGAGATGA	60
Db			
Qy	61	AGACGATGACGACGATGGCTCTGAGGGACCTCAGGGGCTGCCAGCTGGGGGGGGCGCTC	120
Db			
Qy	61	AGACGATGACGACGATGGCTCTGAGGGACCTCAGGGGCTGCCAGCTGGGGGGGGCGCTC	120
Db			
Qy	121	AAGCTGGAGGATCCGGGCTGCCCGCAGACGAGGAGCGGCGCCAGATGGGGTCGATG	180
Db			
Qy	121	AAGCTGGAGGATCCGGGCTGCCCGCAGACGAGGAGCGGCGCCAGATGGGGTCGATG	180
Db			
Qy	181	AAGTCCAAGTTCCTCCAGGTCGGAGGCAATACATCTCAAAAACGAGGCGCAGC	240
Db			
Qy	181	AAGTCCAAGTTCCTCCAGGTCGGAGGCAATACATCTCAAAAACGAGGCGCAGC	240
Db			
Qy	241	CCACATGTCTGTGTACGTCCGGATCCACATCCACCATCAAGCGGGGCTTAATAGC	300
Db			
Qy	241	CCACATGTCTGTGTACGTCCGGATCCACATCCACCATCAAGCGGGGCTTAATAGC	300
Db			
Qy	301	CACAACAGCAACACACAGGAATCAGGAGGCGAGGCTCTGAGGACATCATCTGTTGCC	360
Db			
Qy	301	CACAACAGCAACACACAGGAATCAGGAGGCGAGGCTCTGAGGACATCATCTGTTGCC	360
Db			
Qy	361	CTGTATGATTTACGAGGCCATTCAACACGAGACCTCAGCTTCAGAAGGGGACAGATG	420
Db			
Qy	361	CTGTATGATTTACGAGGCCATTCAACACGAGACCTCAGCTTCAGAAGGGGACAGATG	420
Db			
Qy	421	GTGGTCTCTAGAGGAATCCGGGGAGTGTGGAAGGCTCGATCCCTGGGCCACCCGGAAGG	480
Db			
Qy	421	GTGGTCTCTAGAGGAATCCGGGGAGTGTGGAAGGCTCGATCCCTGGGCCACCCGGAAGG	480
Db			
Qy	481	GGCTACATCCCAAGCAACTATGTGCCCGGTTGACTCTCTGGAGACAGAGGAGTGGTTT	540
Db			
Qy	481	GGCTACATCCCAAGCAACTATGTGCCCGGTTGACTCTCTGGAGACAGAGGAGTGGTTT	540
Db			
Qy	541	TTCAAGGGCATCAGCCGGAAGGACGAGAGGGCCAACTGCTGGTCCCGGCACATGCTG	600
Db			
Qy	541	TTCAAGGGCATCAGCCGGAAGGACGAGAGGGCCAACTGCTGGTCCCGGCACATGCTG	600
Db			
Qy	601	GGCTCCTTCATGATCCGGGATAGCGAGACCATTAAAGGAAGCTACTTTTGTCCGTGCGA	660
Db			
Qy	601	GGCTCCTTCATGATCCGGGATAGCGAGACCATTAAAGGAAGCTACTTTTGTCCGTGCGA	660
Db			
Qy	661	GACTACGACCTCGGACGGAGATACCGTGAACATTTACAAGATTCGGACCCCTGGACAAC	720
Db			
Qy	661	GACTACGACCTCGGACGGAGATACCGTGAACATTTACAAGATTCGGACCCCTGGACAAC	720
Db			
Qy	721	GGGGCTTCACATATCCCCCGAGACACCTTCAGCACTCTGAGGAGCTGGTGGACCAC	780
Db			
Qy	721	GGGGCTTCACATATCCCCCGAGACACCTTCAGCACTCTGAGGAGCTGGTGGACCAC	780
Db			
Qy	781	TACAAGAAGGGGAACGACGGGCTCTGCCAAGAACTGTCGGTGGCTGCATGTCTTCCAAG	840
Db			
Qy	781	TACAAGAAGGGGAACGACGGGCTCTGCCAAGAACTGTCGGTGGCTGCATGTCTTCCAAG	840
Db			
Qy	841	CCCCAGAAGCCTTGGGAGAAAGATGCTGGAGATCCCTTCGGGAATCCCTCAAGCTGGAG	900
Db			
Qy	841	CCCCAGAAGCCTTGGGAGAAAGATGCTGGAGATCCCTTCGGGAATCCCTCAAGCTGGAG	900
Db			
Qy	901	AAGAAACTTGGAGCTGGGCTTGGGAGTGTGGGAAGTCTGGATGGCCACCTACACAAGCACACC	960
Db			
Qy	901	AAGAAACTTGGAGCTGGGCTTGGGAGTGTGGGAAGTCTGGATGGCCACCTACACAAGCACACC	960
Db			
Qy	961	AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCTTCCTGGCAGAG	1020
Db			
Qy	961	AAGTGGCAGTGAAGACGATGAAGCCAGGAGCATGTCGGTGGAGGCTTCCTGGCAGAG	1020
Db			
Qy	1021	GCCAACTGATGAAACTCTGCAGATGACAAAGCTGGTCAAACTTCATGCGGTGGTCACC	1080
Db			
Qy	1021	GCCAACTGATGAAACTCTGCAGATGACAAAGCTGGTCAAACTTCATGCGGTGGTCACC	1080
Db			

QY	1081	AAGGAGCCCATCTACATCATCAGGAGTTTCATGGCCAAAGAAAGCTGTCTGGACTTCTCG	1144
DB			
1081	AAGGAGCCCATCTACATCATCAGGAGTTTCATGGCCAAAGAAAGCTGTCTGGACTTCTCG	1144	
QY	1141	AAAAGTGTAGGGCAGCAAGCAGCCATTGCCAAAACCTCAATTGACTTCTCAGCCCCAGATT	1200
DB			
1141	AAAAGTGTAGGGCAGCAAGCAGCCATTGCCAAAACCTCAATTGACTTCTCAGCCCCAGATT	1200	
QY	1201	GCAGAAAGCATGGCTTTCATCGAGCAGAGAACTACATCCACCGAGACCTCCCGAGCTGCC	1260
DB			
1201	GCAGAAAGCATGGCTTTCATCGAGCAGAGAACTACATCCACCGAGACCTCCCGAGCTGCC	1260	
QY	1261	AACATCTTGGTCTCTGCATCCCTGGTGTGAAGATTGCTGACTTTGGCTGGCCCCGGTCT	1320
DB			
1261	AACATCTTGGTCTCTGCATCCCTGGTGTGAAGATTGCTGACTTTGGCTGGCCCCGGTCT	1320	
QY	1321	ATTGAGGACACGAGTAGACGGCTCGGGAGGGGCCAAGTTCCTCCCATCAAGTGGACAGCT	1380
DB			
1321	ATTGAGGACACGAGTAGACGGCTCGGGAGGGGCCAAGTTCCTCCCATCAAGTGGACAGCT	1380	
QY	1381	CCTGAAGCCATCAACTTTGGCTCCTTCACCATCAAGTCAGACGCTCTGGTCTTTGGTATC	1440
DB			
1381	CCTGAAGCCATCAACTTTGGCTCCTTCACCATCAAGTCAGACGCTCTGGTCTTTGGTATC	1440	
QY	1441	CTGCTGATGGAGATGCTACCTAGGCCGGATCCCTTACCCAGGATGTCAAACCTCGAA	1500
DB			
1441	CTGCTGATGGAGATGCTACCTAGGCCGGATCCCTTACCCAGGATGTCAAACCTCGAA	1500	
QY	1501	GTGATCCGAGCTCTGGAGCTGGATACCGGATGCCTCGCCACAGAACTGCCCAGAGGAG	1560
DB			
1501	GTGATCCGAGCTCTGGAGCTGGATACCGGATGCCTCGCCACAGAACTGCCCAGAGGAG	1560	
QY	1561	CTCTACAAACATCATGATGCGCTGCTGAAAAACCGTCCGGAGGAGCGCGACTTTCGAA	1620
DB			
1561	CTCTACAAACATCATGATGCGCTGCTGAAAAACCGTCCGGAGGAGCGCGACTTTCGAA	1620	
QY	1621	TACATCAGAGTGTGCTGGATGACTTCTACAGGCCACAGAGAGCCAGTACCAACAGCAG	1680
DB			
1621	TACATCAGAGTGTGCTGGATGACTTCTACAGGCCACAGAGAGCCAGTACCAACAGCAG	1680	
QY	1681	CCATGATAGGAGGACACAGGCGAGGGGTGCCAGGTGGTGGCTCGAAGGTGGCTT	1740
DB			
1681	CCATGATAGGAGGACACAGGCGAGGGGTGCCAGGTGGTGGCTCGAAGGTGGCTT	1740	
QY	1741	CCAGCACCATCCGGCAGGGGCCACACCCCTTCTACTCCACAGACACCCACCTCGCTTC	1800
DB			
1741	CCAGCACCATCCGGCAGGGGCCACACCCCTTCTACTCCACAGACACCCACCTCGCTTC	1800	
QY	1801	AGCCACAGTTTCCCTCATCTCTCAGAGTGGGTAGGCTGGAGAAATCTCTTTTTGACTCT	1860
DB			
1801	AGCCACAGTTTCCCTCATCTCTCAGAGTGGGTAGGCTGGAGAAATCTCTTTTTGACTCT	1860	
QY	1861	TTGCAATCCCAATCTGACATCTCAGGAGCCCCCAAGTTTGATATTCTATTCTCTGGA	1920
DB			
1861	TTGCAATCCCAATCTGACATCTCAGGAGCCCCCAAGTTTGATATTCTATTCTCTGGA	1920	
QY	1921	ATGCTTGGATTTAGTTTACAGCTGTGATTTGGAAGGGAACCTTCAAATAGTGAATGA	1980
DB			
1921	ATGCTTGGATTTAGTTTACAGCTGTGATTTGGAAGGGAACCTTCAAATAGTGAATGA	1980	
QY	1981	ATATTTAAATAAAGATATATAATGCAAGTCTTACG	2015
DB			
1981	ATATTTAAATAAAGATATATAATGCAAGTCTTACG	2015	

DE Human cDNA differentially expressed in granulocytic cells #511.
XX Human; ss: granulocytic cell; DNA chip; bacterial infection;
KW viral infection; parasitic infection; protozoal infection;
KW fungal infection; sterile inflammatory disease; psoriasis;
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW adult respiratory distress syndrome; inflammatory bowel disease;
KW Crohn's disease; ulcerative colitis; periodontal disease;
KW granulocyte activation; chronic inflammation; allergy.
XX Homo sapiens.
OS
XX WO200228999-A2.
PN
XX 11-APR-2002.
PD
XX 03-OCT-2001; 2001WO-US30821.
PF
XX 03-OCT-2000; 2000US-237189P.
PR
XX (GENE-) GENE LOGIC INC.
PA
XX Beazer-Barclay Y, Weissman SM, Yamaga S, Vockley J;
PI WPI; 2002-435328/46.
XX
DR Detecting granulocyte activation by detecting differential expression
PT of genes associated with granulocyte activation, which serves as
PT diagnostic markers that is useful for monitoring disease states and
PT drug toxicity -
XX
PS Claim 1; SEQ ID No 511; 114pp; English.
XX
CC The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing
CC the expression level to an expression level in an unactivated
CC GC, where differential expression of Gs is indicative of GCA.
CC Also included are modulating (M2) GA by contacting GC with an agent
CC that alters the expression of at least one gene in Gs; (2) screening (M3)
CC for an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from Gs, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GA; M3 is useful for screening an agent capable of modulating
CC GCA preferably in a tissue; M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease; also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions. The present
CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 1926 BP; 497 A; 522 C; 520 G; 387 T; 0 other;

	Query Match	77.0%	Score 1552;	DB 24;	Length 1926;
	Best Local Similarity	100.0%;	Pred. No. 0;		
	Matches 1552;	Conservative	0;	Mismatches	0;
				Indels	Gaps
QY	178	ATGAAGTCCAAGTTCCTCCAGGTCGGAGGCAATACATCTCTCAAAAACCTGAAACCCAGCGCC	237		
DB	85	ATGAAGTCCAAGTTCCTCCAGGTCGGAGGCAATACATCTCTCAAAAACCTGAAACCCAGCGCC	144		
QY	238	AGCCACACTGCTGTGTGTACGTGCGGATCCACATCCACCATCAAGCCGGGGGCTTAAT	297		
DB	145	AGCCACACTGCTGTGTGTACGTGCGGATCCACATCCACCATCAAGCCGGGGGCTTAAT	204		
QY	298	AGCCACACAGCAACACACACAGGAATCAGGAGGAGGCTCTGAGGACATCATCTGGTGT	357		
DB	205	AGCCACACAGCAACACACACAGGAATCAGGAGGAGGCTCTGAGGACATCATCTGGTGT	264		
QY	358	GCCTGTATGATTACGAGGCCATTCACACAGAGACCTCAGCTTCAGAAAGGGGACCCAG	417		
DB	265	GCCTGTATGATTACGAGGCCATTCACACAGAGACCTCAGCTTCAGAAAGGGGACCCAG	324		
QY	418	ATGGTGGTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGCCACCCGGGAG	477		
DB	325	ATGGTGGTCTAGAGGAATCCGGGGAGTGGTGAAGGCTCGATCCCTGCCACCCGGGAG	384		
QY	478	GAGGGCTACATCCCAAGCAACTATGTGCGCCCGCTTGACTCTCTGGAGACAGAGAGTG	537		
DB	385	GAGGGCTACATCCCAAGCAACTATGTGCGCCCGCTTGACTCTCTGGAGACAGAGAGTG	444		
QY	538	TTTTTCAAGGGCATCAGCCGGAAGGACGAGAGCGGCAACTGCTGGCTCCCGGCAACATG	597		
DB	445	TTTTTCAAGGGCATCAGCCGGAAGGACGAGAGCGGCAACTGCTGGCTCCCGGCAACATG	504		
QY	598	CTGGGCTCTCTATGATCCGGGATACGAGACCCACTAAAGGAAGTACTCTTTGTCCTG	657		
DB	505	CTGGGCTCTCTATGATCCGGGATACGAGACCCACTAAAGGAAGTACTCTTTGTCCTG	564		
QY	658	CGAGACTACGACCTCGCAGGAGATACCGTGAACATTTACAAGATCCGGACCTCGGAC	717		
DB	565	CGAGACTACGACCTCGCAGGAGATACCGTGAACATTTACAAGATCCGGACCTCGGAC	624		
QY	718	AAGGGGGCTTTACATATATCCCGGAGACCTTTCAGCACTCTGAGAGTGTGGGAC	777		
DB	625	AAGGGGGCTTTACATATATCCCGGAGACCTTTCAGCACTCTGAGAGTGTGGGAC	684		
QY	778	CACCTACAAGAGGGGAACGACGGCTCTGCCAGAACTGCTGGTCCCTGCTGATCTTCC	837		
DB	685	CACCTACAAGAGGGGAACGACGGCTCTGCCAGAACTGCTGGTCCCTGCTGATCTTCC	744		
QY	838	AAGCCCCAGAAGCCTTTGGGAGAAAGATGCTCTGGAGATCCCTCGGGAATCCCTCAAGTG	897		
DB	745	AAGCCCCAGAAGCCTTTGGGAGAAAGATGCTCTGGAGATCCCTCGGGAATCCCTCAAGTG	804		
QY	898	GAGAAAGAACTGGAGCTGGGAGTTGGGGAGTCTGGATGGCCACCTTACAAAGACAC	957		
DB	805	GAGAAAGAACTGGAGCTGGGAGTTGGGGAGTCTGGATGGCCACCTTACAAAGACAC	864		
QY	958	ACCAAGTGGCAGTGAAGACAGATGAAGCCAGGAGCATGCTGCTGGAGGCTTCTCTGGCA	1017		
DB	865	ACCAAGTGGCAGTGAAGACAGATGAAGCCAGGAGCATGCTGCTGGAGGCTTCTCTGGCA	924		
QY	1018	GAGGCCAAGCTGATGAAACTCTGACAGATGACAAAGCTGGTCAAACTTCATCGGTGGTC	1077		
DB	925	GAGGCCAAGCTGATGAAACTCTGACAGATGACAAAGCTGGTCAAACTTCATCGGTGGTC	984		
QY	1078	ACCAAGGACCCATCTACATCATCAGGAGTTCTATGGCCAAAGAGAGCTTGTGACTTTT	1137		
DB	985	ACCAAGGACCCATCTACATCATCAGGAGTTCTATGGCCAAAGAGAGCTTGTGACTTTT	1044		
QY	1138	CTGAAAGTGATGAGGCGAGCAAGCCATTGCCCCAAACTATTGACTTCTCAGCCAG	1197		
DB	1045	CTGAAAGTGATGAGGCGAGCAAGCCATTGCCCCAAACTATTGACTTCTCAGCCAG	1104		
QY	1198	ATTGCAGAGGATGGCTTTCATCGAGCAGAGAGGAATACATCCACCGAGACCTCCGAGCT	1257		

Db 1105 ATTGCAAGAGGATGCTTCATCGAGCAGAGAACTACATCCACGAGACCTCCGAGCT 1164
Qy 1258 GCCAAACATCTGCTCTGTCATCCCTGGTGTGTAAGATTGCTGACTTTGGCTGGCCCGG 1317
Db 1165 GCCAACATCTGCTCTGTCATCCCTGGTGTGTAAGATTGCTGACTTTGGCTGGCCCGG 1224
Qy 1318 GTCATTGAGACAAACAGTACACGGCTCGGGAGGAGGCGCAAGTTCCTCCCAAGTGGACA 1377
Db 1225 GTCATTGAGACAAACAGTACACGGCTCGGGAGGAGGCGCAAGTTCCTCCCAAGTGGACA 1284
Qy 1378 GTCCTGAACCATCAACTTTGGCTCTTCACCATCAAGTCAGACGTCCTGGCTTTGGT 1437
Db 1285 GTCCTGAACCATCAACTTTGGCTCTTCACCATCAAGTCAGACGTCCTGGCTTTGGT 1344
Qy 1438 ATCTGCTGATGAGATGCTGACCTACGGCCGGATCCCTTACCCAGGGATGTCAAAACCT 1497
Db 1345 ATCTGCTGATGAGATGCTGACCTACGGCCGGATCCCTTACCCAGGGATGTCAAAACCT 1404
Qy 1498 GAAGTATCCGAGCTCTGGAGCTGGATACCGGATCCCTCGCCAGAGAACTGCCAGAG 1557
Db 1405 GAAGTATCCGAGCTCTGGAGCTGGATACCGGATCCCTCGCCAGAGAACTGCCAGAG 1464
Qy 1558 GAGCTCTACAAATCATGATGCTGCTGGAACCGTCCCGAGGAGGCGCGACCTTC 1617
Db 1465 GAGCTCTACAAATCATGATGCTGCTGGAACCGTCCCGAGGAGGCGCGACCTTC 1524
Qy 1618 GAATACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAGAGCCAGTACCAACAG 1677
Db 1525 GAATACATCCAGAGTGTGCTGGATGACTTCTACACGGCCACAGAGCCAGTACCAACAG 1584
Qy 1678 CAGCCATGATAGGAGGAGCAGGCGAGGCGAGGGGTGCCAGGTGGCT 1729
Db 1585 CAGCCATGATAGGAGGAGCAGGCGAGGCGAGGGGTGCCAGGTGGCT 1636

RESULT 4

ABL61214
ID ABL61214 standard; DNA; 183 BP.
XX ABL61214;
XX
DT 04-SEP-2002 (first entry)
DE Human nucleotide fragment capable of inactivating HIV Nef protein.
XX
XX Nef protein; fusion protein; virucide; anti-HIV; accessory protein;
KW pathogenicity; diagnosis; AIDS; human; ds.
XX
OS Homo sapiens.
XX DE10109532-C1.
XX
PD 13-JUN-2002.
XX
PF 28-FEB-2001; 2001DE-1009532.
XX
PR 28-FEB-2001; 2001DE-1009532.
XX
PA (GEYE/) GEYER M.
PA (PACK/) FACKLER O.
XX
PI Geyer M;
XX
DR WPI; 2002-418264/45.
XX
PT New fusion protein that blocks Nef protein, useful for treatment or
PT diagnosis of acquired immune deficiency syndrome, has high specificity
PT and affinity
XX
PS Claim 12; Page 14; 22pp; German.
XX
CC This invention describes a novel fusion protein for blocking the Nef

CC protein of human immune deficiency virus (HIV) which comprises: (i)
CC protein domain 1 that binds to a di-leucine (LL) motif; (ii) a
CC protein domain 2 that binds to a PxxP motif; and (iii) a polypeptide
CC linker between protein domains 1 and 2. The products of the invention
CC have virucide and anti-HIV activity and are capable of neutralising Nef,
CC an accessory protein essential for pathogenicity of HIV-1. The fusion
CC protein of the invention comprises the LL domain of the beta-subunit of
CC the adapter-protein complex AP-1 and the PxxP binding SH3 domain of
CC tyrosine kinase Hck, linked through a 60 amino acid peptide. The products
CC of the invention are used for in vitro diagnosis of AIDS and for
CC treatment of AIDS. The LL and PxxP motifs are specific for Nef, which,
CC unlike HIV protease, has no human homologue, so the fusion protein (which
CC binds Nef with very high affinity) should cause essentially no side
CC effects. This sequence represents a human derived nucleotide fragment
CC used in the construction of the fusion protein of the invention and which
CC contains a PXXP-motif binding motif useful to the invention.
XX
SQ Sequence 183 BP; 41 A; 50 C; 56 G; 36 T; 0 other;

Query Match 9.1%; Score 183; DB 24; Length 183;
Best Local Similarity 100.0%; Pred. No. 1.8e-79;
Matches 183; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 337 TCTGAGGACATCATCGTGTGCTCCCTGTATGATTACGAGGCCATTACACGAAAGCCTC 396
Db 1 TCTGAGGACATCATCGTGTGCTCCCTGTATGATTACGAGGCCATTACACGAAAGCCTC 60
Qy 397 AGCTTCCAGAGAGGGGGACCCAGATGGTGTCTCTAGAGGAATCCGGGGAGTGGTGAAGGCT 456
Db 61 AGCTTCCAGAGAGGGGGACCCAGATGGTGTCTCTAGAGGAATCCGGGGAGTGGTGAAGGCT 120
Qy 457 CGATCCCTGGCCACCCCGAAGAGGGCTTACATCCCAAGCAACTATGTCCGCCCGGTTGAC 516
Db 121 CGATCCCTGGCCACCCCGAAGAGGGCTTACATCCCAAGCAACTATGTCCGCCCGGTTGAC 180
Qy 517 TCT 519
Db 181 TCT 183

RESULT 5.

ABL61215
ID ABL61215 standard; DNA; 1416 BP.
XX
XX ABL61215;
XX
DT 04-SEP-2002 (first entry)
DE Rat/human fusion construct capable of inactivating HIV Nef protein.
XX
XX Nef protein; fusion protein; virucide; anti-HIV; accessory protein;
KW pathogenicity; diagnosis; AIDS; rat; human; ds.
XX
OS Rattus sp.
OS Homo sapiens.
OS Synthetic.
XX
XX DE10109532-C1.
XX
PD 13-JUN-2002.
XX
PF 28-FEB-2001; 2001DE-1009532.
XX
PR 28-FEB-2001; 2001DE-1009532.
XX
PA (GEYE/) GEYER M.
PA (PACK/) FACKLER O.
XX
PI Geyer M;
XX
DR WPI; 2002-418264/45.
XX
PT New fusion protein that blocks Nef protein, useful for treatment or

PT diagnosis of acquired immune deficiency syndrome, has high specificity
 XX and affinity
 PS
 XX
 XX
 XX
 XX
 CC Claim 13; Page 14-15; 22pp; German.
 CC This invention describes a novel fusion protein for blocking the Nef
 CC protein of human immune deficiency virus (HIV) which comprises: (i)
 CC protein domain 1 that binds to a di-leucine (LL) motif; (ii) a
 CC protein domain 2 that binds to a Pxxp motif; and (iii) a polypeptide
 CC linker between protein domains 1 and 2. The products of the invention
 CC have virucide and anti-HIV activity and are capable of neutralising Nef,
 CC an accessory protein essential for pathogenicity of HIV-1. The fusion
 CC protein of the invention comprises the LL domain of the beta-subunit of
 CC the adapter-protein complex AP-1 and the Pxxp binding SH3 domain of
 CC tyrosine kinase Hck, linked through a 60 amino acid peptide. The products
 CC of the invention are used for in vitro diagnosis of AIDS and for
 CC treatment of AIDS. The LL and Pxxp motifs are specific for Nef, which,
 CC unlike HIV protease, has no human homologue, so the fusion protein (which
 CC binds Nef with very high affinity) should cause essentially no side
 CC effects. This sequence represents a fusion construct composed of a rat
 CC nucleotide fragment which contains a dileucine (LL) motif and a human
 CC nucleotide fragment containing a Pxxp-motif binding domain useful to the
 CC invention.
 XX
 SQ Sequence 1416 BP; 340 A; 383 C; 386 G; 307 T; 0 other;
 Query Match 9.0%; Score 181; DB 24; Length 1416;
 Best Local Similarity 100.0%; Pred. No. 1.8e-78;
 Matches 181; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 339 TGAGGACATCATCGTGGTTCCTGTATGATTACGAGGCCATTACACCAAGACCTCAG 398
 DB 1233 TGAGGACATCATCGTGGTTCCTGTATGATTACGAGGCCATTACACCAAGACCTCAG 1292
 QY 399 CTTCAGAGGGGACACAGATGGTCTAGAGGAATCCGGGAGTGGTGAAGGCTCG 458
 DB 1293 CTTCAGAGGGGACACAGATGGTGGTCTAGAGGAATCCGGGAGTGGTGAAGGCTCG 1352
 QY 459 ATCCCTGGCCACCCGGAAGGGCTACATCCCAAGCACTATGTCCCGCGTTGACTC 518
 DB 1353 ATCCCTGGCCACCCGGAAGGGCTACATCCCAAGCACTATGTCCCGCGTTGACTC 1412
 QY 519 T 519
 DB 1413 T 1413
 RESULT 6
 ABL61216
 ID ABL61216 standard; DNA; 1542 BP.
 XX
 XX ABL61216;
 AC
 XX
 XX
 DT 04-SEP-2002 (first entry)
 XX
 DE Rat/human fusion construct capable of inactivating HIV Nef protein.
 XX
 XX Nef protein; fusion protein; virucide; anti-HIV; accessory protein;
 KW pathogenicity; diagnosis; AIDS; rat; human; ds.
 KW
 XX
 OS Rattus sp.
 OS Homo sapiens.
 OS Synthetic.
 PN DE10109532-C1.
 XX
 XX 13-JUN-2002.
 PD
 XX 28-FEB-2001; 2001DE-1009532.
 PF
 XX 28-FEB-2001; 2001DE-1009532.
 PR
 XX
 PA (GEYE/) GEYER M.

PA (PACK/) FACKLER O.
 XX
 PI Geyer M;
 XX
 DR WPI; 2002-418264/45.
 XX
 PT New fusion protein that blocks Nef protein, useful for treatment or
 PT diagnosis of acquired immune deficiency syndrome, has high specificity
 PT and affinity
 XX
 PS Claim 16; Page 15-16; 22pp; German.
 XX
 CC This invention describes a novel fusion protein for blocking the Nef
 CC protein of human immune deficiency virus (HIV) which comprises: (i)
 CC protein domain 1 that binds to a di-leucine (LL) motif; (ii) a
 CC protein domain 2 that binds to a Pxxp motif; and (iii) a polypeptide
 CC linker between protein domains 1 and 2. The products of the invention
 CC have virucide and anti-HIV activity and are capable of neutralising Nef,
 CC an accessory protein essential for pathogenicity of HIV-1. The fusion
 CC protein of the invention comprises the LL domain of the beta-subunit of
 CC the adapter-protein complex AP-1 and the Pxxp binding SH3 domain of
 CC tyrosine kinase Hck, linked through a 60 amino acid peptide. The products
 CC of the invention are used for in vitro diagnosis of AIDS and for
 CC treatment of AIDS. The LL and Pxxp motifs are specific for Nef, which,
 CC unlike HIV protease, has no human homologue, so the fusion protein (which
 CC binds Nef with very high affinity) should cause essentially no side
 CC effects. This sequence represents a fusion construct composed of a rat
 CC nucleotide fragment which contains a dileucine (LL) motif and a human
 CC nucleotide fragment containing a Pxxp-motif binding domain useful to the
 CC invention.
 XX
 SQ Sequence 1542 BP; 369 A; 419 C; 427 G; 327 T; 0 other;
 Query Match 9.0%; Score 181; DB 24; Length 1542;
 Best Local Similarity 100.0%; Pred. No. 1.8e-78;
 Matches 181; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 339 TGAGGACATCATCGTGGTTCCTGTATGATTACGAGGCCATTACACCAAGACCTCAG 398
 DB 1290 TGAGGACATCATCGTGGTTCCTGTATGATTACGAGGCCATTACACCAAGACCTCAG 1349
 QY 399 CTTCAGAGGGGACACAGATGGTCTAGAGGAATCCGGGAGTGGTGAAGGCTCG 458
 DB 1350 CTTCAGAGGGGACACAGATGGTCTAGAGGAATCCGGGAGTGGTGAAGGCTCG 1409
 QY 459 ATCCCTGGCCACCCGGAAGGGCTACATCCCAAGCACTATGTCCCGCGTTGACTC 518
 DB 1410 ATCCCTGGCCACCCGGAAGGGCTACATCCCAAGCACTATGTCCCGCGTTGACTC 1469
 QY 519 T 519
 DB 1470 T 1470
 RESULT 7
 AAT19957
 ID AAT19957 standard; CDNA to mRNA; 369 BP.
 XX
 XX AAT19957;
 AC
 XX
 XX 17-JUL-1996 (first entry)
 DT
 XX
 XX Human gene signature HUMGS01089.
 DE
 XX
 XX Gene signature; messenger RNA; mRNA; relative abundance; frequency;
 KW human; cloning; mapping; non-biased library; diagnosis; detection;
 KW cell typing; abnormal cell function; ss.
 KW
 XX Homo sapiens.
 OS
 XX
 XX WO9514772-A1.
 PN
 XX
 XX 01-JUN-1995.
 PD

```
XX 11-NOV-1994; 94WO-JP01916.
XX 12-NOV-1993; 93JP-0355504.
XX (MATSU) MATSUBARA K.
XX (OKUBO) OKUBO K.
XX Matsubara K, Okubo K;
XX WPI; 1995-206931/27.
XX
XX Identifying gene signatures in 3'-directed human cDNA library - e.g.
XX for diagnosis of abnormal cell function, by preparing cDNA that
XX reflects relative abundance of corresp. mRNA in specific human
XX tissues
XX
XX Claim 1; Page 520; 2245pp; Japanese.
XX
XX A single-stranded DNA (or its complementary strand or the corresp.
XX double-stranded DNA) which comprises one of the 7837 "GS" sequences
XX given in AAT19001-T26837 and which is able to hybridize to part of
XX human genomic DNA, cDNA or mRNA is claimed. The GS (Gene Signature)
XX sequences were obtained from 3'-directed cDNA libraries prepared
XX from various human tissues; synthesis of cDNA was initiated from the
XX 3'-end of mRNA by using poly(T) as the sole primer. Since the 3'-
XX untranslated sequence is unique to a particular mRNA species, almost
XX all the 3'-oriented cDNAs hybridize with specific mRNAs. Each library
XX is constructed so as to reflect accurately the relative abundance of
XX different mRNAs in the particular tissue from which it was derived.
XX The appearance frequency of a given GS in a cDNA library can be
XX determined (esp. using primers and probes derived from the GS
XX sequences) as a means of diagnosing abnormal cell function or for
XX recognising different cell types.
XX
XX Sequence 369 BP; 82 A; 97 C; 102 G; 75 T; 13 other;
XX
Query Match 8.4%; Score 169; DB 16; Length 369;
Best Local Similarity 100.0%; Pred. No. 1.4e-72;
Matches 169; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1535 CTCGCCAGAGAACTGCCAGAGGAGCTCTACAAATCATGATGCGCTCTGGAACACC 1594
DB 33 CTCGCCAGAGAACTGCCAGAGGAGCTCTACAAATCATGATGCGCTCTGGAACACC 92
QY 1595 GTCGGGAGGAGCGCGGACCTTCGAATACATCCAGAGTGTCTGGATGACTTCTACACGG 1654
DB 93 GTCGGGAGGAGCGCGGACCTTCGAATACATCCAGAGTGTCTGGATGACTTCTACACGG 152
QY 1655 CCACAGAGAGCCAGTACCAACAGCAGCCATGATAGGAGGAGCCAGGGCA 1703
DB 153 CCACAGAGAGCCAGTACCAACAGCAGCCATGATAGGAGGAGCCAGGGCA 201
RESULT 8
ABA50558
ID ABA50558 standard; DNA; 171 BP.
XX
XX ABA50558;
XX
XX 01-FEB-2002 (first entry)
XX
XX Human breast cell single exon nucleic acid probe #9253.
XX
XX Human; microarray; single exon probe; gene expression; breast;
XX disease; cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
```

```
PF 30-JAN-2001; 2001WO-US00662.
XX
XX 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes,
XX useful for measuring gene expression in sample derived from human
XX breast, comprises number of single exon nucleic acid probes -
XX
XX Claim 4; SEQ ID NO 9253; 327pp + sequence listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human breast and Br 474 cells. The method involves contacting
XX the probes with a collection of detectably labelled nucleic acids
XX derived from mRNA of human breast, and then measuring the label
XX bound to each probe of the microarray. The probes are useful for
XX verifying the expression of regions of genomic DNA predicted to
XX encode proteins. They are useful for gene discovery, and for
XX determining predisposition and/or prognosing breast disease. Gene
XX expression analysis is useful for assessing the toxicity of chemical
XX agents on cells. The microarray of this invention presents a far greater
XX diversity of probes for measuring gene expression, with far less bias
XX than expressed sequence tag microarrays. The method is suitable for
XX rapid production of functional information from genomic sequence. The
XX present sequence is a single exon nucleic acid probe of the invention.
XX Note: The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;
XX
Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1352 GGGCCAAAGTTCCTCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCTTACCA 1411
DB 1 GGGCCAAAGTTCCTCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCTTACCA 60
QY 1412 TCAAGTCAGAGCTCTGGTCCCTTTGGTATCCTGCTGATGGAGATCGTCACTTACGGCGGA 1471
DB 61 TCAAGTCAGAGCTCTGGTCCCTTTGGTATCCTGCTGATGGAGATCGTCACTTACGGCGGA 120
QY 1472 TCCCTTACCCAGG 1484
DB 121 TCCCTTACCCAGG 133
RESULT 9
ABA68516
ID ABA68516 standard; DNA; 171 BP.
XX
XX ABA68516;
XX
XX 01-FEB-2002 (first entry)
XX
XX Human foetal liver single exon nucleic acid probe #16821.
XX
XX Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
XX Homo sapiens.
XX
```



```
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488901/53.
XX Human genome-derived single exon nucleic acid probes useful for
XX analyzing gene expression in human cervical epithelial cells -
XX Claim 25; SEQ ID No 13341; 487pp; English.
XX The present invention relates to human single exon nucleic acid probes
XX (SENPs). The present sequence is one such probe. The SENPs are derived
XX from human HeLa cells. The SENPs can be used to produce a single exon
XX microarray, which can be used for measuring human gene expression in a
XX sample derived from human cervical epithelial cells. By measuring gene
XX expression, the probes are therefore useful in grading and/or staging
XX of diseases of the cervix, notably cervical cancer.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;

Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1352 GGGCCAAAGTTCCTGAGTGGACAGCTCCTGAGCCATCAACTTTGGCTCCTTCACCA 1411
DB 1 GGGCCAAAGTTCCTGAGTGGACAGCTCCTGAGCCATCAACTTTGGCTCCTTCACCA 60

QY 1412 TCAAGTCAGAGCTCTGGTCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 1471
DB 61 TCAAGTCAGAGCTCTGGTCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 120

QY 1472 TCCCTTACCAGG 1484
DB 121 TCCCTTACCAGG 133

RESULT 14
AA148728
ID AA148728 standard; DNA; 171 BP.
AC AA148728;
XX 17-OCT-2001 (first entry)
XX Probe #17414 used to measure gene expression in human placenta sample.
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX Homo sapiens.
XX WO200157272-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US00663.
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression
XX in a human breast -
XX Claim 25; SEQ ID No 9026; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes.
```

```
DR WPI; 2001-48897/53.
XX Human genome-derived single exon nucleic acid probes useful for
XX analyzing gene expression in human placenta -
XX Claim 25; SEQ ID No 17414; 654pp; English.
XX The present invention relates to single exon nucleic acid probes (SENPs).
XX The present sequence is one such probe. The probes are useful for
XX producing a microarray for predicting, measuring and displaying gene
XX expression in samples derived from human placenta. The probes are useful
XX for antenatal diagnosis of human genetic disorders.
XX Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;

Query Match 6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1352 GGGCCAAAGTTCCTGAGTGGACAGCTCCTGAGCCATCAACTTTGGCTCCTTCACCA 1411
DB 1 GGGCCAAAGTTCCTGAGTGGACAGCTCCTGAGCCATCAACTTTGGCTCCTTCACCA 60

QY 1412 TCAAGTCAGAGCTCTGGTCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 1471
DB 61 TCAAGTCAGAGCTCTGGTCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 120

QY 1472 TCCCTTACCAGG 1484
DB 121 TCCCTTACCAGG 133

RESULT 15
AA109035
ID AA109035 standard; DNA; 171 BP.
AC AA109035;
XX 09-OCT-2001 (first entry)
XX Probe #9026 used to measure gene expression in human breast sample.
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX Homo sapiens.
XX WO200157270-A2.
XX 09-AUG-2001.
XX 29-JAN-2001; 2001WO-US00661.
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression
XX in a human breast -
XX Claim 25; SEQ ID No 9026; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes.
```

CC The present sequence is one such probe. The probes are useful for
CC measuring human gene expression in a human breast sample, where the probe
CC hybridises at high stringency to a nucleic acid expressed in the human
CC breast. The probes are useful for predicting, diagnosing, grading,
CC staging, monitoring and prognosing diseases of the human breast,
CC particularly those diseases with polygenic aetiology. The diseases
CC include: breast cancer, disorders of development, inflammatory diseases
CC of the breast, fibrocystic changes, proliferative breast disease and
CC non-carcinoma tumours.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX

SQ Sequence 171 BP; 35 A; 53 C; 46 G; 37 T; 0 other;

```
Query Match          6.6%; Score 133; DB 22; Length 171;
Best Local Similarity 100.0%; Pred. No. 7.1e-55;
Matches 133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1352 GGGCCAAGTTCCCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 1411
Db      1 GGGCCAAGTTCCCCCATCAAGTGGACAGCTCCTGAAGCCATCAACTTTGGCTCCTTCACCA 60

Qy 1412 TCAAGTCAGACGCTGCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 1471
Db      61 TCAAGTCAGACGCTGCTTGGTATCCTGCTGATGGAGATCGTCACCTACGCCGGA 120

Qy 1472 TCCCTTACCCAGG 1484
Db      121 TCCCTTACCCAGG 133
```

Search completed: July 4, 2003, 02:31:01
Job time : 458 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 04:47:18 ; Search time 458 Seconds
(without alignments)
9907.809 Million cell updates/sec

Title: US-10-007-010-3

Perfect score: 2015

Sequence: 1 cggaggcacggaagatgagg.....atataaatgcaagtcttacc 2015

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 2185239 seqs, 1125999159 residues

Word size : 0

Total number of hits satisfying chosen parameters: 2390332

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Listing first 45 summaries

Database : N_Geneseq_101002.*

1: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	31	1.5	31	AAI30734	Human single nucle
2	31	1.5	31	AAI30735	Human single nucle
3	31	1.5	31	AAI30736	Human single nucle
4	31	1.5	31	AAI30737	Human single nucle
5	31	1.5	31	AAI30738	Human single nucle
6	27	1.3	33	AAH41498	Human tyrosine kin
7	26	1.3	32	AAH41491	Human tyrosine kin
8	26	1.3	32	AAH41492	Human tyrosine kin
9	25	1.2	32	AAH41501	Human tyrosine kin

10	25	1.2	51	23	ABL00375	Human silent nonco
11	24	1.2	32	22	AAH41500	Human tyrosine kin
12	24	1.2	78	22	AAC90044	PCR primer used to
13	21	1.0	21	22	AAF95624	Human gene single
14	21	1.0	21	22	AAF95625	Human gene single
15	21	1.0	21	22	AAF95626	Human gene single
16	21	1.0	21	22	AAF95627	Human gene single
17	21	1.0	21	22	AAF95628	Human gene single
18	21	1.0	21	22	AAF95629	Human gene single
19	21	1.0	21	22	AAF95630	Human gene single
20	20	1.0	20	16	AAT41207	Human gene signatu
21	20	1.0	20	16	AAT41208	Human gene signatu
22	19	0.9	51	22	AAI33024	Human SNP oligonuc
23	19	0.9	51	22	AAI33025	Human SNP oligonuc
24	18	0.9	19	21	AAH82879	cdk4 ribozyme bind
25	18	0.9	19	22	AAH58041	Cell-cycle depende
26	18	0.9	20	20	AAH29342	Chemically modifie
27	18	0.9	20	20	AAH29331	JNK2-specific prob
28	18	0.9	20	21	AAC62874	JNK antisense olig
29	18	0.9	20	21	AAC62885	JNK antisense olig
30	18	0.9	20	21	AAA48651	Antisense oligonuc
31	18	0.9	20	22	AAH23754	JNK1 antisense oli
32	18	0.9	20	22	AAF99183	Immunostimulatory
33	18	0.9	20	24	ABL39057	Immunostimulatory
34	18	0.9	34	22	AAH41497	Human tyrosine kin
35	18	0.9	48	24	ABK30196	CYP2D6 gene polymo
36	18	0.9	51	24	ABK30195	CYP2D6 gene polymo
37	17	0.8	19	21	AAH82878	cdk4 ribozyme bind
38	17	0.8	19	22	AAH58040	Cell-cycle depende
39	17	0.8	20	20	AAH01356	PCR primer for mou
40	17	0.8	20	22	AAF72970	Human daxx inhibit
41	17	0.8	21	24	ABK40441	Forward PCR primer
42	17	0.8	23	14	AAQ49744	PRK primer pTK2.
43	17	0.8	23	16	AAT03086	Protein tyrosine-k
44	17	0.8	25	21	AAZ37264	PCR primer for SGR
45	17	0.8	57	22	AAH04769	Synthetic gene shG

ALIGNMENTS

RESULT 1

AAI30734

ID AAI30734 standard; DNA; 31 BP.

XX

AC AAI30734;

XX

DT 18-OCT-2001 (first entry)

XX

DE Human single nucleotide polymorphism (SNP) HCK 1.

XX

KW Human; resequence; genotype; disease; forensic; paternity testing;

XX single nucleotide polymorphism; SNP; ss.

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Variation replace(16,T)

FT /*tag= a

FT /standard_name= "single nucleotide polymorphism"

PN WO200156800-A2.

XX

XX 13-SEP-2001.

PD

XX 07-MAR-2001; 2001WO-US07268.

XX

XX 07-MAR-2000; 2000US-0187510.

PR 22-MAY-2000; 2000US-0206129.

XX

PA (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX

PI Cargill M, Ireland JS, Lander ES;

CC	The invention relates to the identification of nucleic acid molecules
CC	(AAI29513-AAI31314) from the human genome which include polymorphic sites
CC	which can predispose individuals to disease. Various genes from a number
CC	of individuals were resequenced and single nucleotide polymorphisms
CC	(SNPs) in these genes discovered. The method is useful for predicting the
CC	presence, absence or severity of a particular phenotype or disorder (e.g.
CC	diabetes) associated with a particular genotype. The nucleic acids
CC	containing the polymorphic sites may be useful in forensics and paternity
CC	testing.
XX	
XX	Sequence 31 BP; 8 A; 8 C; 9 G; 6 T; 0 other;
XX	
XX	Query Match 1.5%; Score 31; DB 22; Length 31;
XX	Best Local Similarity 100.0%; Pred. No. 0.0001;
XX	Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX	
QY	1195 CAGATTGCAGAGGCATGGCCTTCATCGAGC 1225
DB	1 CAGATTGCAGAGGCATGGCCTTCATCGAGC 31
XX	
XX	AAI30736;
XX	
DT	18-OCT-2001 (first entry)
XX	
DE	Human single nucleotide polymorphism (SNP) HCK 3.
XX	
KW	Human; resequencing; genotype; disease; forensic; paternity testing;
KW	single nucleotide polymorphism; SNP; ss.
XX	
OS	Homo sapiens.
XX	
XX	Key Location/Qualifiers
PH	Variation replace(16,A)
FT	/*tag= a
FT	/standard_name= "single nucleotide polymorphism"
XX	
PN	WO200166800-A2.
XX	
PD	13-SEP-2001.
XX	
PF	07-MAR-2001; 2001WO-US07268.
XX	
PR	07-MAR-2000; 2000US-0187510.
PR	22-MAY-2000; 2000US-0206129.
XX	
PA	(WHED) WHITEHEAD INST BIOMEDICAL RES.
XX	
PI	Cargill M, Ireland JS, Lander ES;
XX	
DR	WPI; 2001-522952/57.
XX	
PT	Nucleic acid molecules from the human genome which include polymorphic
PT	sites, useful in methods for predicting the presence, absence or
PT	severity of a particular phenotype or disorder (e.g. diabetes)
PT	associated with a particular genotype -
XX	
PS	Claim 1; Page 104; 145pp; English.
XX	
CC	The invention relates to the identification of nucleic acid molecules
CC	(AAI29513-AAI31314) from the human genome which include polymorphic sites
CC	which can predispose individuals to disease. Various genes from a number
CC	of individuals were resequenced and single nucleotide polymorphisms
CC	(SNPs) in these genes discovered. The method is useful for predicting the
CC	presence, absence or severity of a particular phenotype or disorder (e.g.
CC	diabetes) associated with a particular genotype. The nucleic acids
CC	containing the polymorphic sites may be useful in forensics and paternity
CC	testing.
XX	

SQ Sequence 31 BP; 6 A; 9 C; 6 G; 10 T; 0 other;

Query Match 1.5%; Score 31; DB 22; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1405 TTCACCATCAAGTCAGACGTCGTGGTCCCTTTG 1435
Db 1 TTCACCATCAAGTCAGACGTCGTGGTCCCTTTG 31

RESULT 4
AAI30737
ID AAI30737 standard; DNA; 31 BP.
XX AAI30737;
AC AAI30737;
XX 18-OCT-2001 (first entry)
DE Human single nucleotide polymorphism (SNP) HCK 4.
XX Human; resequence; genotype; disease; forensic; paternity testing;
KW single nucleotide polymorphism; SNP; ss.
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH Variation replace(16,A)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX WO200166800-A2.
XX 13-SEP-2001.
XX 07-MAR-2001; 2001WO-US07268.
XX 07-MAR-2000; 2000US-0187510.
XX 22-MAY-2000; 2000US-0206129.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX Cargill M, Ireland JS, Lander ES;
PI WPI; 2001-522952/57.
XX Nucleic acid molecules from the human genome which include polymorphic sites, useful in methods for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype -
XX Claim 1; Page 104; 145pp; English.
XX The invention relates to the identification of nucleic acid molecules (AAI29513-AAI31314) from the human genome which include polymorphic sites of individuals were resequenced and single nucleotide polymorphisms (SNPs) in these genes discovered. The method is useful for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype. The nucleic acids containing the polymorphic sites may be useful in forensics and paternity testing.
XX Sequence 31 BP; 7 A; 7 C; 10 G; 7 T; 0 other;

Query Match 1.5%; Score 31; DB 22; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 GTTGGGGAAGTCTGGATGGCCACCTACAC 951
Db 1 GTTGGGGAAGTCTGGATGGCCACCTACAC 31

RESULT 5
AAI30738
ID AAI30738 standard; DNA; 31 BP.
XX AAI30738;
AC AAI30738;
XX 18-OCT-2001 (first entry)
DE Human single nucleotide polymorphism (SNP) HCK 5.
XX Human; resequence; genotype; disease; forensic; paternity testing;
KW single nucleotide polymorphism; SNP; ss.
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH Variation replace(16,G)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX WO200166800-A2.
XX 13-SEP-2001.
XX 07-MAR-2001; 2001WO-US07268.
XX 07-MAR-2000; 2000US-0187510.
XX 22-MAY-2000; 2000US-0206129.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX Cargill M, Ireland JS, Lander ES;
PI WPI; 2001-522952/57.
XX Nucleic acid molecules from the human genome which include polymorphic sites, useful in methods for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype -
XX Claim 1; Page 104; 145pp; English.
XX The invention relates to the identification of nucleic acid molecules (AAI29513-AAI31314) from the human genome which include polymorphic sites of individuals were resequenced and single nucleotide polymorphisms (SNPs) in these genes discovered. The method is useful for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype. The nucleic acids containing the polymorphic sites may be useful in forensics and paternity testing.
XX Sequence 31 BP; 12 A; 11 C; 5 G; 3 T; 0 other;

Query Match 1.5%; Score 31; DB 22; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 219 AAAAAGTGAACCCAGCCAGCCACACTGT 249
Db 1 AAAAAGTGAACCCAGCCAGCCACACTGT 31

RESULT 6
AAH41498/c
ID AAH41498 standard; DNA; 33 BP.
XX AAH41498;
AC AAH41498;
XX 23-AUG-2001 (first entry)
XX Human tyrosine kinase Hck PCR primer SEQ ID NO:10.

```

XX KW Human; tyrosine kinase Hck binding protein; tyrosine kinase; Hck;
XX KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
XX KW Hck signal transduction; human immunodeficiency virus; HIV infection;
XX KW anticancer; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200132869-A1.
XX PD 10-MAY-2001.
XX PF 26-OCT-2000; 2000WO-JP07500.
XX PR 29-OCT-1999; 99JP-0309957.
XX PS (SSSE ) SSP CO LTD.
XX PA Taniyama T, Narita T;
XX PI WPI; 2001-316440/33.
XX DR New proteins which bind to human tyrosine kinase Hck for promotion of
XX PT apoptosis and for the elucidation of the mechanism of Hck signal
XX PT transduction
XX PS Example 3; Page 33; 45pp; Japanese.
XX CC The present invention describes a protein, designated HSB-1, which binds
XX CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids
XX CC encoding the protein and its derivatives; (2) recombinant vectors
XX CC containing the nucleic acids; and (3) host cells transformed by the
XX CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes
XX CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism
XX CC of Hck signal transduction and of the role of Hck in human
XX CC immunodeficiency virus (HIV) infection. They can be used for the
XX CC treatment of infections and other diseases with which Hck is associated.
XX CC They promote the anticancer activity of tumour necrosis factor alpha.
XX CC The present sequence represents a PCR primer for the human tyrosine
XX CC kinase Hck, which is used in an example from the present invention.
XX SQ Sequence 33 BP; 2 A; 8 C; 11 G; 12 T; 0 other;

Query Match 1.3%; Score 27; DB 22; Length 33;
Best Local Similarity 100.0%; Pred. No. 0.0093;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1657 ACAGAGAGCCAGTACCAACAGAGCCCA 1683
Db 33 ACAGAGAGCCAGTACCAACAGAGCCCA 7

RESULT 7
AAH41491
ID AAH41491 standard; DNA; 32 BP.
XX AC AAH41491;
XX DT 23-AUG-2001 (first entry)
XX DE Human tyrosine kinase Hck binding protein cloning PCR primer SEQ.3.
XX KW Human; tyrosine kinase Hck binding protein; tyrosine kinase; Hck;
XX KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
XX KW Hck signal transduction; human immunodeficiency virus; HIV infection;
XX KW anticancer; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200132869-A1.
XX PD 10-MAY-2001.

```

```

XX PF 26-OCT-2000; 2000WO-JP07500.
XX PR 29-OCT-1999; 99JP-0309957.
XX PA (SSSE ) SSP CO LTD.
XX PI Taniyama T, Narita T;
XX DR WPI; 2001-316440/33.
XX PT New proteins which bind to human tyrosine kinase Hck for promotion of
XX PT apoptosis and for the elucidation of the mechanism of Hck signal
XX PT transduction
XX PS Example 1; Page 30; 45pp; Japanese.
XX CC The present invention describes a protein, designated HSB-1, which binds
XX CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids
XX CC encoding the protein and its derivatives; (2) recombinant vectors
XX CC containing the nucleic acids; and (3) host cells transformed by the
XX CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes
XX CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism
XX CC of Hck signal transduction and of the role of Hck in human
XX CC immunodeficiency virus (HIV) infection. They can be used for the
XX CC treatment of infections and other diseases with which Hck is associated.
XX CC They promote the anticancer activity of tumour necrosis factor alpha.
XX CC The present sequence represents a PCR primer used in the cloning of
XX CC HSB-1, which is used in an example from the present invention.
XX SQ Sequence 32 BP; 8 A; 5 C; 9 G; 10 T; 0 other;

Query Match 1.3%; Score 26; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.029;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 350 TCGTGGTTGCCCTGTATGATTACGAG 375
Db 7 TCGTGGTTGCCCTGTATGATTACGAG 32

RESULT 8
AAH41492/c
ID AAH41492 standard; DNA; 32 BP.
XX AC AAH41492;
XX DT 23-AUG-2001 (first entry)
XX DE Human tyrosine kinase Hck binding protein cloning PCR primer SEQ.4.
XX KW Human; tyrosine kinase Hck binding protein; tyrosine kinase; Hck;
XX KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
XX KW Hck signal transduction; human immunodeficiency virus; HIV infection;
XX KW anticancer; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200132869-A1.
XX PD 10-MAY-2001.
XX PF 26-OCT-2000; 2000WO-JP07500.
XX PR 29-OCT-1999; 99JP-0309957.
XX PA (SSSE ) SSP CO LTD.
XX PI Taniyama T, Narita T;
XX DR WPI; 2001-316440/33.

```

PT New proteins which bind to human tyrosine kinase Hck for promotion of
PT apoptosis and for the elucidation of the mechanism of Hck signal
PT transduction -
XX
PS
XX Example 1; Page 31; 45pp; Japanese.
XX
CC The present invention describes a protein, designated HSB-1, which binds
CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids
CC encoding the protein and its derivatives; (2) recombinant vectors
CC containing the nucleic acids; and (3) host cells transformed by the
CC vectors and expressing the protein. HSB-1 has cytostatic activity, binds
CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes
CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism
CC of Hck signal transduction and of the role of Hck in human
CC immunodeficiency virus (HIV) infection. They can be used for the
CC treatment of infections and other diseases with which Hck is associated.
CC They promote the anticancer activity of tumour necrosis factor alpha.
CC The present sequence represents a PCR primer used in the cloning of
CC HSB-1, which is used in an example from the present invention.
XX
SQ Sequence 32 BP; 7 A; 10 C; 9 G; 6 T; 0 other;

Query Match 1.3%; Score 26; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.029;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 796 GACGGGCTCTGCCAGAACTGTCGGT 821
DB 32 GACGGGCTCTGCCAGAACTGTCGGT 7
|||||
RESULT 9
AAH41501/C
ID AAH41501 standard; DNA; 32 BP.
XX
AC AAH41501;
XX
XX
XX 23-AUG-2001 (first entry)
XX
DE Human tyrosine kinase Hck binding protein cloning PCR primer SEQ:15.
XX
XX Human; tyrosine kinase Hck binding protein; tyrosine kinase; Hck;
KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
KW Hck signal transduction; human immunodeficiency virus; HIV infection;
KW anticancer; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200132869-A1.
PN
XX
XX 10-MAY-2001.
PD
XX
XX 26-OCT-2000; 2000WO-JP07500.
PF
XX
XX 29-OCT-1999; 99JP-0309957.
PR
XX
XX (SSSE) SSP CO LTD.
PA
XX
XX Taniyama T, Narita T;
PI
XX
XX WPI; 2001-316440/33.
DR
XX
XX New proteins which bind to human tyrosine kinase Hck for promotion of
PT apoptosis and for the elucidation of the mechanism of Hck signal
PT transduction -
XX
XX Example 4; Page 41; 45pp; Japanese.
PS
XX
CC The present invention describes a protein, designated HSB-1, which binds
CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids
CC encoding the protein and its derivatives; (2) recombinant vectors
CC containing the nucleic acids; and (3) host cells transformed by the
CC vectors and expressing the protein. HSB-1 has cytostatic activity, binds

CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes
CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism
CC of Hck signal transduction and of the role of Hck in human
CC immunodeficiency virus (HIV) infection. They can be used for the
CC treatment of infections and other diseases with which Hck is associated.
CC They promote the anticancer activity of tumour necrosis factor alpha.
CC The present sequence represents a PCR primer used in the cloning of
CC HSB-1, which is used in an example from the present invention.
XX
SQ Sequence 32 BP; 8 A; 9 C; 10 G; 5 T; 0 other;

Query Match 1.2%; Score 25; DB 22; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.089;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 505 GCCCGCGTGACTCTCTCGAGACAG 529
DB 32 GCCCGCGTGACTCTCTCGAGACAG 8
|||||
RESULT 10
ABL00375
ID ABL00375 standard; DNA; 51 BP.
XX
XX
AC ABL00375;
XX
XX 05-MAR-2002 (first entry)
DT
XX
XX Human silent noncoding SNP oligonucleotide SEQ ID NO:366.
DE
XX Human; single nucleotide polymorphism; SNP; polymorphism; cytostatic;
KW immunosuppressive; antiinflammatory; neuroprotective; antimicrobial;
KW autoimmune disease; inflammation; cancer; nervous system disease;
KW infection; polymorphic protein; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200138586-A2.
PN
XX
XX 31-MAY-2001.
PD
XX
XX 22-NOV-2000; 2000WO-US32311.
PF
XX
XX 24-NOV-1999; 99US-0167383.
PR
XX
XX (CURA-) CURAGEN CORP.
PA
XX
XX Shimkets RA, Leach M;
PI
XX
XX WPI; 2001-355949/37.
DR
XX
XX Isolated human nucleic acids comprising one or more single nucleotide
PT polymorphisms, useful for treating a subject suffering from a
PT pathology, e.g. autoimmune diseases, ascribed to the presence of a
PT sequence polymorphism -
XX
XX
XX Claim 1; Page 359; 674pp; English.
PS
XX
XX ABL00010 to ABL01104 represent human nucleic acid oligonucleotides
CC comprising one or more single nucleotide polymorphisms (SNPs). ABB56531
CC to ABB56903 represent human peptides encoded by some of the SNP
CC oligonucleotides. The sequences from the present invention can have
CC immunosuppressive, cytostatic, antiinflammatory, neuroprotective and
CC antimicrobial activities. Nucleic acids, polypeptides, oligonucleotides
CC and antibodies from the present invention can be used for treating a
CC subject suffering from, at risk for, or suspected of, suffering from a
CC pathology ascribed to the presence of a sequence polymorphism. The
CC pathology may be autoimmune diseases, inflammation, cancer, diseases of
CC the nervous system, and infection by pathogenic microorganisms. The SNPs
CC are also useful for determining which forms of a characterised
CC polymorphism are present in individuals. The antibodies may be used in
CC the detection, quantitation and/or cellular or tissue localisation of a
CC polymorphic protein (e.g., for use in measuring levels of the

CC polymorphic protein within appropriate physiological samples).

XX
SQ Sequence 51 BP; 10 A; 17 C; 13 G; 11 T; 0 other;
Query Match 1.2%; Score 25; DB 23; Length 51;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 722 GGGGCTTCTACATATCCCGCGAAG 746
|||||
Db 1 GGGGCTTCTACATATCCCGCGAAG 25

RESULT 11

AAH41500
ID AAH41500 standard; DNA; 32 BP.
XX
AC AAH41500;
XX
DT 23-AUG-2001 (first entry)
XX
DE Human tyrosine kinase Hck binding protein cloning PCR primer SEQ:14.
XX
KW Human; tyrosine kinase Hck binding protein; tyrosine kinase: Hck;
KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
KW Hck signal transduction; human immunodeficiency virus; HIV infection;
KW anticancer; PCR primer; ss.
XX
OS Homo sapiens.

XX
PI WO200132869-A1.

XX
PN 10-MAY-2001.

XX
PD 26-OCT-2000; 2000WO-JP07500.

XX
PF 29-OCT-1999; 99JP-0309957.

XX
PR (SSSE) SSP CO LTD.

XX
PA Taniyama T, Narita T;

XX
PI WPI; 2001-316440/33.

XX
DR New proteins which bind to human tyrosine kinase Hck for promotion of

XX
PT apoptosis and for the elucidation of the mechanism of Hck signal

XX
PT transduction

XX
PS Example 4; Page 41; 45pp; Japanese.

XX
SQ The present invention describes a protein, designated HSB-1, which binds

XX
CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids

XX
CC encoding the protein and its derivatives; (2) recombinant vectors

XX
CC containing the nucleic acids; and (3) host cells transfected by the

XX
CC vectors and expressing the protein. HSB-1 has cytosolic activity, binds

XX
CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes

XX
CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism

XX
CC of Hck signal transduction and of the role of Hck in human

XX
CC immunodeficiency virus (HIV) infection. They can be used for the

XX
CC treatment of infections and other diseases with which Hck is associated.

XX
CC They promote the anticancer activity of tumour necrosis factor alpha.

XX
CC The present sequence represents a PCR primer used in the cloning of

XX
CC HSB-1, which is used in an example from the present invention.

XX
SQ Sequence 32 BP; 9 A; 4 C; 10 G; 9 T; 0 other;

Query Match

Best Local Similarity 1.2%; Score 24; DB 22; Length 32;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 529 GAGGAGTGGTTTTCAGGGCATC 552

Db 9 GAGGAGTGGTTTTCAGGGCATC 32

RESULT 12

AAAC90044

ID AAC90044 standard; DNA; 78 BP.

XX
AC AAC90044;

XX
DT 13-MAR-2001 (first entry)

XX
DE PCR primer used to create a library of RRT-Hck SH3 domains.

XX
KW SH3 domain; human; Src homology region 3 domain; RT-loop; Hck protein;

XX
KW PCR primer; ss.

XX
OS Homo sapiens.

XX
PN WO200072742-A2.

XX
PD 07-DEC-2000.

XX
PF 26-MAY-2000; 2000WO-FI00477.

XX
PR 26-MAY-1999; 99US-0136085.

XX
PA (SAKS/) SAKSELA K.

XX
PI Saksela K, Hiipakka M;

XX
DR WPI; 2001-061424/07.

XX
PT A method for generating Src homology region 3 (SH3) domains with

XX
PT tailored binding properties or artificial SH3 domains, comprises

XX
PT employing random manipulation of the SH3 RT-loop sequence

XX
PS Example 1; Page 10; 34pp; English.

XX
SQ The present invention relates to a method for generating Src homology

XX
CC region 3 (SH3) domains with tailored binding properties. The method

XX
CC comprises producing a collection of SH3 domains containing a randomised

XX
CC RT-loop (RRT-SH3 domains). Human p59 Hck was used in the present

XX
CC invention as the SH3 domain. The present sequence is a PCR primer, which

XX
CC was used to create a library of RRT-Hck SH3 domains. The generated SH3

XX
CC domains are useful for inhibiting, activating or modifying the functions

XX
CC of cellular or pathogen-encoded proteins for research or therapeutic

XX
CC purposes.

XX
SQ Sequence 78 BP; 13 A; 13 C; 17 G; 17 T; 18 other;

Query Match

Best Local Similarity 1.2%; Score 24; DB 22; Length 78;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 GACCTCAGCTTCCAGAGGGGAC 414

Db 55 GACCTCAGCTTCCAGAGGGGAC 78

RESULT 13

AAF95624

ID AAF95624 standard; DNA; 21 BP.

XX
AC AAF95624;

XX
DT 06-JUN-2001 (first entry)

XX
DE Human gene single nucleotide polymorphism #385.

XX
KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;

XX
KW polymorphism; vascular disease; coronary artery disease; forensics;

XX
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;

XX
KW pulmonary embolism; paternity test; ds.

```
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Variation replace(11,C)
FT FT /*tag= a
FT FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US24503.
XX
XX 10-SEP-1999; 99US-0153357.
XX 26-JUL-2000; 2000US-0220947.
XX 16-AUG-2000; 2000US-0225724.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis -
XX
XX Examples; Page 75; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX genes. The sequences at a number of polymorphic sites are also provided
XX in the specification. In particular, the method can be used in the
XX diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX disease, stroke, peripheral vascular diseases, venous thromboembolism
XX and pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX useful in forensics, paternity testing, genetic analysis and phenotype
XX correlations to diseases. The present sequence is an example of one of
XX the human gene SNPs shown in the specification.
XX
XX Sequence 21 BP; 3 A; 7 C; 6 G; 5 T; 0 other;
XX
XX Query Match 1.0%; Score 21; DB 22; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 8.3;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 507 CCGCGTTGACCTCTCTGGAGAC 527
XX
XX Db 1 CCGCGTTGACCTCTCTGGAGAC 21
XX
XX RESULT 14
XX AAF95625
XX ID AAF95625 standard; DNA; 21 BP.
XX
XX AC AAF95625;
XX
XX DT 06-JUN-2001 (first entry)
XX
XX DE Human gene single nucleotide polymorphism #386.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(11,T)
```

```
FT
FT
XX /*tag= a
XX /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US24503.
XX
XX 10-SEP-1999; 99US-0153357.
XX 26-JUL-2000; 2000US-0220947.
XX 16-AUG-2000; 2000US-0225724.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis -
XX
XX Examples; Page 75; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
XX in an individual, involving determining the sequence at various
XX polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX genes. The sequences at a number of polymorphic sites are also provided
XX in the specification. In particular, the method can be used in the
XX diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX disease, stroke, peripheral vascular diseases, venous thromboembolism
XX and pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX useful in forensics, paternity testing, genetic analysis and phenotype
XX correlations to diseases. The present sequence is an example of one of
XX the human gene SNPs shown in the specification.
XX
XX Sequence 21 BP; 8 A; 4 C; 7 G; 2 T; 0 other;
XX
XX Query Match 1.0%; Score 21; DB 22; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 8.3;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 773 TGGACCACCTACAGAGGGGA 793
XX
XX Db 1 TGGACCACCTACAGAGGGGA 21
XX
XX RESULT 15
XX AAF95626
XX ID AAF95626 standard; DNA; 21 BP.
XX
XX AC AAF95626;
XX
XX DT 06-JUN-2001 (first entry)
XX
XX DE Human gene single nucleotide polymorphism #387.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(11,C)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX PN
```

```
XX
PD 15-MAR-2001.
XX
XX PF 07-SEP-2000; 2000WO-US24503.
XX
XX 10-SEP-1999; 99US-0153357.
PR 26-JUL-2000; 2000US-0220947.
PR 16-AUG-2000; 2000US-0225724.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis -
XX
XX Examples; Page 75; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism
CC and pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification.
XX
XX Sequence 21 BP; 2 A; 5 C; 6 G; 8 T; 0 other;
SQ
Query Match 1.08; Score 21; DB 22; Length 21;
Best Local Similarity 100.0%; Pred. NO. 8.3;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 347 TCATCGTGGTGGCCCTGATG 367
Db 1 TCATCGTGGTGGCCCTGATG 21
|||||
Search completed: July 4, 2003, 07:04:56
Job time : 459 secs
```


Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACCTTGGCCTGGCCCGG 1317
|||||
Db 20 GACCTTGGCCTGGCCCGG 3

RESULT 2

US-08-910-629A-42
; Sequence 42, Application US/08910629A
; Patent No. 5877309

GENERAL INFORMATION:

; APPLICANT: Robert A. McKay
; APPLICANT: Nicholas M. Dean
; APPLICANT: Brett Monia
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 86

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053

COMPUTER READABLE FORM:

; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; MEDIUM TYPE: STORAGE
; COMPUTER: PENTIUM
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/910,629A
; FILING DATE: August 13, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

FILING DATE:

; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:

LENGTH: 20

; TYPE: Nucleic Acid

; STRANDEDNESS: Single

; TOPOLOGY: Linear

; ANTI-SENSE: NO

US-08-910-629A-42

Query Match 0.9%; Score 18; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACCTTGGCCTGGCCCGG 1317
|||||
Db 1 GACCTTGGCCTGGCCCGG 18

RESULT 3

US-09-209-668-7/c
; Sequence 7, Application US/09209668A
; Patent No. 6114517

GENERAL INFORMATION:

; APPLICANT: Monia, Brett P.

; APPLICANT: Xu, Xiaoxing S.

; TITLE OF INVENTION: METHODS OF MODULATING TUMOR NECROSIS FACTOR

; TITLE OF INVENTION: alpha-INDUCED EXPRESSION OF CELL ADHESION MOLECULES

; FILE REFERENCE: ISPH-0336
; CURRENT APPLICATION NUMBER: US/09/209,668A
; CURRENT FILING DATE: 1998-12-10
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence

US-09-209-668-7

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACCTTGGCCTGGCCCGG 1317
|||||
Db 20 GACCTTGGCCTGGCCCGG 3

RESULT 4

US-09-287-796-31/c
; Sequence 31, Application US/09287796A
; Patent No. 6133246

GENERAL INFORMATION:

; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS

; FILE REFERENCE: ISPH-0350

; CURRENT APPLICATION NUMBER: US/09/287,796A

; CURRENT FILING DATE: 1999-04-07

; EARLIER APPLICATION NUMBER: 09/130,616

; EARLIER FILING DATE: 1998-08-07

; EARLIER APPLICATION NUMBER: 08/910,629

; EARLIER FILING DATE: 1997-08-03

; NUMBER OF SEQ ID NOS: 165

; SEQ ID NO 31

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic Sequence

US-09-287-796-31

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACCTTGGCCTGGCCCGG 1317
|||||
Db 20 GACCTTGGCCTGGCCCGG 3

RESULT 5

US-09-287-796-42
; Sequence 42, Application US/09287796A
; Patent No. 6133246

GENERAL INFORMATION:

; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS

; FILE REFERENCE: ISPH-0350

; CURRENT APPLICATION NUMBER: US/09/287,796A

; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-287-796-42

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||

Db 1 GACTTTGGCCTGGCCCGG 18

RESULT 6

US-09-130-616-31/c
; Sequence 31, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-130-616-31

Query Match 0.9%; Score 18; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||

Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 7

US-09-130-616-42
; Sequence 42, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07

; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-130-616-42

Query Match 0.9%; Score 18; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||

Db 1 GACTTTGGCCTGGCCCGG 18

RESULT 8

US-08-730-876-2/c
; Sequence 2, Application US/08730876
; Patent No. 5859314
; GENERAL INFORMATION:
; APPLICANT: HIBBS, Margaret L.;
; APPLICANT: DUNN, Ashley R.;
; APPLICANT: GRAY, Dianne;
; APPLICANT: HODGSON, George;
; APPLICANT: TARTINGTON, David M.;
; APPLICANT: ARMES, Jane
; TITLE OF INVENTION: ANIMALS WITH TARGETED GENE DELETION
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44mb
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/730,876
; FILING DATE: 18-Oct-1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,578
; FILING DATE: 20-Oct-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5859314man D. Hanson
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5369 - JEL/NDH/SLH
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-730-876-2

Query Match 0.8%; Score 17; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 GGCAGTTGGGAGT 932
|||||

Db 17 GGGCAGTTGGGAAGT 1

RESULT 9

US-09-490-692-71/c
; Sequence 71, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-490-692-71

Query Match 0.8%; Score 17; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 TCAGGAGGATGATGAAG 44
|||||
Db 18 TCAGGAGGATGATGAAG 2

RESULT 10

US-08-222-616-2/c
; Sequence 2, Application US/08222616
; Patent No. 5635177
; GENERAL INFORMATION:
; APPLICANT: Bennett, Brian D.
; APPLICANT: Goeddel, David
; APPLICANT: Lee, James M.
; APPLICANT: Matthews, William
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,616
; FILING DATE: 4-APR-1994
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00586
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/826935
; FILING DATE: 22-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 821P2
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-222-616-2

Query Match 0.8%; Score 17; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GACGCTGTCCTTTGG 1436
|||||
Db 23 GACGCTGTCCTTTGG 7

RESULT 11

US-08-446-648-2/c
; Sequence 2, Application US/08446648
; Patent No. 6331302
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Bennett, Brian D.
; APPLICANT: Goeddel, David
; APPLICANT: Lee, James M.
; APPLICANT: Matthews, William
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST ANTIBODIES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/446,648
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222616
; FILING DATE: 04-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER: 40,378
; REFERENCE/DOCKET NUMBER: P0821P3PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-08-446-648-2

Query Match 0.8%; Score 17; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GACGTCGTGCTCTTGG 1436
Db 23 GACGTCGTGCTCTTGG 7

RESULT 12
PCT-US95-04228-2/c
; Sequence 2, Application PC/TUS9504228
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Bennett, Brian D.
; APPLICANT: Goeddel, David
; APPLICANT: Lee, James M.
; APPLICANT: Matthews, William
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST ANTIBODIES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/04228
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222616
; FILING DATE: 04-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Wendy M. Lee
; REGISTRATION NUMBER: 00,000
; REFERENCE/DOCKET NUMBER: 821P3PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-04228-2

Query Match 0.8%; Score 17; DB 5; Length 23;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GACGTCGTGCTCTTGG 1436
Db 23 GACGTCGTGCTCTTGG 7

RESULT 13
US-09-506-073-82/c
; Sequence 82, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/506,073
; CURRENT FILING DATE: 2000-02-18
; EARLIER APPLICATION NUMBER: US 09/143,214

; EARLIER FILING DATE: 1998-08-28
; EARLIER APPLICATION NUMBER: PCT/US98/13961
; EARLIER FILING DATE: 1998-07-06
; EARLIER APPLICATION NUMBER: US 08/888,982
; EARLIER FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US 08/756,806
; EARLIER FILING DATE: 1996-11-26
; EARLIER APPLICATION NUMBER: PCT/US95/07111
; EARLIER FILING DATE: 1995-05-31
; EARLIER APPLICATION NUMBER: US 08/250,856
; EARLIER FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
; US-09-506-073-82

Query Match 0.8%; Score 16; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 155 GAGCGGCGCCAGGAT 170
Db 20 GAGCGGCGCCAGGAT 5

RESULT 14
US-08-859-998-598
; Sequence 598, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA

QY 1420 GACGTCGTGCTCTTGG 1436
Db 23 GACGTCGTGCTCTTGG 7

RESULT 12
PCT-US95-04228-2/c
; Sequence 2, Application PC/TUS9504228
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Bennett, Brian D.
; APPLICANT: Goeddel, David
; APPLICANT: Lee, James M.
; APPLICANT: Matthews, William
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST ANTIBODIES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/04228
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222616
; FILING DATE: 04-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Wendy M. Lee
; REGISTRATION NUMBER: 00,000
; REFERENCE/DOCKET NUMBER: 821P3PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-04228-2

Query Match 0.8%; Score 17; DB 5; Length 23;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GACGTCGTGCTCTTGG 1436
Db 23 GACGTCGTGCTCTTGG 7

RESULT 13
US-09-506-073-82/c
; Sequence 82, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/506,073
; CURRENT FILING DATE: 2000-02-18
; EARLIER APPLICATION NUMBER: US 09/143,214

```
;
; FEATURE:
; OTHER INFORMATION:.. oligonucleotide primer
US-08-859-998-598

Query Match      0.8%; Score 16; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1236 CATCCACCGAGACCTC 1251
Db      8 CATCCACCGAGACCTC 23

RESULT 15
US-09-225-928-598
; Sequence 598, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
;      Johhadze, George
;      Bidilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;      EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 598:
US-09-225-928-598

Query Match      0.8%; Score 16; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1236 CATCCACCGAGACCTC 1251
Db      8 CATCCACCGAGACCTC 23

Search completed: July 4, 2003, 10:39:34
Job time : 100 secs
```


Db 95 TCAAGTGGACAGCTCTGAAGCC 117
|||||

RESULT 4

US-08-237-401A-25
; Sequence 25, Application US/08237401A
; Patent No. 5837448
; GENERAL INFORMATION:
; APPLICANT: Lemke Ph.D. et al., Greg E.
; TITLE OF INVENTION: PROTEIN-TYROSINE KINASE GENES
; NUMBER OF SEQUENCES: 54
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: US
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/237,401A
; FILING DATE: 02-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/884,486
; FILING DATE: 15-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Halle Ph.D., Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 07251/007001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 678-5070
; TELEFAX: (619) 678-5099
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 147 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; IMMEDIATE SOURCE:
; CLONE: Tyro-13
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..147
US-08-237-401A-25

Query Match 1.1%; Score 23; DB 2; Length 147;
Best Local Similarity 100.0%; Pred. No. 0.094;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1367 TCAAGTGGACAGCTCTGAAGCC 1389
|||||

Db 95 TCAAGTGGACAGCTCTGAAGCC 117

RESULT 5

US-08-306-691B-29
; Sequence 29, Application US/08306691B
; Patent No. 5734039
; GENERAL INFORMATION:
; APPLICANT: Calabretta, Bruno
; APPLICANT: Skorski, Tomasz
; TITLE OF INVENTION: ANTISENSE
; TITLE OF INVENTION: OLIGONUCLEOTIDES TARGETING COOPERATING ONCOGENES
; NUMBER OF SEQUENCES: 55
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seidel, Gonda, Lavorigna & Monaco, P.C.

; STREET: Two Penn Center, Suite 1800
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: U.S.A.
; ZIP: 19102

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 720 Kb
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/306,691B
; FILING DATE: September 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Monaco, Daniel A.
; REGISTRATION NUMBER: 30,480
; REFERENCE/DOCKET NUMBER: 8321-8
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-8383
; TELEFAX: (215) 568-5549
; TELEX: No. 5734039e
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 170 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-306-691B-29

Query Match 1.1%; Score 23; DB 1; Length 170;
Best Local Similarity 100.0%; Pred. No. 0.095;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 GATGCTGGGAGATCCCTCGGA 884
|||||

Db 87 GATGCTGGGAGATCCCTCGGA 109

RESULT 6

PCT-US93-06251-71
; Sequence 71, Application PC/TUS9306251
; GENERAL INFORMATION:
; APPLICANT: Wickstrom, Eric and Rife, Jason P.
; TITLE OF INVENTION: Trivalent Synthesis of Oligonucleotides Containing
; TITLE OF INVENTION: Stereospecific Alkylphosphonates and Arylphosphonates
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: NY
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/06251
; FILING DATE: 19930630
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8586
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 516-742-4343
; TELEFAX: 516-742-4366

70

```

; REFERENCE/DOCKET NUMBER: ALX-101PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 255 1400
; TELEFAX: (203) 254 1101
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1611
; TYPE: NUCLEIC ACID
; STRANDEDNESS: Double
; TOPOLOGY: Linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: Chromosome 20
; PUBLICATION INFORMATION:
; AUTHORS: Anderson, Stephen K.
; AUTHORS: Gibbs, Carol P.
; AUTHORS: Tanaka, Akio
; AUTHORS: Kung, Hsing-Jien
; AUTHORS: Fujita, Donald J.
; TITLE: Human Cellular src Gene:
; TITLE: Nucleotide Sequence and Derived Amino
; TITLE: Acid Sequence of the Region Coding for
; TITLE: the Carboxy-Terminal Two-Thirds of
; TITLE: pp60c-src
; JOURNAL: Molecular and Cellular Biology
; VOLUME: 5
; ISSUE: 5
; PAGES: 1122-1129
; DATE: May, 1985
; PUBLICATION INFORMATION:
; AUTHORS: Tanaka, Akio
; AUTHORS: Gibbs, Carol P.
; AUTHORS: Arthur, Richard R.
; AUTHORS: Anderson, Stephen K.
; AUTHORS: Kung, Hsing-Jien
; AUTHORS: Fujita, Donald J.
; TITLE: DNA Sequence Encoding the
; TITLE: Amino-Terminal Region of the Human c-src
; TITLE: Protein: Implications of Sequence
; TITLE: Divergence among src-type Kinase
; TITLE: Oncogenes
; JOURNAL: Molecular and Cellular Biology
; VOLUME: 7
; ISSUE: 5
; PAGES: 1978-1983
; DATE: May, 1987
; PCT-US93-00445-3

Query Match 1.1%; Score 23; DB 5; Length 1611;
Best Local Similarity 100.0%; Pred. No. 0.099;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 GATGCTGGGAGATCCCTCGGA 884
Db 781 GATGCTGGGAGATCCCTCGGA 803

RESULT 9
US-09-173-581-12
; Sequence 12, Application US/09173581A
; Patent No. 6013455
; GENERAL INFORMATION:
; APPLICANT: Bandman, Olga
; APPLICANT: Tang, Y. Tom
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Yue, Henry
; APPLICANT: Guegler, Karl J.
; APPLICANT: Corley, Neil C.
; APPLICANT: Gorgone, Gina

Query Match 1.1%; Score 22; DB 4; Length 1574;
Best Local Similarity 100.0%; Pred. No. 0.31;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1082 AGGAGCCCATCTACATCATCAC 1103
Db 532 AGGAGCCCATCTACATCATCAC 553

RESULT 11
PCT-US95-08493-12
; Sequence 12, Application PC/TUS9508493
; GENERAL INFORMATION:
; APPLICANT: Wood, Clive
; APPLICANT: Caruso, Anthony
; APPLICANT: Novel mlk Receptor Tyrosine Kinases
; TITLE OF INVENTION: Novel mlk Receptor Tyrosine Kinases
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; APPLICANT: Gorgone, Gina
```

ADDRESSEE: LEGAL AFFAIRS
STREET: 87 Cambridgepark Drive
CITY: Cambridge
STATE: MA
COUNTRY: USA
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE: 04-SEP-1996
APPLICATION NUMBER: PCT/US95/08493
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Brown, Scott A.
REGISTRATION NUMBER: 32,724
REFERENCE/DOCKET NUMBER: G15234A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8224
TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 3398 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
FEATURE:
NAME/KEY: CDS
LOCATION: 121..2961
PCT-US95-08493-12

Query Match 1.0%; Score 21; DB 5; Length 3398;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1290 TAAGATTGCTGACATTGGCCT 1310
|||||
Db 2568 TAAGATTGCTGACATTGGCCT 2588

RESULT 12
US-08-093-383-2/c
Sequence 2, Application US/08093383
Patent No. 5489529
GENERAL INFORMATION:
APPLICANT: DeBoer, Herman A.
APPLICANT: Heyneker, Herbert L.
APPLICANT: Seeburg, Peter H.
TITLE OF INVENTION: DNA for Expression of Bovine Growth Hormone
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/093,383
FILING DATE: 14-JUL-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/619827
FILING DATE: 28-NOV-1990

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/198824
FILING DATE: 05-APR-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 06/632361
FILING DATE: 19-JUL-1984
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 06/303687
FILING DATE: 18-SEP-1981
ATTORNEY/AGENT INFORMATION:
NAME: Johnston, Sean A.
REGISTRATION NUMBER: F35,910
REFERENCE/DOCKET NUMBER: 46C4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3562
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 579 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-093-383-2
Query Match 1.0%; Score 20; DB 1; Length 579;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GATGAAGACGATGACGACGA 75
|||||
Db 67 GATGAAGACGATGACGACGA 48

RESULT 13
US-08-707-793A-3
Sequence 3, Application US/08707793A
Patent No. 5776696
GENERAL INFORMATION:
APPLICANT: SALOME, SCOTT P.
TITLE OF INVENTION: A HIGH THROUGHPUT ASSAY USING
FUSION PROTEINS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merck & Co., Inc.
STREET: P.O. Box 2000, 126 E. Lincoln Ave.
CITY: Rahway
STATE: NJ
COUNTRY: USA
ZIP: 07065-0900
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/707,793A
FILING DATE: 04-SEP-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Camara, Valerie J
REGISTRATION NUMBER: 35,090
REFERENCE/DOCKET NUMBER: 19494
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-594-3902
TELEFAX: 908-594-4720
TELEX:
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 675 base pairs

;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: Genomic DNA
US-08-707-793A-3

Query Match 1.0%; Score 20; DB 1; Length 675;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 688 GTGAACATTACAAGATCCG 707
|||||
Db 526 GTGAACATTACAAGATCCG 545

RESULT 14

US-08-707-792A-3
; Sequence 3, Application US/08707792A
; Patent No. 5783398
; GENERAL INFORMATION:
; APPLICANT: MARCY, ALICE
; APPLICANT: SALOWE, SCOTT P.
; APPLICANT: WISNIEWSKI, DOUGLAS
; TITLE OF INVENTION: A HIGH THROUGHPUT ASSAY USING
; TITLE OF INVENTION: FUSION PROTEINS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065-0900

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/707,792A
FILING DATE: 04-SEP-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Camara, Valerie J
REGISTRATION NUMBER: 35,090
REFERENCE/DOCKET NUMBER: 19524
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-594-3902
TELEFAX: 908-594-4720
TELEX:

;; INFORMATION FOR SEQ ID NO: 3:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 675 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: Genomic DNA
US-08-707-792A-3

Query Match 1.0%; Score 20; DB 1; Length 675;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 688 GTGAACATTACAAGATCCG 707
|||||
Db 526 GTGAACATTACAAGATCCG 545

RESULT 15

US-09-099-053-1

;; Sequence 1, Application US/09099053
;; Patent No. 6388063
;; GENERAL INFORMATION:
;; APPLICANT: Greg Plowman
;; APPLICANT: Susan Onrust
;; APPLICANT: David Markby
;; APPLICANT: Sara Courtneidge
;; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF
;; TITLE OF INVENTION: SAD RELATED DISORDERS
;; NUMBER OF SEQUENCES: 28
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/099,053
FILING DATE: Herewith

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/049,914
FILING DATE: June 18, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 235/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

;; INFORMATION FOR SEQ ID NO: 1:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1548 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-09-099-053-1

Query Match 1.0%; Score 20; DB 4; Length 1548;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 AAGTCAGACGTCTGGTCCTT 1433
|||||
Db 1264 AAGTCAGACGTCTGGTCCTT 1283

Search completed: July 4, 2003, 04:49:24
Job time: 127 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 04:49:28 ; Search time 5237 Seconds
(without alignments)
11197.662 Million cell updates/sec

Title: US-10-007-010-3
Perfect score: 2015
Sequence: 1 cggaggcagcgagatgagg.....atataaatgcaagtcttaag 2015

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2054640 seqs, 14551402878 residues

Word size : 0
Total number of hits satisfying chosen parameters: 995600

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Listing first 45 summaries

Database : GenEmbl.*

- 1: gb_ba.*
- 2: gb_htg.*
- 3: gb_in.*
- 4: gb_om.*
- 5: gb_ov.*
- 6: gb_pat.*
- 7: gb_ph.*
- 8: gb_pl.*
- 9: gb_pr.*
- 10: gb_ro.*
- 11: gb_sts.*
- 12: gb_sy.*
- 13: gb_un.*
- 14: gb_vi.*
- 15: em_ba.*
- 16: em_fun.*
- 17: em_hum.*
- 18: em_in.*
- 19: em_mu.*
- 20: em_om.*
- 21: em_or.*
- 22: em_ov.*
- 23: em_pat.*
- 24: em_ph.*
- 25: em_pl.*
- 26: em_ro.*
- 27: em_sts.*
- 28: em_un.*
- 29: em_vi.*
- 30: em_htg_hum.*
- 31: em_htg_inv.*
- 32: em_htg_other.*
- 33: em_htg_mus.*
- 34: em_htg_pln.*
- 35: em_htg_rod.*
- 36: em_htg_mam.*
- 37: em_htg_vrt.*
- 38: em_sy.*
- 39: em_htgo_hum.*
- 40: em_htgo_mus.*
- 41: em_htgo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	26	1.3	72	14	ALRSRCB	J02351 Rous sarcom
2	25	1.2	51	6	AX165171	AX165171 Sequence
3	18	0.9	19	6	AX129247	AX129247 Sequence
c 4	18	0.9	20	6	AR110470	AR110470 Sequence
c 5	18	0.9	20	6	AR116450	AR116450 Sequence
6	18	0.9	20	6	AR116461	AR116461 Sequence
c 7	18	0.9	20	6	AX104119	AX104119 Sequence
c 8	18	0.9	20	6	AX164692	AX164692 Sequence
c 9	18	0.9	20	6	AX355435	AX355435 Sequence
c 10	18	0.9	48	6	AX427069	AX427069 Sequence
c 11	18	0.9	51	6	AX427068	AX427068 Sequence
12	17	0.8	19	6	AX129246	AX129246 Sequence
c 13	17	0.8	20	6	AR029423	AR029423 Sequence
c 14	17	0.8	20	6	AR126642	AR126642 Sequence
c 15	17	0.8	21	6	AX201544	AX201544 Sequence
c 16	17	0.8	23	6	I44506	I44506 Sequence 2
c 17	17	0.8	57	6	AX179479	AX179479 Sequence
c 18	17	0.8	63	9	AF339072	AF339072 Cheirogal
c 19	17	0.8	63	9	AF339077	AF339077 Pan trogl
c 20	17	0.8	71	4	AF055530	AF055530 Didelphis
c 21	16	0.8	22	6	AX465576	AX465576 Sequence
22	16	0.8	24	6	AR090478	AR090478 Sequence
c 23	16	0.8	24	6	AR197513	AR197513 Sequence
c 24	16	0.8	64	6	A67729	A67729 Sequence 59
25	16	0.8	71	9	HSU38ASNR	X97582 H.sapiens s
c 26	15	0.7	18	6	AR190730	AR190730 Sequence
27	15	0.7	19	6	I77125	I77125 Sequence 11
28	15	0.7	31	6	AR069592	AR069592 Sequence
c 29	15	0.7	31	6	AX249143	AX249143 Sequence
30	15	0.7	31	6	AX249144	AX249144 Sequence
31	15	0.7	31	6	AX249145	AX249145 Sequence
32	15	0.7	31	6	AX249146	AX249146 Sequence
33	15	0.7	31	6	AX249147	AX249147 Sequence
c 34	15	0.7	36	6	AX069497	AX069497 Sequence
c 35	15	0.7	36	6	AX069498	AX069498 Sequence
36	15	0.7	43	6	AX141093	AX141093 Sequence
37	15	0.7	43	6	AX146963	AX146963 Sequence
c 38	15	0.7	44	6	AX473094	AX473094 Sequence
c 39	15	0.7	45	6	AR028569	AR028569 Sequence
40	15	0.7	48	6	A18448	A18448 oligonucleo
41	15	0.7	51	6	AX159179	AX159179 Sequence
42	15	0.7	51	6	AX159180	AX159180 Sequence
c 43	15	0.7	51	6	AX199202	AX199202 Sequence
44	15	0.7	60	6	AX455886	AX455886 Sequence
c 45	15	0.7	65	6	AX482877	AX482877 Sequence

ALIGNMENTS

RESULT 1	ALRSRCB	ALRSRCB	72 bp ss-RNA	linear	VRL 28-APR-1993
LOCUS	Rous sarcoma virus (RSV) src gene, partial.				
DEFINITION	J02351				
ACCESSION	J02351.1	GI:210266			
VERSION	c-myc proto-oncogene; kinase; protein kinase; src oncogene.				
SOURCE	Rous sarcoma virus (Prague A strain) DNA, clones pCH1.pCH7 & pCH20.				
ORGANISM	Rous sarcoma virus				
REFERENCE	1 (bases 1 to 72)				
AUTHORS	Bryant, D. and Parsons, J.T.				
TITLE	Site-directed point mutation in the src gene of rous sarcoma virus results in an inactive src gene product				
JOURNAL	J. Virol. 45 (3), 1211-1216 (1983)				

MEDLINE 83164366
PUBMED 6300458
COMMENT A 'g' to 'a' transition at base 55 results in the incorporation of Thr instead of Ala at amino acid 433. This change decreases the protein kinase activity of the product and abolishes the pp60-src mediated cellular transformation activity.

FEATURES
source 1..72
/organism="Rous sarcoma virus"
/db_xref="taxon:11886"
<1..>72
/note="v-src protein"
/codon_start=1
/protein_id="AAA42584.1"
/db_xref="GI:210267"
/translation="EYTAHQAKFKIKWTAPEAALYGR"
BASE COUNT 17 a 25 c 21 g 9 t
ORIGIN 52 bp upstream of BglII site.

Query Match 1.3%; Score 26; DB 14; Length 72;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 GCCAAGTCCCATCAAGTGGACG 1379
|||||
Db 22 GCCAAGTCCCATCAAGTGGACG 47

RESULT 2
AX165171
LOCUS AX165171 51 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 366 from Patent WO0138586.
ACCESSION AX165171
VERSION AX165171.1 GI:14546000
KEYWORDS human.
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 51)
AUTHORS Shimkets, R.A. and Leach, M.
TITLE Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
JOURNAL Patent: WO 0138586-A 366 31-MAY-2001;
Curagen Corporation (US)
FEATURES source 1..51
/organism="Homo sapiens"
/db_xref="taxon:9606"
variation 26
/note="single nucleotide polymorphism
Accession number cg42665067"
BASE COUNT 10 a 17 c 13 g 11 t
ORIGIN

Query Match 1.2%; Score 25; DB 6; Length 51;
Best Local Similarity 100.0%; Pred. No. 0.045;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 722 GGGGCTTCTACATATCCCCCGAAG 746
|||||
Db 1 GGGGCTTCTACATATCCCCCGAAG 25

RESULT 3
AX129247
LOCUS AX129247 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 465 from Patent WO0130362.
ACCESSION AX129247
VERSION AX129247.1 GI:14135552
KEYWORDS human.
SOURCE Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 19)
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 465 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES source 1..19
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/note="Cdk4 ribozyme binding site"
BASE COUNT 1 a 6 c 7 g 5 t
ORIGIN

Query Match 0.9%; Score 18; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 GCTGACTTGGCCTGGCC 1314
|||||
Db 2 GCTGACTTGGCCTGGCC 19

RESULT 4
AR110470/c
LOCUS AR110470 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6114517.
ACCESSION AR110470
VERSION AR110470.1 GI:12826746
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia, B.P. and Xu, X.S.
TITLE Methods of modulating tumor necrosis factor .alpha.-induced expression of cell adhesion molecules
JOURNAL Patent: US 6114517-A 7 05-SEP-2000;
FEATURES source 1..20
Location/Qualifiers
BASE COUNT 4 a 7 c 7 g 2 t
ORIGIN

Query Match 0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||
Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 5
AR116450/c
LOCUS AR116450 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 31 from patent US 6133246.
ACCESSION AR116450
VERSION AR116450.1 GI:14096772
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay, R., Dean, N., Monia, B.P., Nero, P.S. and Gaarde, W.A.
TITLE Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JOURNAL Patent: US 6133246-A 31 17-OCT-2000;
FEATURES source 1..20
Location/Qualifiers
/organism="unknown"


```
BASE COUNT      4 a      7 c      7 g      2 t
ORIGIN
Query Match      0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1300 GACTTTGGCCTGGCCCGG 1317
      |||||||
Db      20 GACTTTGGCCTGGCCCGG 3

RESULT 6
LOCUS      AR116461
DEFINITION Sequence 42 from patent US 6133246.
ACCESSION  AR116461
VERSION     AR116461.1 GI:14096783
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS    McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
TITLE      Antisense oligonucleotide compositions and methods for the
JOURNAL    modulation of JNK proteins
PATENT     US 6133246-A 42 17-OCT-2000;
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="unknown"
BASE COUNT      2 a      7 c      7 g      4 t
ORIGIN
Query Match      0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1300 GACTTTGGCCTGGCCCGG 1317
      |||||||
Db      1 GACTTTGGCCTGGCCCGG 18

RESULT 7
LOCUS      AX104119/c
DEFINITION Sequence 311 from Patent WO0122972.
ACCESSION  AX104119
VERSION     AX104119.1 GI:13920316
KEYWORDS
SOURCE      synthetic construct.
ORGANISM    artificial sequences.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Krieg,A.M., Schetter,C. and Vollmer,J.C.
TITLE      Immunostimulatory nucleic acids
JOURNAL    Patent: WO 0122972-A 311 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="synthetic construct"
            /db_xref="taxon:32630"
BASE COUNT      4 a      7 c      7 g      2 t
ORIGIN
Query Match      0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1300 GACTTTGGCCTGGCCCGG 1317
      |||||||
Db      20 GACTTTGGCCTGGCCCGG 3

RESULT 8
LOCUS      AX164692/c
DEFINITION Sequence 2 from Patent WO0134792.
ACCESSION  AX164692
VERSION     AX164692.1 GI:14545586
KEYWORDS
SOURCE      synthetic construct.
ORGANISM    artificial sequences.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Potapova,O., Gorospe,M. and Holbrook,N.J.
TITLE      Compositions and methods for the diminution or elimination of
JOURNAL    various cancers
PATENT     WO 0134792-A 2 17-MAY-2001;
            THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="synthetic construct"
            /db_xref="taxon:32630"
            /note="Synthetic"
BASE COUNT      4 a      7 c      7 g      2 t
ORIGIN
Query Match      0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1300 GACTTTGGCCTGGCCCGG 1317
      |||||||
Db      20 GACTTTGGCCTGGCCCGG 3

RESULT 9
LOCUS      AX355435/c
DEFINITION Sequence 463 from Patent WO0197843.
ACCESSION  AX355435
VERSION     AX355435.1 GI:18620103
KEYWORDS
SOURCE      synthetic construct.
ORGANISM    artificial sequences.
REFERENCE   1
AUTHORS    Weiner,G. and Hartmann,G.
TITLE      Methods for enhancing antibody-induced cell lysis and treating
JOURNAL    cancer
PATENT     WO 0197843-A 463 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="synthetic construct"
            /db_xref="taxon:32630"
            /note="Synthetic oligonucleotide-phosphorothioate
            backbone"
BASE COUNT      4 a      7 c      7 g      2 t
ORIGIN
Query Match      0.9%; Score 18; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1300 GACTTTGGCCTGGCCCGG 1317
      |||||||
Db      20 GACTTTGGCCTGGCCCGG 3

RESULT 10
LOCUS      AX427069/c
DEFINITION Sequence 33 from Patent WO0196604.
ACCESSION  AX427069
```

VERSION AX427069.1 GI:21530452
KEYWORDS synthetic construct.
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Bee,G., Kohne,D.E., Korb,L., Peterson,T. and Yguerabide,J.
TITLE Assay for genetic polymorphisms using scattered light detectable labels
JOURNAL Patent: WO 0196604-A 33 20-DEC-2001;
Genicon Sciences Corporation (US)
FEATURES Location/Qualifiers
source 1..48
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Exemplary probe for CYP2D6 allele detection"

BASE COUNT 9 a 20 c 10 g 9 t
ORIGIN

Query Match 0.9%; Score 18; DB 6; Length 48;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1003 GAGGCCTTCTGCGCAG 1020
Db 45 GAGGCCTTCTGCGCAG 28
|||||

RESULT 11
AX427068/c
LOCUS AX427068 51 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 32 from Patent WO0196604.
ACCESSION AX427068
VERSION AX427068.1 GI:21530451
KEYWORDS synthetic construct.
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Bee,G., Kohne,D.E., Korb,L., Peterson,T. and Yguerabide,J.
TITLE Assay for genetic polymorphisms using scattered light detectable labels
JOURNAL Patent: WO 0196604-A 32 20-DEC-2001;
Genicon Sciences Corporation (US)
FEATURES Location/Qualifiers
source 1..51
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Exemplary probe for CYP2D6 allele detection"

BASE COUNT 9 a 21 c 10 g 11 t
ORIGIN

Query Match 0.9%; Score 18; DB 6; Length 51;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1003 GAGGCCTTCTGCGCAG 1020
Db 48 GAGGCCTTCTGCGCAG 31
|||||

RESULT 12
AX129246
LOCUS AX129246 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 464 from Patent WO0130362.
ACCESSION AX129246
VERSION AX129246.1 GI:14135551
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1 (bases 1 to 19)

AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 464 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="Homo sapiens"
/db_xref="taxon:9606"
/note="cdk4 ribozyme binding site"

BASE COUNT 1 a 5 c 7 g 6 t
ORIGIN

Query Match 0.8%; Score 17; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 GCTGACTTTGGCCTGGC 1313
Db 3 GCTGACTTTGGCCTGGC 19
|||||

RESULT 13
AR029423/c
LOCUS AR029423 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5859314.
ACCESSION AR029423
VERSION AR029423.1 GI:5941396
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Hibbs,M.L., Dunn,A.R., Graill,D., Hodgson,G., Tarlington,D.M. and Ames,J.
TITLE Mice with targeted tyrosine kinase, lyn, disruption
JOURNAL Patent: US 5859314-A 2 12-JAN-1999;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"

BASE COUNT 4 a 10 c 2 g 4 t
ORIGIN

Query Match 0.8%; Score 17; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 GGCAGTTTGGGGAAGT 932
Db 17 GGCAGTTTGGGGAAGT 1
|||||

RESULT 14
AR126642/c
LOCUS AR126642 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 71 from patent US 6180353.
ACCESSION AR126642
VERSION AR126642.1 GI:14113235
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Dean,N.M. and Cowsert,L.M.
TITLE Antisense modulation of dxxx expression
JOURNAL Patent: US 6180353-A 71 30-JAN-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"

BASE COUNT 3 a 9 c 1 g 7 t
ORIGIN

Query Match 0.8%; Score 17; DB 6; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.8e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 28 TCAGGAGGATGATGAAG 44
 Db 18 TCAGGAGGATGATGAAG 2

RESULT 15
 AX201544/c
 LOCUS AX201544 21 bp DNA linear PAT 30-AUG-2001
 DEFINITION Sequence 223 from Patent WO0153486.
 ACCESSION AX201544
 VERSION AX201544.1 GI:15391386
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct
 artificial sequences.
 REFERENCE 1 (bases 1 to 21)
 AUTHORS Ashkenazi,A.J., Goddard,A., Godowski,P.J., Gurney,A.L.,
 Hillan,K.J., Marsters,S.A., Pan,J., Pitti,R.M., Roy,M.A., Smith,V.,
 Stone,D.M., Watanabe,C.K. and Wood,W.I.
 TITLE Compositions and methods for the treatment of tumour
 JOURNAL Patent: WO 0153486-A 223 26-JUL-2001;
 Genentech, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..21
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Synthetic Oligonucleotide Probe."
 BASE COUNT 7 a 8 c 3 g 3 t
 ORIGIN

Query Match 0.8%; Score 17; DB 6; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 907 CTTGGAGCTGGGCAGTT 923
 Db 19 CTTGGAGCTGGGCAGTT 3

Search completed: July 4, 2003, 08:32:26
 Job time : 5240 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 06:11:39 ; Search time 2904 Seconds

(without alignments)
11237.571 Million cell updates/sec

Title: US-10-007-010-3

Perfect score: 2015

Sequence: 1 cggaggcaggaagatgagg.....atatataatgcaagtcttaccg 2015

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 16154066 seqs, 8097743376 residues

Word size : 0

Total number of hits satisfying chosen parameters: 357874

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Listing first 45 summaries

Database :

EST.*

- 1: em_estba.*
- 2: em_esthum.*
- 3: em_estin.*
- 4: em_estmu.*
- 5: em_estov.*
- 6: em_estpl.*
- 7: em_estro.*
- 8: em_htc.*
- 9: gb_estl.*
- 10: gb_est2.*
- 11: gb_htc.*
- 12: gb_est3.*
- 13: gb_est4.*
- 14: gb_est5.*
- 15: em_estfun.*
- 16: em_estom.*
- 17: gb_gss.*
- 18: em_gss_hum.*
- 19: em_gss_inv.*
- 20: em_gss_pla.*
- 21: em_gss_vrt.*
- 22: em_gss_fun.*
- 23: em_gss_mam.*
- 24: em_gss_mus.*
- 25: em_gss_Other.*
- 26: em_gss_pro.*
- 27: em_gss_rod.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	18	0.9	93	10	AW238943	AW238943 xb29h03.y
2	17	0.8	52	12	BF636617	BF636617 NF091E04D
3	16	0.8	53	13	BJ048171	BJ048171 BJ048171
4	16	0.8	56	17	AZ801785	AZ801785 2M0060E22
5	16	0.8	64	9	AA117806	AA117806 mo65a02.r
6	16	0.8	66	9	AI906791	AI906791 IL-BT125-

C	7	16	0.8	66	9	AI906801	AI906801 RC-BT125-
C	8	16	0.8	66	9	AI906818	AI906818 RC-BT125-
C	9	16	0.8	67	9	AA235459	AA235459 zt31a12.s
C	10	16	0.8	68	10	AV832681	AV832681 AV832681
C	11	16	0.8	72	17	B35762	B35762 HS-1030-B1-
C	12	16	0.8	73	17	BH801576	BH801576 1008117H1
C	13	16	0.8	79	13	BJ034007	BJ034007 BJ034007
C	14	16	0.8	82	9	AA761095	AA761095 ny13h05.s
C	15	16	0.8	88	9	AA620617	AA620617 af84b06.s
C	16	16	0.8	97	14	H61808	H61808 yu41c09.s1
C	17	15	0.7	33	10	AW053793	AW053793 LESq11.yg
C	18	15	0.7	36	14	D12082	D12082 HUM0S16A04
C	19	15	0.7	44	14	D19127	D19127 HUM0S01342
C	20	15	0.7	44	17	BH643552	BH643552 1008058F0
C	21	15	0.7	54	17	B33982	B33982 HS-1023-B2-
C	22	15	0.7	55	14	R54182	R54182 yg98b12.r1
C	23	15	0.7	55	17	BH415966	BH415966 1007045F1
C	24	15	0.7	58	13	BM307600	BM307600 sak31d09.
C	25	15	0.7	58	14	C01969	C01969 HUMG5000398
C	26	15	0.7	59	13	BM018730	BM018730 603646626
C	27	15	0.7	61	14	C02010	C02010 HUMG5000453
C	28	15	0.7	62	14	H25116	H25116 y143b09.s1
C	29	15	0.7	62	17	TA158A09P	TA158A09P
C	30	15	0.7	63	17	AZ307924	AZ307924 IM0010E24
C	31	15	0.7	64	10	BE636462	BE636462 SMOVL2CAS
C	32	15	0.7	64	17	AZ960593	AZ960593 2M0228N10
C	33	15	0.7	67	9	AL644576	AL644576 AL644576
C	34	15	0.7	70	9	AI215407	AI215407 qb07f12.x
C	35	15	0.7	74	17	CNS030KY	AI222379 Tetraodon
C	36	15	0.7	75	14	F33772	F33772 HSPD27429.H
C	37	15	0.7	75	17	AZ467917	AZ467917 IM0279E08
C	38	15	0.7	76	9	AA826784	AA826784 nr89f05.s
C	39	15	0.7	77	9	AA743582	AA743582 ny29c01.s
C	40	15	0.7	80	9	AA930335	AA930335 VS59c04.r
C	41	15	0.7	81	9	AA585407	AA585407 PTH327A.H
C	42	15	0.7	81	17	AF179956	AF179956 AF179956
C	43	15	0.7	84	17	B40784	B40784 HS-1052-B1-
C	44	15	0.7	84	17	CNS03VXT	AL266906 Tetraodon
C	45	15	0.7	85	10	AV533467	AV533467 AV533467

ALIGNMENTS

RESULT 1
AW238943
LOCUS
DEFINITION
93 bp mRNA linear EST 13-DEC-1999
xb29h03.y1 NCI_CGAP_Lu31 Homo sapiens cDNA clone IMAGE:2577749 5' similar to gb:X12597 HIGH MOBILITY GROUP PROTEIN HMGL (HUMAN)
) contains element THR repetitive element ; , mRNA sequence.

AW238943
VERSION
KEYWORDS
SOURCE
AW238943.1 GI:6571333
EST.
human.

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 93)

AUTHORS

TITLE

JOURNAL

COMMENT

NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)

Other_ESTs: xb29h03.x1
Contact: Robert Strausberg, Ph.D.
Email: cgaps-femail.nih.gov

Tissue Procurement: ATCC cDNA Library Preparation: Life Technologies, Inc. cDNA Library Arrayed by: Christa Prange, The I.M.A.G.E. Consortium DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html
Seq primer: -40RP from Gibco

TITLE
JOURNAL
COMMENT

and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0060 row: E column: 22
Seq primer: CGTTGTAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 56.
Location/Qualifiers
1. .56
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC2M060E22"
/clone_lib="Mouse 10kb plasmid UUC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides and T4
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gil4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

18 a 3 c 24 g 11 t

Query Match 0.8%; Score 16; DB 17; Length 56;
Best Local Similarity 100.0%; Pred. No. 8.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 GTGAAGAGGGAGATCA 60
|||||
Db 12 GTGAAGAGGGAGATCA 27

RESULT 5
AA117806
LOCUS
DEFINITION
IMAGE:558410 5', mRNA sequence.
ACCESSION
AA117806
VERSION
AA117806.1 GI:1672822
SOURCE
house mouse.
MUS musculus

REFERENCE
AUTHORS

Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisels,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,

TITLE
JOURNAL
COMMENT

Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LML; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:339202
Seq primer: -28ml3 rev1 ET from Amersham
High quality sequence stop: 52.
Location/Qualifiers
1. .64
/organism="Mus musculus"
/strain="NIH Swiss"
/db_xref="taxon:10090"
/clone="IMAGE:558410"
/clone_lib="Stratagene mouse heart (#937316)"
/sex="pooled"
/tissue_type="heart"
/dev_stage="13 day embryos"
/lab_host="SOLR (kanamycin resistant)"
/note="Organ: heart; Vector: pBluescript SK-; Site:1:
EcoRI; Site:2: XhoI; Cloned unidirectionally. Primer:
Oligo dt. 93 pooled NIH/Swiss 13 day embryo hearts.
Average insert size: 1.0 kb; Uni-ZAP XR Vector; -5',
adaptor sequence: 5' GAATTCGGCAGGAG 3' -3' adaptor
sequence: 5' CTCGAGTTTTTTTTTTTTTTT 3' "

BASE COUNT
ORIGIN

26 a 3 c 29 g 6 t

Query Match 0.8%; Score 16; DB 9; Length 64;
Best Local Similarity 100.0%; Pred. No. 8.5e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GAAGGTGAAGAGGGAG 56
|||||
Db 27 GAAGGTGAAGAGGGAG 42

RESULT 6
AI906791
LOCUS
DEFINITION
IMAGE:558410 5', mRNA sequence.
ACCESSION
AI906791.1 GI:6497199
VERSION
AI906791.1
KEYWORDS
EST.
SOURCE
human.
Homo sapiens

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 66)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
20202663
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922

Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/seq/gethtml.pl?t1=ILat2=IL-BT125-004.html
&t3=090299&t4=1)
Seq primer: puc 18 forward.
Location/Qualifiers

FEATURES

source
1. .66
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BT125"
/sex="female"
/dev_stage="Adult"
/note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196 716 - Ludwig Institute for Cancer Research) profiles into the puc 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
15 a 12 c 21 g 15 t

BASE COUNT
ORIGIN

Query Match 0.8%; Score 16; DB 9; Length 66;
Best Local Similarity 100.0%; Pred. No. 8.6e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1575 GATGCGCTGCTGGAAA 1590
|||||
Db 45 GATGCGCTGCTGGAAA 60

RESULT 7

AI906801/c
LOCUS
DEFINITION RC-BT125-030399-008 BT125 Homo sapiens cDNA, mRNA sequence.
ACCESSION AI906801
VERSION AI906801.1 GI:6497209
KEYWORDS EST.
SOURCE human.

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 66)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zaglo,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.

TITLE

Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags

JOURNAL

Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE
COMMENT
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil

Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/seq/gethtml.pl?t1=RC&t2=RC-BT125-008.html
&t3=030399&t4=1)
Seq primer: puc 18 forward.
Location/Qualifiers

FEATURES

source
1. .66
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BT125"

/sex="female"
/dev_stage="Adult"
/note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196 716 - Ludwig Institute for Cancer Research) profiles into the puc 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
15 a 21 c 12 g 18 t

Query Match 0.8%; Score 16; DB 9; Length 66;
Best Local Similarity 100.0%; Pred. No. 8.6e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1575 GATGCGCTGCTGGAAA 1590
|||||
Db 22 GATGCGCTGCTGGAAA 7

RESULT 8

AI906818
LOCUS
DEFINITION RC-BT125-040399-020 BT125 Homo sapiens cDNA, mRNA sequence.
ACCESSION AI906818
VERSION AI906818.1 GI:6497226
KEYWORDS EST.
SOURCE human.

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 66)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zaglo,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.

TITLE

Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags

JOURNAL

Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE
COMMENT
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil

Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/seq/gethtml.pl?t1=RC&t2=RC-BT125-020.html
&t3=040399&t4=1)
Seq primer: puc 18 forward.
Location/Qualifiers

FEATURES

source
1. .66
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BT125"
/sex="female"
/dev_stage="Adult"
/note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196 716 - Ludwig Institute for Cancer Research) profiles into the puc 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
18 a 12 c 21 g 15 t

BASE COUNT
ORIGIN

University of Washington
Seattle, WA 98195, USA
Tel: (206) 616-8744
Fax: (206) 685-7301
Email: kzackron@u.washington.edu
Sequence Tagged Connector
Plate: CT810 row: D column: 3
Class: BAC ends
High quality sequence stop: 72.

FEATURES source

Location/Qualifiers
1. .72
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="plate-CT810 Col-3 Row-D"
/clone_lib="CIT Human Genomic Sperm Library C"
/sex="M"
/note="Organ: sperm; Vector: pBelobAC11; BAC Clones in E-Coli DH10B"

BASE COUNT 13 a 20 c 17 g 21 t 1 others
ORIGIN

Query Match 0.8%; Score 16; DB 17; Length 72;
Best Local Similarity 100.0%; Pred. No. 8.7e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1020 GGCCACGCGATGAAA 1035
|||||
Db 60 GGCCACGCGATGAAA 45

RESULT 12 BH801576 LOCUS

DEFINITION 1008117H12.2EL_y1 1008 - RescueMu Grid I Zea mays genomic, DNA
sequence.
ACCESSION BH801576
VERSION BH801576.1 GI:20314787
KEYWORDS GSS.
SOURCE Zea mays.
ORGANISM Zea mays

REFERENCE AUTHORS

TITLE Maize genomic sequences found using engineered RescueMu transposon
JOURNAL Unpublished (2001)
COMMENT Department of Biological Sciences
Stanford University
855 California Ave, Palo Alto, CA 94304, USA
Tel: 650 723 2227
Fax: 650 725 8221
Email: walbot@stanford.edu
Possible ligation site of ends cut by 2 different endonucleases.
Reverse complemented post-ligation sequence from source sequence.
Plate: 1008117 row: 20
Class: transposon-tagged.

FEATURES source

Location/Qualifiers
1. .73
/organism="Zea mays"
/cultivar="mixed background W23/A188/B73"
/db_xref="taxon:4577"
/clone_lib="1008 - RescueMu Grid I"
/tissue_type="leaf"
/dev_stage="adult"
/lab_host="DH10B"
/note="Organ: leaf; Vector: RescueMu (engineered from pBlueScript backbone); Site_1: BamHI; Site_2: BglII; RescueMu is a 4.9 kb, modified maize Mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on RescueMu, go to the web

site www.zmdb.iastate.edu and follow the links for 'RescueMu.' Grid I was grown at Berkeley in 2001. DNA was extracted from leaf punches, double digested using BamHI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin."

BASE COUNT 22 a 19 c 22 g 10 t
ORIGIN

Query Match 0.8%; Score 16; DB 17; Length 73;
Best Local Similarity 100.0%; Pred. No. 8.7e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 60 AAGACGATGACGACGA 75
|||||

Db 1 AAGACGATGACGACGA 16
|||||

RESULT 13 BJ034007 LOCUS

DEFINITION BJ034007 NIBB Mochii normalized Xenopus neurula library Xenopus laevis cDNA clone XL025o10 5', mRNA sequence.
ACCESSION BJ034007
VERSION BJ034007.1 GI:17379716
KEYWORDS EST.
SOURCE African clawed frog.
ORGANISM Xenopus laevis

79 bp mRNA linear EST 05-DEC-2001
BJ034007 NIBB Mochii normalized Xenopus neurula library Xenopus laevis cDNA clone XL025o10 5', mRNA sequence.

QY 60 AAGACGATGACGACGA 75
|||||

Db 1 AAGACGATGACGACGA 16
|||||

REFERENCE AUTHORS

TITLE Expressed genes in X. laevis embryo
JOURNAL Unpublished (2001)
COMMENT Contact: Tadasu Shin-i
Center For Genetic Resource Information
National Institute of Genetics
1111 Yata, Mishima, Shizuoka 411-8540, Japan
Tel: 81-559-81-6856
Fax: 81-559-81-6855
Email: tshini@genes.nig.ac.jp.
Location/Qualifiers
1. .79
/organism="Xenopus laevis"
/db_xref="taxon:8355"
/clone="XL025o10"
/clone_lib="NIBB Mochii normalized Xenopus neurula library"
/tissue_type="whole embryo"
/dev_stage="stage 15"
/note="Vector: pBSRN3; Site_1: NotI; Site_2: EcoRI; cDNAs were oligo-dT primed and directionally cloned. Staging according to Nieuwkoop and Faber. Library is subtracted and was constructed by N. Garrett and A.M. Zorn, (Wellcome/CRC Institute)."

FEATURES source

Location/Qualifiers
17 a 14 c 25 g 23 t
BASE COUNT 17 a 14 c 25 g 23 t
ORIGIN

Query Match 0.8%; Score 16; DB 13; Length 79;
Best Local Similarity 100.0%; Pred. No. 8.9e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 80 TCTGAGGGGACCTCAG 95
|||||

Db 55 TCTGAGGGGACCTCAG 70
|||||

RESULT 14 AA761095/c LOCUS

DEFINITION nyl3H05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1271673
82 bp mRNA linear EST 07-FEB-1998
AA761095

similar to SW:GLI4_HUMAN P10075 GLI4 PROTEIN ;, mRNA sequence.

AA761095
VERSION AA761095.1 GI:2810025
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 82)
JOURNAL NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
COMMENT National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-femail.nih.gov
Tissue Procurement: Louis M. Staudt, M.D., Ph.D., David Allman, Ph.D., Gerald Marti, M.D.
cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio-llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 1924 Std Error: 0.00
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.

FEATURES
source Location/Qualifiers
1..82
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1271673"
/clone_lib="NCI_CGAP_GCB1"
/tissue_type="germinal center B cell"
/lab_host="DH10B"
/note="Vector: p7T73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was prepared from human tonsillar cells enriched for germinal center B cells by flow sorting (CD20+, IgD+), provided by Dr. Louis M. Staudt (NCI), Dr. David Allman (NCI) and Dr. Gerald Marti (CBER). cDNA synthesis was primed with a Not I - oligo(dT) primer [5'-TGTTACCAATCTGAAGTGGAGCGCGCCGCTCATTTTTTTTTTTT-3',]. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization, and was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 7 a 35 c 22 g 18 t
ORIGIN

Query Match 0.8%; Score 16; DB 9; Length 82;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 96 GGGCTGCCGAGCTGGG 111
|||||
Db 69 GGGCTGCCGAGCTGGG 54

RESULT 15
AA620617/c
LOCUS
DEFINITION af84b06.sl Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1048691
3' similar to SW:RR4_HUMAN P10075 HKR4 PROTEIN ;, mRNA sequence.
ACCESSION AA620617
VERSION AA620617.1 GI:2524556
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 88)
AUTHORS Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S., Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin, J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B., White, Y., Wyllie, T., Waterston, R. and Wilson, R.
WashU-NCI human EST Project
Unpublished (1997)
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Possible reversed clone: similarity on wrong strand
Possible reversed clone: polyt not found
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.

FEATURES
source Location/Qualifiers
1..88
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1048691"
/clone_lib="Soares_testis_NHT"
/sex="male"
/lab_host="DH10B"
/note="Vector: p7T73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was prepared from mRNA obtained from Clontech Laboratories, Inc., and primed with a Not I - oligo(dT) primer [5'-TGTTACCAATCTGAAGTGGAGCGCGCCGCTCATTTTTTTTTTTT-3',]. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization to Cots5, and was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 17 a 33 c 25 g 13 t
ORIGIN

Query Match 0.8%; Score 16; DB 9; Length 88;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 96 GGGCTGCCGAGCTGGG 111
|||||
Db 75 GGGCTGCCGAGCTGGG 60

Search completed: July 4, 2003, 10:37:47
Job time : 2908 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 4, 2003, 06:57:16 ; Search time 98 Seconds
(without alignments)
6305.650 Million cell updates/sec

Title: US-10-007-010-3

Perfect score: 2015

Sequence: 1 cggaggcaggaagatgagg.....atataaatgcaagtcttacg 2015

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 441362 seqs, 153338381 residues

Word size : 0

Total number of hits satisfying chosen parameters: 687286

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Listing first 45 summaries

Database : Issued_Patents_NA.*

- 1: /cgn2.6/prodata/1/ina/5A_COMB.seq.*
- 2: /cgn2.6/prodata/1/ina/5B_COMB.seq.*
- 3: /cgn2.6/prodata/1/ina/6A_COMB.seq.*
- 4: /cgn2.6/prodata/1/ina/6B_COMB.seq.*
- 5: /cgn2.6/prodata/1/ina/PCTUS_COMB.seq.*
- 6: /cgn2.6/prodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
c 1	18	0.9	20	US-08-910-629A-31	Sequence 31, Appl
c 2	18	0.9	20	US-08-910-629A-42	Sequence 42, Appl
c 3	18	0.9	20	US-09-209-668-7	Sequence 7, Appl
c 4	18	0.9	20	US-09-287-796-31	Sequence 31, Appl
c 5	18	0.9	20	US-09-287-796-42	Sequence 42, Appl
c 6	18	0.9	20	US-09-130-616-31	Sequence 31, Appl
c 7	18	0.9	20	US-09-130-616-42	Sequence 42, Appl
c 8	17	0.8	20	US-08-730-876-2	Sequence 2, Appl
c 9	17	0.8	20	US-09-490-692-71	Sequence 71, Appl
c 10	17	0.8	23	US-08-222-616-2	Sequence 2, Appl
c 11	17	0.8	23	US-08-446-648-2	Sequence 2, Appl
c 12	17	0.8	23	PCT-US95-04228-2	Sequence 2, Appl
c 13	16	0.8	20	US-09-506-073-82	Sequence 82, Appl
c 14	16	0.8	24	US-08-859-998-598	Sequence 598, Appl
c 15	16	0.8	24	US-09-225-928-598	Sequence 598, Appl
c 16	15	0.7	18	US-08-951-923-51	Sequence 51, Appl
c 17	15	0.7	18	US-08-584-040-6218	Sequence 6218, Ap
c 18	15	0.7	19	US-08-400-580A-11	Sequence 11, Appl
c 19	15	0.7	31	US-08-942-423-51	Sequence 51, Appl
c 20	15	0.7	36	US-08-951-923-52	Sequence 52, Appl
c 21	15	0.7	36	US-08-724-586-3	Sequence 3, Appl
c 22	15	0.7	36	US-09-421-632-3	Sequence 3, Appl
c 23	15	0.7	36	US-09-932-190-3	Sequence 3, Appl
c 24	15	0.7	45	US-08-039-198B-3	Sequence 3, Appl
c 25	15	0.7	72	US-08-707-237A-47	Sequence 47, Appl
c 26	14	0.7	17	US-08-584-040-7661	Sequence 7661, Ap
c 27	14	0.7	18	US-08-105-483-197	Sequence 197, App

c 28	14	0.7	18	1	US-08-220-151-78	Sequence 78, Appl
c 29	14	0.7	18	1	US-08-413-118-78	Sequence 78, Appl
c 30	14	0.7	18	1	US-08-224-657-54	Sequence 54, Appl
c 31	14	0.7	18	1	US-08-709-209-197	Sequence 197, App
c 32	14	0.7	18	1	US-08-458-101-197	Sequence 197, App
c 33	14	0.7	18	2	US-08-184-009-52	Sequence 52, Appl
c 34	14	0.7	18	2	US-08-173-489C-11	Sequence 11, Appl
c 35	14	0.7	18	2	US-08-417-210A-52	Sequence 52, Appl
c 36	14	0.7	18	2	US-08-585-684B-2737	Sequence 2737, Ap
c 37	14	0.7	18	2	US-08-458-356-52	Sequence 52, Appl
c 38	14	0.7	18	3	US-08-473-446-78	Sequence 78, Appl
c 39	14	0.7	18	4	US-09-038-073-2737	Sequence 2737, Ap
c 40	14	0.7	18	4	US-08-460-736-52	Sequence 52, Appl
c 41	14	0.7	18	4	US-09-354-138-54	Sequence 54, Appl
c 42	14	0.7	20	1	US-08-639-763-6	Sequence 6, Appl
c 43	14	0.7	20	4	US-09-270-542-161	Sequence 161, App
c 44	14	0.7	20	4	US-09-798-096-87	Sequence 87, Appl
c 45	14	0.7	21	1	US-08-056-200-44	Sequence 44, Appl

ALIGNMENTS

RESULT 1
US-08-910-629A-31/c
; Sequence 31, Application US/08910629A
; Patent No. 5877309
; GENERAL INFORMATION:
; APPLICANT: Robert A. McKay
; APPLICANT: Nicholas M. Dean
; APPLICANT: Brett Monia
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; MEDIUM TYPE: STORAGE
; COMPUTER: PENTIUM
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/910,629A
; FILING DATE: August 13, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-910-629A-31

Query Match 0.9%; Score 18; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
| | | | | | | | | | | | | | | |
Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 2

US-08-910-629A-42
; Sequence 42, Application US/08910629A
; Patent No. 5877309
; GENERAL INFORMATION:
; APPLICANT: Robert A. McKay
; APPLICANT: Nicholas M. Dean
; APPLICANT: Brett Monia
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053

COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; MEDIUM TYPE: STORAGE

COMPUTER: PENTIUM

OPERATING SYSTEM: WINDOWS 95

SOFTWARE: WORDPERFECT 6.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/910,629A

FILING DATE: August 13, 1997

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0215

TELEPHONE: (609) 779-2400

TELEFAX: (609) 779-8488

INFORMATION FOR SEQ ID NO: 42:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

ANTI-SENSE: No

US-08-910-629A-42

Query Match 0.9%; Score 18; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
| | | | | | | | | | | | | | | |
Db 1 GACTTTGGCCTGGCCCGG 18

RESULT 3

US-09-209-668-7/c
; Sequence 7, Application US/09209668A
; Patent No. 6114517
; GENERAL INFORMATION:
; APPLICANT: Robert A.
; APPLICANT: Nicholas M. Dean
; APPLICANT: Brett P.
; APPLICANT: Xu, Xiaoxing S.
; TITLE OF INVENTION: METHODS OF MODULATING TUMOR NECROSIS FACTOR
; TITLE OF INVENTION: alpha-INDUCED EXPRESSION OF CELL ADHESION MOLECULES

; FILE REFERENCE: ISPH-0336
; CURRENT APPLICATION NUMBER: US/09/209,668A
; CURRENT FILING DATE: 1998-12-10
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
; US-09-209-668-7

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
| | | | | | | | | | | | | | | |
Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 4

US-09-287-796-31/c
; Sequence 31, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0350
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
; US-09-287-796-31

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
| | | | | | | | | | | | | | | |
Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 5

US-09-287-796-42
; Sequence 42, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0350
; CURRENT APPLICATION NUMBER: US/09/287,796A

; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-287-796-42

Query Match 0.9%; Score 18; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||
Db 1 GACTTTGGCCTGGCCCGG 18

RESULT 6

US-09-130-616-31/c
; Sequence 31, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-130-616-31

Query Match 0.9%; Score 18; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||
Db 20 GACTTTGGCCTGGCCCGG 3

RESULT 7

US-09-130-616-42
; Sequence 42, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07

; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-130-616-42

Query Match 0.9%; Score 18; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 GACTTTGGCCTGGCCCGG 1317
|||||
Db 1 GACTTTGGCCTGGCCCGG 18

RESULT 8

US-08-730-876-2/c
; Sequence 2, Application US/08730876
; Patent No. 5859314
; GENERAL INFORMATION:
; APPLICANT: HIBBS, Margaret L.;
; APPLICANT: DUNN, Ashley R.;
; APPLICANT: GRAILL, Dianne;
; APPLICANT: HODGSON George;
; APPLICANT: TARLINGTON, David M.;
; APPLICANT: ARMES, Jane
; TITLE OF INVENTION: ANIMALS WITH TARGETED GENE DELETION
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44mb
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/730,876
; FILING DATE: 18-Oct-1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,578
; FILING DATE: 20-Oct-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5859314man D. Hanson
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5369 - JEL/NDH/SLH
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-730-876-2

Query Match 0.8%; Score 17; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 GGGCAGTTTGGGAAGT 932
|||||

Db 17 GGGCAGTTTGGGAAGT 1

RESULT 9

US-09-490-692-71/c

; Sequence 71, Application US/09490692

; Patent No. 6180353

; GENERAL INFORMATION:

; APPLICANT: Nicholas M. Dean

; APPLICANT: Lex M. Cowser

; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION

; FILE REFERENCE: RTS-0120

; CURRENT APPLICATION NUMBER: US/09/490,692

; CURRENT FILING DATE: 2000-01-24

; NUMBER OF SEQ ID NOS: 176

; SEQ ID NO 71

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-490-692-71

Query Match 0.8%; Score 17; DB 4; Length 20;

Best Local Similarity 100.0%; Pred. No. 89;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 TCAGGAGGATGATGAAG 44

|||||

Db 18 TCAGGAGGATGATGAAG 2

RESULT 10

US-08-222-616-2/c

; Sequence 2, Application US/08222616

; Patent No. 5635177

; GENERAL INFORMATION:

; APPLICANT: Bennett, Brian D.

; APPLICANT: Goeddel, David

; APPLICANT: Lee, James M.

; APPLICANT: Matthews, William

; APPLICANT: Tsai, Siao Ping

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST

; NUMBER OF SEQUENCES: 42

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 5.25 inch, 360 kb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patin (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/222,616

; FILING DATE: 4-APR-1994

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/US93/00586

; FILING DATE: 22-JAN-1993

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/826935

; FILING DATE: 22-JAN-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Lee, Wendy M.

; REGISTRATION NUMBER:

; REFERENCE/DOCKET NUMBER: 821P2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415/225-1994

; TELEFAX: 415/952-9881

; TELEX: 910/371-7168

; INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 23 bases

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-222-616-2

Query Match 0.8%; Score 17; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 89;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GAGCTCTGGTCCCTTGG 1436

|||||

Db 23 GAGCTCTGGTCCCTTGG 7

RESULT 11

US-08-446-648-2/c

; Sequence 2, Application US/08446648

; Patent No. 6331302

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Bennett, Brian D.

; APPLICANT: Goeddel, David

; APPLICANT: Lee, James M.

; APPLICANT: Matthews, William

; APPLICANT: Tsai, Siao Ping

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST ANTIBODIES

; NUMBER OF SEQUENCES: 45

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatIn (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/446,648

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/222616

; FILING DATE: 04-APR-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Lee, Wendy M.

; REGISTRATION NUMBER: 40,378

; REFERENCE/DOCKET NUMBER: P0821P3PCT

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415/225-1994

; TELEFAX: 415/952-9881

; TELEX: 910/371-7168

; INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 23 base pairs

; TYPE: Nucleic Acid

; STRANDEDNESS: Single

; TOPOLOGY: Linear

US-08-446-648-2

Query Match 0.8%; Score 17; DB 4; Length 23;

Best Local Similarity 100.0%; Pred. No. 89;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1420 GACGCTGCTGCTTTGG 1436
Db 23 GACGCTGCTGCTTTGG 7

RESULT 12
PCT-US95-04228-2/c
; Sequence 2, Application PC/TUS9504228
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Bennett, Brian D.
; APPLICANT: Goeddel, David
; APPLICANT: Lee, James M.
; APPLICANT: Matthews, William
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE AGONIST ANTIBODIES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/04228
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222616
; FILING DATE: 04-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Wendy M. Lee
; REGISTRATION NUMBER: 00,000
; REFERENCE/DOCKET NUMBER: 821P3PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-04228-2

Query Match 0.8%; Score 17; DB 5; Length 23;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1420 GACGCTGCTGCTTTGG 1436
Db 23 GACGCTGCTGCTTTGG 7
RESULT 13
US-09-506-073-82/c
; Sequence 82, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/506,073
; CURRENT FILING DATE: 2000-02-18
; EARLIER APPLICATION NUMBER: US 09/143,214

; EARLIER FILING DATE: 1998-08-28
; EARLIER APPLICATION NUMBER: PCT/US98/13961
; EARLIER FILING DATE: 1998-07-06
; EARLIER APPLICATION NUMBER: US 08/888,982
; EARLIER FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US 08/756,806
; EARLIER FILING DATE: 1996-11-26
; EARLIER APPLICATION NUMBER: PCT/US95/07111
; EARLIER FILING DATE: 1995-05-31
; EARLIER APPLICATION NUMBER: US 08/250,856
; EARLIER FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
; US-09-506-073-82

Query Match 0.8%; Score 16; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 155 GAGCGGGCGCCAGGAT 170
Db 20 GAGCGGGCGCCAGGAT 5

RESULT 14
US-08-859-998-598
; Sequence 598, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA

```
;
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
US-08-859-998-598

Query Match      0.8%; Score 16; DB 2; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 CATCCACCGAGACCTC 1251
Db      8 CATCCACCGAGACCTC 23

RESULT 15
US-09-225-928-598
; Sequence 598, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
;              Jokhadze, George
;              Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;              EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA: US/09/225,928
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 598:
US-09-225-928-598

Query Match      0.8%; Score 16; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 CATCCACCGAGACCTC 1251
Db      8 CATCCACCGAGACCTC 23
```

Search completed: July 4, 2003, 10:39:34
Job time : 100 secs

Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 TCAGGAGGATGATGAAG 44
|||||
Db 18 TCAGGAGGATGATGAAG 2

RESULT 15
AX201544/c
LOCUS AX201544 21 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 223 from Patent WO0153486.
ACCESSION AX201544
VERSION AX201544.1 GI:15391386
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Ashkenazi,A.J., Goddard,A., Godowski,P.J., Gurney,A.L.,
Hillan,K.J., Marsters,S.A., Pan,J., Pitti,R.M., Roy,M.A., Smith,V.,
Stone,D.M., Watanabe,C.K. and Wood,W.I.
TITLE Compositions and methods for the treatment of tumour
JOURNAL Patent: WO 0153486-A 223 26-JUL-2001;
Genentech, Inc. (US)
FEATURES
Location/Qualifiers
1..21
source
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic Oligonucleotide Probe."
BASE COUNT 7 a 8 c 3 g 3 t
ORIGIN

Query Match. 0.8%; Score 17; DB 6; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 907 CTTGGAGCTGGGCACTT 923
|||||
Db 19 CTTGGAGCTGGGCACTT 3

Search completed: July 4, 2003, 08:32:26
Job time : 5240 secs

